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Summary of Thesis 
 
 
Alterations in the hypothalamo-pituitary-thyroid (HPT) axis have been reported 
following growth hormone (GH) replacement. The aim of this study was to examine 
potential mechanisms responsible for GH-induced changes in the HPT axis. 
Furthermore, we aimed to explore the relationship between changes in the serum 
concentration of thyroid hormones and peripheral biomarkers of thyroid hormone 
action, before and after GH replacement. 
 
Twenty men with severe GH deficiency participated in a prospective, 
observational study of physiological GH replacement. Research measurements 
were conducted immediately prior to commencing, and 3-6 months after, GH 
replacement.  
 
Following GH replacement, the ratio of freeT3:freeT4 in serum increased. In 
subcutaneous fat, Type 2 deiodinase enzyme activity declined. Type 1 and Type 3 
deiodinase activity remained unchanged following GH substitution. Serum TSH, 
thyroglobulin and thyroid binding globulin levels were unchanged by GH therapy. 
 
Hepatic-derived serum markers of thyroid hormone action, including ferritin 
and caeruloplasmin, declined following GH replacement. In contrast, serum markers 
of bone turnover increased in parallel with changes in serum concentration of 
thyroid hormones. Resting energy expenditure and cardiac time intervals did not 
change throughout the study.  Health-related quality of life (QOL) improved 
following GH replacement in the full study group. However, the improvement in QOL 
was poorer than expected in subjects who experienced a fall in serum free T4.  
 
This study confirms the significant impact of GH replacement on the thyroid 
axis. In vitro analysis of subcutaneous fat from hypopituitary subjects demonstrates 
that GH replacement is associated with significant changes in deiodinase 
16 
 
 
isoenzyme activity. However, the observed variation in enzyme activity does not 
explain changes in the circulating concentration of thyroid hormones induced by GH 
replacement. Notwithstanding the underlying mechanism, changes in the HPT axis, 
induced by GH replacement, have complex clinical implications for patients with 
hypopituitarism.   
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Chapter 1  
 
 
Introduction 
 
 
1.1 Hypopituitarism 
 
Hypopituitarism, a biochemical deficiency in one or more of the hormones released 
from the pituitary gland, can result from disease of the pituitary itself or the 
hypothalamus (1). It has a reported incidence of 42 cases per million and a 
prevalence ranging from 300 - 450 cases per million (2). Hypopituitarism is a 
heterogeneous disease with a variable degree of hormone deficiency among 
different patients – some will have isolated hormone deficiencies while others may 
have multiple pituitary hormone deficiencies (MPHD). 
 
Benign adenomas arising within the pituitary gland are the commonest cause 
of acquired hypopituitarism in adulthood (3, 4). A recent population study in the 
south of England estimated the prevalence of pituitary adenomas to be 
approximately 78 cases per 100,000 inhabitants (5). Other tumours, adjacent to the 
pituitary (parasellar area) and in the hypothalamus (e.g. craniopharyngioma) are 
another common cause of hypopituitarism. Pituitary hormone deficiency may result 
from the compressive effect of the tumour itself or from the treatment of the tumour 
i.e. surgery and/or radiotherapy (1). Less common causes of acquired 
hypopituitarism in adulthood include cranial radiotherapy, post-partum haemorrhage 
causing pituitary necrosis (Sheehan’s syndrome), infiltrative conditions such as 
sarcoidosis, lymphocytic hypophysitis, infections such as tuberculosis and 
metastatic tumours. Also, traumatic brain injury is an increasingly recognised cause 
of hypopituitarism (6, 7). Finally, less than 10% of cases are idiopathic and may be 
accompanied by an empty sella turcica on imaging (empty sella syndrome) (2, 4). 
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The symptoms of hypopituitarism are highly variable due to interaction of 
multiple different hormone deficiency syndromes (8). For examples ACTH 
deficiency can cause weight loss, whereas weight gain can occur due to fluid 
retention in hypothyroidism (TSH deficiency). Furthermore, partial deficiency of 
pituitary hormones may not cause any noticeable symptoms but in the case of 
ACTH deficiency, could be unmasked by stress or intercurrent illness. Specific 
symptoms of ACTH deficiency include weight loss, fatigue, anorexia and loss of 
body hair. Severe ACTH deficiency may result in hyponatraemia due to water 
retention. Gonadotrophin deficiency leads to oligo/amennorhoea in women while 
men suffer impotence and erectile dysfunction. TSH deficiency results in the 
classical symptoms of hypothyroidism including cold intolerance, fatigue, muscle 
stiffness, weight gain, constipation and dry skin.  
 
 
1.2 Growth Hormone Deficiency 
 
Growth hormone secreting cells (somatotrophs) account for the majority of cells 
composing the anterior pituitary in humans. Despite this, GH deficiency (GHD) is 
among the commonest pituitary hormone insufficiency observed in adults with 
hypopituitarism (9).  
 
Adults with GHD comprise two distinct groups – those with a prior diagnosis 
of GHD in childhood and those who acquire GHD in adulthood due to hypothalamic 
and/or pituitary disease (10). Childhood-onset GHD is most commonly isolated and 
idiopathic. Children usually present with short stature or impaired height velocity 
(11, 12). GH replacement is long established for treatment of childhood-onset GHD 
in order to optimise linear growth and height potential before closure of the 
epiphyses. Interestingly, up to 25% of cases with idiopathic childhood-onset GHD 
will have normal GH reserves if re-tested in adulthood. The underlying 
pathophysiology in such cases is poorly understood.  Children with severe GHD and 
additional pituitary hormone deficiencies secondary to organic pituitary disease 
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such as craniopharyngioma will have persistent GHD in adulthood and do not 
routinely require re-testing (12, 13). 
 
The symptoms of adult-onset GHD are subtle and common-place, including 
fatigue, poor exercise capacity, abdominal obesity and impaired psychosocial 
function. Essentially, there is no pathognomonic feature. This contrasts with 
childhood-onset GHD where growth failure acts as a useful biological marker of 
GHD. In addition, the majority of adults with GHD have deficiencies of other pituitary 
hormones, further complicating the clinical picture. For example, ACTH deficiency 
can cause weight loss, whereas weight gain can occur due to hypothyroidism and 
GHD. We cannot, therefore, rely on symptoms alone for case detection in GHD.   
 
Identifying patients at risk of GHD, such as those with hypothalamic pituitary 
disease, previous cranial radiotherapy and head injury, is crucial (14). Toogood et al 
have demonstrated that in patients with MPHD, the severity of GHD is related to the 
degree of hypopituitarism (15). Therefore, patients with other clinically or 
biochemically detectable pituitary hormone abnormalities are also a high risk group. 
They should be screened for GHD if GH replacement would be appropriate. GHD is 
established on both clinical and biochemical criteria but despite significant advances 
in our understanding of adult GHD, accurate diagnosis remains challenging. 
Selecting the appropriate patient, performing a reliable diagnostic test and 
understanding the clinical caveats, as well as the analytical limitations, are the 
crucial steps (14).  
 
 
1.2.1 Diagnosis of GHD 
 
Multiple tests are available for the diagnosis of GHD in adulthood and debate 
still exists about the most appropriate test. The availability of multiple testing 
modalities emphasises the complexities involved in making an accurate diagnosis 
and the need to individualise testing for each patient’s clinical circumstances. The 
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‘ideal test’ will provide clear separation between normal and GHD patients even 
allowing for factors that may attenuate GH secretion such as age and obesity. 
 
International consensus guidelines has converged around the insulin 
tolerance test and the growth-hormone releasing hormone (GHRH) + Arginine test 
(combined test) as the best available test of GHD in adults. These tests provide 
sufficient sensitivity and specificity to establish a reliable diagnosis when 
appropriate cut-offs are used (16, 17). The glucagon stimulation test is a second 
line test but is nonetheless well validated for assessing GH secretory capacity when 
first line tests are unavailable or contra-indicated (18, 19). Other tests, such as 
clonidine stimulation or arginine alone are available but less well validated. 
 
IGF-1 is a peptide hormone that mediates most of the biological actions of 
growth hormone. Circulating IGF-1 is principally composed of endocrine IGF-1 
produced in the liver under GH stimulation. A small amount of autocrine IGF-1 is 
also produced in peripheral tissues such as bone and can be controlled by other 
factors released from surrounding cells.  IGF-1 has a very high affinity for binding 
proteins (IGFBP) and circulates in a ternary complex, bound to IGFBP-3 and the 
acid-labile subunit. It exerts its effect by activation of the IGF-1 receptor which is 
widely distributed in many tissues (20). 
 
The value of serum IGF-1 and IGF binding protein-3 (IGFBP-3) in the 
diagnosis of GH deficiency is a matter of contention among endocrinologists. While 
serum IGF-1 levels less than 2 standard deviations (SD) below the age-matched 
mean, in a well- nourished adult with pituitary disease, is highly suggestive of GHD 
(21), it is clear that serum IGF-1 and/or IGFBP-3 can be normal in patients with 
undisputed GHD. Various investigators have reported normal IGF-1 values in 37-
70% of GHD adults (22-24). Further studies, however, showed that age, the time of 
onset of GHD, and the degree of hypopituitarism, all had a significant influence on 
serum IGF-1 levels - sometimes expressed as standard deviation scores (IGF-1 
SDS) or Z scores. In the study by Aimaretti et al, 70% of GHD adults under the age 
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of 40 years had a serum IGF-1 level below the age-related 3rd centile, but the 
corresponding percentage for those over the age of 40 was only 35% (25). In a 
large retrospective analysis of patients with GHD from the KIMS database, Lissett et 
al found that 86% of patients with childhood-onset GHD compared to 52% with 
adult-onset GHD, had serum IGF-1 SDS less than -2 (26). The latter study also 
identified gender, BMI and number of additional pituitary hormone deficiencies as 
factors which influence serum IGF-1 SDS. While recognising the above-mentioned 
caveats, it is now generally accepted that in well-nourished patients without liver 
disease, a low IGF-1 in the presence of 3 or more anterior pituitary hormone 
deficiencies, provides very strong evidence of GHD. Further testing in this context is 
optional (21). However, for many patients with suspected GHD, a provocative test of 
growth hormone reserve is required. In addition, since the presence of other 
pituitary hormone deficiencies is the strongest predictor of GHD and no provocative 
test has 100% specificity, it is recommended that adult patients who appear to have 
isolated GHD undergo two provocative tests to confirm the diagnosis, particularly if 
the serum IGF-1 is not low. 
 
 
1.3 Clinical manifestations of the syndrome of adult GHD  
 
Severe GHD in adults can give rise to several clinical abnormalities. Body 
composition is altered due to increased fat mass and reduced muscle mass. 
Exercise capacity is reduced and quality of life is impaired. The plasma lipid profile 
is unfavourable and cardiovascular morbidity may be increased (27).  A growing 
recognition of this clinical syndrome in the last 20 years has led to the therapeutic 
use of growth hormone (GH) replacement in adults with severe GHD. This 
treatment has been shown to improve many abnormal parameters.  
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1.3.1 Body composition 
 
Both adults and children with GHD have increased visceral fat mass and 
reduced lean body mass. A variety of studies, using different methodologies to 
estimate body composition, have demonstrated similar results. In a six-moth study 
of GH replacement in hypopituitary adults (n=68), Johannson et al used dual energy 
x-ray absorptiometry and bioimpedance measurements to evaluate changes in body 
composition (28). They reported a median decline of 2.6kg in fat mass accompanied 
by a 2kg increase in lean body mass. A similar study by Whitehead et al (n=14), 
using computed tomography, showed a median reduction of 2.2kg fat mass an 
3.6kg increase in lean body mass over six month (29).  
 
In routine clinical practice, anthropometric measurement of waist:hip ratio is a  
useful surrogate of visceral fat mass in GHD patients. A recent, international trial of 
1,034 patients receiving GH replacement, as part of routine clinical care, has 
confirmed the utility of waist:hip ratio in longitudinal monitoring of body composition 
(30). 
 
 
1.3.2 Lipid profile 
 
GHD is associated with an adverse lipid profile; total and LDL cholesterol 
(LDL-C) is elevated in comparison to healthy controls; HDL cholesterol (HDL-C) is 
variably reported to be reduced or similar to GH sufficient subjects (31). Sustained 
reductions in total cholesterol and LDL-C have been reported with the use of 
physiologic doses of GH replacement in adulthood (32, 33). An effect on HDL 
cholesterol is less convincing and GH replacement does not appear to impact on 
serum triglyceride concentration. The impact of GH on the pro-atherogenic lipid 
particle, Lp(a), is controversial. Variable results have been reported using different 
assay methodologies. However, the balance of evidence is in favour of GH 
increasing the serum concentration of Lp(a) (34, 35). 
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1.3.3 Exercise capacity and cardiac function 
 
Cardiorespiratory function is impaired in adults with GHD. Robust evidence 
supports an improvement in exercise capacity following GH replacement (36). The 
relative contributions of cardiac function and muscles strength are debated. Studies 
examining the effects of GH replacement on muscle strength, using a variety of 
methodologies have produced mixed results. A recent meta-analysis concluded that 
there was insufficient evidence supporting a positive effect of GH on muscle 
strength (37).  
 
Childhood-onset GHD is associated with reduced cardiac output and 
impaired diastolic function. However, the abnormalities in adult-onset GHD appear 
to be less marked (38, 39). GH has been associated with a subtle increase in LV 
wall thickness and stroke volume; diastolic function may also improve. However, 
there is only limited evidence, from placebo-controlled studies, that GH 
replacement, improves cardiac function in adults (40). In addition, the therapeutic 
window for the cardiac effect of GH replacement is likely to be relatively narrow 
since acromegaly, a condition of excess GH secretion, is clearly associated with a 
dilated cardiomyopathy and cardiac failure (41).   
 
  
1.3.4 Bone strength 
 
GH plays an important role in the accrual of adult bone mass following the 
completion of linear growth in adolescence (42).  GHD adults have a reduced bone 
density in comparison with healthy individuals; the severity of GHD appears to 
correlate with the degree of bone loss (43, 44). GH activates the bone remodelling 
cycle. This is reflected in the increased serum and urine concentration of bone 
turnover markers after systemic exposure to GH (45). Placebo controlled studies 
have shown that GH replacement leads to an initial decline in bone mineral density 
(BMD) due expansion of the bone remodelling space. However, the overall effect of 
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sustained, long-term GH replacement in adulthood is an improvement in BMD (46). 
The fracture rate in GHD subjects is increased; however there is currently 
insufficient data to support a decreased fracture rate in adults receiving GH 
replacement (47).   
 
1.3.5 Quality of life 
 
Improved vitality was one of the main benefits reported in the first use of GH 
in adulthood  (48). Since then, impaired well-being and a deficit in self-reported 
health status have been clearly defined in GHD adults (49, 50). This may, in part, be 
related to altered body composition and reduced exercise capacity. However, 
studies which have employed both generic and disease-specific health status 
questionnaires have outlined deficits in numerous physical and emotional domains 
of quality of life (QOL) (29, 51, 52). Placebo-controlled trials of GH replacement in 
adulthood have clearly demonstrated an improvement in QOL (49, 53). Intriguingly, 
there does not appear to be a dose-response element to the effect of GH on QOL. 
Subjects over-treated with pharmacological doses of GH, resulting in a high serum 
IGF-1 level, achieve a similar increment in QOL scores as those treated with 
physiological dose of GH whose IGF-1 level was maintained within the normal 
range (54).  
 
Poor QOL is seen as a core clinical feature of the syndrome of adult GHD 
and is a key indication for replacement of GH in adulthood. The disease-specific 
questionnaire –Assessment of Growth Hormone deficiency in Adulthood (AGHDA) 
is a sensitive tool for the measurement of QOL in adults with GHD and it has 
demonstrated excellent reproducibility in monitoring the response to GH 
replacement (55). The reasons underlying the variable response to GH, in respect 
of QOL, are unclear. However, the interaction of GH with other pituitary axes may 
be an important consideration in this respect.  
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1.4 Interaction of GH with other hypothalamic–pituitary axes 
 
GHD in adulthood is typically part of a syndrome of multiple pituitary 
hormone deficiencies. GH replacement has been shown to have significant 
interaction with other pituitary axes and their replacement regimens. In vitro human 
studies have shown that GH inhibits the activity of 11β-hydroxysteroid 
dehydrogenase 1 (11β-HSD1) (56). This enzyme catalyses the conversion of the 
inactive compound, cortisone, to the hormonally active cortisol. Therefore, GH 
replacement, at physiological doses, reduces tissue exposure to cortisol. Cortisol 
promotes adipocyte differentiation, adipogensis and visceral fat deposition (57). It 
has been postulated that modulation of glucocorticoid metabolism may account, in 
part, for the reduction in fat mass observed after GH replacement (58). 
 
In addition, female sex steroids have an important influence on the response 
to GH replacement. Oestrogen confers a degree of hepatic GH resistance (59). 
Therefore, pre-menopausal women, in comparison to men, require a higher dose of 
GH to generate an equivalent serum concentration of IGF-1. In contrast, 
replacement of the adrenal androgen, dihydroepiandosteone (DHEA), which is 
under the control of ACTH, reduces GH dose requirements in women with 
hypopituitarism (60). The mechanism underlying the interaction of DHEA with the 
GH-IGF-1 axis is still unclear. 
 
Previous research has described complex alterations in the hypothalamic-
pituitary-thyroid (HPT) axis following GH replacement (61). Studies in adults with 
hypopituitarism have reported a reduction in circulating T4 levels, with between 36-
47% of previously euthyroid subjects requiring thyroxine replacement (62, 63). Also, 
15-18% of patients with concurrent central hypothyroidism required an increase in 
thyroxine dose to maintain serum T4 concentration in the normal range. However, 
this effect has not been demonstrated universally (64, 65). Serum T3 levels have 
been reported to rise or remain unchanged (64, 66-69). A variety of changes in 
serum TSH have been reported. Older studies reported an increase in TSH which 
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may be explained by contamination of cadaveric GH with TSH (70). Contemporary 
studies more commonly report no change (62, 63, 66) or a decrease in TSH (68, 
69) after replacement of GH. The serum concentration of reverse T3, an inactive 
hormone by-product of T4, has been reported to decline in previous, small studies 
of GH replacement (63, 67).  
 
The mechanism underlying the changes observed in the HPT axis is a matter 
of debate. Some authors have speculated that alterations in serum binding proteins, 
such as thyroid binding globulin (TBG) may account for the observed fluctuations 
following GH replacement (71). However, the ratio of freeT4: total T4 is unchanged 
in most prospective studies which argues against an impact of GH on TBG 
concentration. The hypothesis that GH affects the peripheral interconversion of 
thyroid hormones is supported by a number of studies in this field.  
 
The prohormone, T4, accounts for the majority of thyroid hormone produced 
from the thyroid. T4 is activated in numerous peripheral tissues, by deiodination, to 
produce T3 (Figure 1.1). Several studies of GH replacement have shown a rise in 
serum T3 and fall in reverse T3, concurrent with a fall in T4, suggesting that GH 
directly affects the interconversion of thyroid hormones in peripheral tissue. 
However, no direct human evidence exists to support this theory. Furthermore, the 
clinical impact of the changes in the HPT axis, recorded after GH replacement in 
adults, is unclear. 
 
 
1.5 Iodothyronine deiodinase enzymes 
 
Iodothyronine deiodinase enzymes are responsible for the local activation 
and inactivation of thyroid hormones. In healthy humans, they maintain 3,5,3’-
triiodothyronine (T3) homeostasis, both in the serum and in peripheral tissue, by 
controlling the formation and degradation of T3 (72). When replete in iodine, the 
major hormone produced by the thyroid is thyroxine (T4); this is a prohormone and 
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must be activated into T3 in peripheral tissues, by removal of an iodine moiety from 
the outer (phenolic) ring (Figure 1.1).  
 
 
 
 
 
 
 
Figure 1.1 
 
Peripheral metabolism of iodothyronines by deiodinase isoenzymes (DIO1, DIO2, 
DIO3). Removal of an iodine moiety (blue circles) from the outer ring of T4 
(deiodination) produces the active hormone T3 which can interact with the thyroid 
hormone nuclear receptor. Alternatively, removal of an iodine moiety from the inner 
ring of T4 deactivates the compound into reverse T3 (rT3). T3 can be deactivated, 
by undergoing further deiodination with DIO3, producing the inactive T2 molecule 
which is rapidly metabolised. 
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The activity of deiodinase enzymes in certain tissues, most notably the liver, 
is also reflected in the serum concentration of thyroid hormones. In euthyroid 
human subjects, 80% of circulating T3 is formed by deiodination of T4 in peripheral 
tissue (73). Reverse T3 (rT3), an inactive hormone by-product, can also be 
produced peripherally, by removal of the inner (tyrosyl) ring.   
 
There are three subtypes of deiodinase enzymes - DIO1, DIO2 and DIO3 - 
which are differentially expressed depending on the tissue type (Table 1.1). For 
example, DIO1 is highly expressed in liver and kidney while DIO2 is expressed 
more avidly in brain, pituitary and brown adipose tissue. T4 is converted into the 
biologically active hormone T3 by outer ring deiodination – a reaction catalysed by 
DIO2 and DIO1. DIO3 converts T4 and T3, into the biologically inactive rT3 and T2 
respectively. The enzymes work synergistically to control the cytosolic pool of T3 
and the saturation of the nuclear thyroid hormone receptor (TR) depending on the 
needs or function of a particular tissue. The activity and expression of deiodinase 
isoenzymes can be affected by a variety of factors. 
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Table 1.1 
 
Properties of iodothyronine deiodinase isoenzymes. Details of their physiological 
role as well as their known actions in disease states are outlined.  
 
Property DIO 1 DIO 2 DIO 3 
Cellular location Plasma membrane Endoplasmic 
reticulum 
Plasma membrane 
Half-life 12 hours  20 minutes Several hours 
Tissues with high 
activity 
Liver, kidney, 
thyroid 
Brown adipose 
tissue, placenta, 
brain, skeletal 
muscle 
Brain, placenta, 
skin, 
haem(74)angiomas 
Physiological 
role 
Clearance of rT3 Major source of 
plasma T3 and 
intracellular T3, 
thermogenesis 
Embryonic 
development, 
clearance of T4 
and T3 
Role in disease Generates most of 
plasma T3 in 
thyrotoxicosis 
 Increases 
clearance of T3 
and T4 in sick 
euthyroid 
syndrome. 
Consumptive 
hypothyroidism in 
large 
haemagiomas 
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The complex, dynamic and adaptive nature of the deiodinase enzyme 
system is highlighted by the changes that occur in enzyme activity and mRNA 
expression during certain illness. Critical illness, in particular, is notable for 
significant alterations circulating concentrations of thyroid hormone (75). A low 
circulating T3 concentration is the most consistent finding, accompanied by a low or 
normal serum T4 level or elevated rT3 in the presence of a normal TSH level. The 
syndrome has been termed “low T3 syndrome” or “non-thyroidal illness”.  
Alterations in deiodinase activity are, at least in part, responsible for this syndrome. 
Various lines of evidence point to a reduction in DIO1 activity – with reduced 
conversion of T4 to T3 – as well as up regulated DIO3 activity leading to increased 
clearance of T3 (76). The lack of a rise in serum TSH, in response to a lowering of 
serum T3 suggests that central hypothyroidism is also a component of the 
syndrome (77). The severity of illness and risk of poor outcomes correlates with the 
degree of T3 suppression; however, whether this syndrome is adaptive or 
pathological (and therefore worthy of treatment) is a matter of controversy.  
 
Deiodinase enzymes are also influenced by fluctuations in the circulating 
concentration of T3 and T4 (78). A rise in serum T3 leads to reciprocal changes in 
DIO2 and DIO3 activity. DIO3 expression is upregulated, increasing the clearance 
of T3 while the expression of DIO2 is downregulated, reducing the production of T3. 
In contrast, if T3 levels decline, the DIO3 expression becomes suppressed (72).  
 
Deiodinase enzymes are membrane associated proteins – DIO1 and DIO3 
are found in the plasma membrane while DIO2 is intracellular but bound to the 
membrane of the sarcoplasmic reticulum. They belong to the family of 
selenoproteins which are specialised peptides which contain the rare amino acid 
selenocysteine in their active centre (79).  Experimental evidence suggests that 
selenium (Se) is essential for enhancing the catalytic efficiency of deiodinase 
enzymes – a mutant enzyme containing cysteine alone has a 100 fold lower activity 
in driving the deiodination of thyroid hormone moieties (79, 80). Clinically, the 
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activity of deiodinase enzymes can be affected by severe selenium deficiency or 
marked alteration in selenium exposure (81, 82). 
 
Drugs can also affect deiodinase enzyme activity. The anti-thyroid drug, 
propyltiouracil (PTU) inhibits DIO1 activity (83). In hyperthyroidism DIO1 (as 
opposed to DIO2) is responsible for much of the circulating T3.  Therefore, inhibition 
of DIO1 in liver, kidney and thyroid accounts for the rapid reduction in the circulating 
concentration of T3 observed when thyrotoxicosis is treated with PTU (84). 
Amiodarone, an iodine-containing anti-arrhythmic, also inhibits the activity of DIO1 
and perhaps DIO2 (85, 86). This leads to an initial fall in serum T3 followed by a 
compensatory rise in both T4 and TSH (87).  
 
The direct effect of GH on deiodinase enzyme activity or expression in 
human tissue has, thus far, not been studied. The well described alterations in the 
HPT axis following GH replacement, in both adults and children, are highly 
suggestive of changes in peripheral deiodinase enzyme activity. In particular, the 
rise in the serum T3:T4 ratio implies an increased production, or decreased 
clearance, of T3 in peripheral tissue.  
 
 
 
1.6 Central hypothyroidism 
 
Central hypothyroidism refers to TSH and/or TRH deficiency and is a rare cause of 
thyroid hormone deficiency. In adults, central hypothyroidism is normally acquired in 
the context of organic pituitary and/or hypothalamic disease in patients with multiple 
pituitary hormone deficiencies (MPHD). In children and adolescents congenital 
causes of central hypothyroidism, due to specific genetic defects, are more common 
(discussed below). 
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1.6.1 Epidemiology & Aetiology 
 
The rarity of the disease and difficulties making the diagnosis make 
estimation of the true prevalence and incidence very challenging. A recent Spanish 
study estimated the prevalence of central hypothyroidism to be 45.5 cases per 
100,000 of the general population; pituitary adenomas were the commonest cause 
of central hypothyroidism accounting for 60% of cases (2).  Further research, from 
disease-specific studies, provides further insight into the epidemiology of central 
hypothyroidism. In patients with pituitary adenomas, the commonest cause of 
hypopituitarism in adults, rates of TSH deficiency between 15 – 60% have been 
reported (88-91). The wide range is likely due to differences in biochemical 
diagnostic criteria, tumour size and extent of treatment. Indeed a study of 
macroproalctinomas in men found a rate of central hypothyroidism of 26% in 
patients with a tumour diameter greater than 40mm; larger tumour diameter 
correlated strongly with lower serum freeT4 concentration following treatment (92).   
Pituitary tumour apoplexy is also associated with substantial rates of TSH 
deficiency; Lubina et al reported that 54% were diagnosed with central 
hypothyroidism (93).  Less common causes of hypopituitarism in adults may be 
associated with differing rates of central hypothyroidism.  Treatment of 
craniopharyngioma, for example, has been reported to result in central 
hypothyroidism in up to 90% of cases (94, 95). This is locally invasive tumour, 
derived from the embryonic squamous remnants of Rathke’s pouch, which often 
requires multi-modality treatment including radiotherapy. This may account for the 
high rates of central hypothyroidism. In contrast, Rathke’s cleft cyst is associated 
with a much lower rate of TSH deficiency, between 7-35% in symptomatic patients 
(96, 97).  
 
Non-classical causes of acquired central hypothyroidism include 
radiotherapy, lymphocytic hypophysitis, traumatic brain injury and medication. 
Radiotherapy to the head and neck, for non-pituitary tumours, is associated with 
significant rates of hypopituitarism. Agha et al reported a 9% rate of central 
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hypothyroidism in adults treated with radiotherapy for primary non-pituitary brain 
tumours (98). Furthermore, TSH deficiency has been observed in approximately 5% 
of patients irradiated for nasopharyngeal or paranasal sinus tumours (99). The risk 
of hypopituitarism is directly related to the total radiation dose. Lymphocytic 
hypophysitis is an autoimmune inflammatory condition of the pituitary and 
infundibulum which is more common in women. ACTH deficiency is particularly 
common in lymphocytic hypophysitis in comparison with other hypothalamic 
pituitary disease; however, central hypothyroidism is present in 59% of published 
cases (100).  
 
Damage to the hypothalamic-pituitary axis in the setting of head trauma has 
been recognised for several decades, with post-mortem data demonstrating 
pituitary gland infarction in up to one third of patients after fatal TBI (101). Recently, 
several clinical studies have demonstrated a high frequency of hypothalamic-
pituitary hormone deficiencies among adult TBI survivors. Notwithstanding the 
methodological differences between various studies, there is a broad agreement 
that anterior hypopituitarism is a common finding after moderate and severe head 
injury with an estimated prevalence of approximately 25% among adult long-term 
survivors (102). GH and gonadotrophin are, by far, the commonest deficiencies; 
however, central hypothyroidism has been reported in between 1-10% of TBI 
survivors (103).    
 
Bexarotene is a synthetic retinoid analogue (rexinoid) approved for the 
treatment of cutaneous T-cell lymphoma. In clinical studies, Bexarotene induced 
clinical and biochemical evidence of central hypothyroidism in 40% of subjects 
(104). This side effect appears to be dose dependent and those previously treated 
with interferon α appear to be particularly susceptible. Under physiological 
conditions, thyroid hormone activates the thyroid hormone receptor (TR) in the 
pituitary by forming a heterodimer with the retinoid X receptor and providing 
negative feedback against TSH secretion (105). It would seem that rexinoid drugs, 
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such as Bexarotene, can directly suppress TSH secretion via the rexinoid X 
receptor. This side effect is reversible upon discontinuation of the drug.   
 
Congenital causes of central hypothyroidism are increasingly recognised. 
Familial isolated TSH deficiency is caused by a single base pair substitution in the 
gene encoding the TSHβ subunit. This syndrome is autosomal recessive and has 
now been described in several kindreds (106). Also, TRH receptor mutations have 
been rarely described (107). Central hypothyroidism due to a genetic mutation is, 
more commonly, part of a MPHD syndrome. For example, mutation of POU1F1, a 
pituitary-specific transcription factor typically causes severe GHD and central 
hypothyroidism (108). Similarly, mutation in PROP1, a transcription factor involved 
in embryonic pituitary maturation, leads to combined pituitary hormone deficiencies. 
The phenotype in PROP1 mutations is variable but often includes central 
hypothyroidism (109). Germline mutations in the HESX1 gene have also been 
reported to cause MPHD and are often accompanied by septo-optic dysplasia. 
Mutations in LHX3 and LHX4 can also cause congenital hypothyroidism; the former 
is associated with a rigid cervical spine, while the latter is often accompanied by 
cerebellar defects and abnormalities of the central skull base. 
 
 
1.6.2 Diagnosis 
 
The diagnosis of central hypothyroidism is very challenging. Typical 
symptoms of hypothyroidism may be milder than in primary thyroid failure and goitre 
is absent (110). In acquired central hypothyroidism there appears to be constitutive 
activation of the TSH receptor which maintains some thyroxine secretion in the face 
of falling TSH levels (111, 112). Also, hypothyroid symptoms may be obscured due 
to co-existing features of other pituitary hormone deficits such as GH or ACTH 
deficiency.  
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There is no reliable marker of central hypothyroidism and the diagnosis is 
largely biochemical, based on the finding of a low free serum thyroid hormone 
concentration with inappropriately low serum TSH concentration (110). The 
diagnosis is complicated by the fact that a serum T4 concentration within the 
population reference range, similar to the situation of primary hypothyroidism, does 
not exclude central hypothyroidism.  
 
Previous investigators have described a mathematical model to define the 
relationship between serum TSH and free T4 – the TSH index – in patients with 
pituitary disease (113). This model may detect a pathologically subnormal serum 
TSH in patients with pituitary disease or inappropriate suppression of TSH in 
patients receiving thyroxine. However, this model has not been validated in other 
cohorts of patients with pituitary disease or using other T4 and TSH assays. Also, 
this model does not account for alteration in the serum T3/T4 ratio induced by GH 
replacement.  
 
Furthermore, some patients with genuine central hypothyroidism have an 
elevated serum TSH concentration despite a low serum freeT4. Abnormal 
glycosylation of the TSH molecule, largely a function of TRH, leads to impaired TSH 
bioactivity despite a high circulating concentration. In vivo and ex vivo experiments 
suggest that increased sialation in the carbohydrate moiety probably accounts for 
the reduced bioactivity of the TSH molecule (114). Therefore, patients with central 
hypothyroidism may have immunologically active TSH in the serum, detected in 
vitro by commercial assay kits; however, this is not biologically active in vivo. 
Despite the putative role of TRH in the post-translational modification of the TSH 
molecule, abnormal TSH bioactivity was observed in patients with both pituitary and 
hypothalamic lesions. 
 
TSH dynamics have been proposed as a mechanism for differentiating 
patients with TSH deficiency from those who are euthyroid. The normal, nocturnal 
surge in TSH release is blunted or ablated in central hypothyroidism; in fact this 
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appears to be one of earliest abnormalities in TSH secretion in patients developing 
central hypothyroidism (115). Previous investigators have proposed frequent serum 
sampling for TSH over a 24 hour period as a potential mechanism for diagnosing 
central hypothyroidism (116). Using this technique, some investigators have 
claimed to have diagnosed mild (or early) central hypothyroidism which was not 
apparent on baseline thyroid function tests (117). However, this approach to 
diagnosis is controversial. There is a lack of correlation between abnormalities in 
TSH circadian rhythm and circulating thyroid hormone concentration. In addition, 
the nocturnal surge can be blunted, temporarily, in other circumstances such as 
following pituitary surgery (115, 118).  Also, this test of TSH dynamics is clearly 
cumbersome and costly, requiring admission to hospital for 24 hours.  
 
Thyrotrophin-releasing-hormone (TRH) stimulation of TSH has also been 
proposed as a dynamic evaluation which could separate TSH sufficient patients with 
pituitary disease from those who have insufficient TSH reserves (90, 115, 119). The 
test involves injection of 10µg/kg of TRH intravenously and measuring the TSH 
response in the serum with repeated sampling over one hour. Healthy individuals 
show a consistent and prompt rise in TSH levels. A normal response is defined as a 
rise in TSH, greater than 4.0 - 5.0mU/L, (typically five-fold above baseline) within 30 
minutes and a rapid decline in serum TSH thereafter (120). Early data suggested 
that central hypothyroidism due primary pituitary disease led to a blunted TSH 
response to TRH (less than 150% rise from baseline) while hypothalamic disease 
resulted in a delayed or prolonged response (121). However, defects at the 
hypothalamic level are common in patients treated for pituitary disease and vice 
versa. In addition, it is now clear that patients with undoubted central 
hypothyroidism may occasionally exhibit a normal response to TRH (117, 122). 
Therefore, this test has limited clinical utility in routine clinical practice.  
 
Finally, in patients treated for hypothalamic-pituitary disease, the pattern of 
fluctuation of serum thyroid hormone concentration over time may provide an 
indication about TSH reserve. Regulation of serum freeT4 concentration in healthy 
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individuals is highly conserved such that variation typically does not exceed 10% 
over time (123). Therefore, temporal decline in serum free T4 greater than 20%, in 
comparison with the initial freeT4 (for example before pituitary surgery or 
radiotherapy) would support a diagnosis of central hypothyroidism. Limited data 
supports this approach and clearly this diagnostic metric will require long-term 
follow up of patients with repeated measurement of serum free T4 in the same 
bioassay (124).  
 
 
1.6.3 Treatment and monitoring 
 
 Thyroxine dosing in central hypothyroidism has largely been extrapolated 
from data in primary hypothyroidism although limited data in patients with pituitary 
disease supports a body weight adapted dose of 1.6μg/kg/day (125).  Recent 
studies, in patients with central hypothyroidism, have highlighted the difficulty in 
optimising thyroxine replacement (126). As a consequence, patients with central 
hypothyroidism, compared to those with primary thyroid failure, are at risk of under-
replacement with thyroxine . 
 
Serum TSH cannot be used as a homeostatic guide in the same manner as 
in primary hypothyroidism. However, measurement of serum TSH is not pointless. 
Suppression of TSH, in central hypothyroidism, is considered an appropriate 
response to thyroxine in the context of hypothalamic pituitary disease (110). A 
database study of patients with pituitary disease prescribed thyroxine in a tertiary 
referral centre in USA showed the majority of patients, considered euthyroid by their 
physician, had a suppressed TSH (127). These results were concordant with a 
Belgian study of 108 patients with central hypothyroidism who were taking a 
replacement dose of thyroxine comparable to that in primary hypothyroidism (mean 
dose 1.6±0.5μg/kg); 75% had a suppressed TSH (124). Ferretti et al also showed 
that half of the final thyroxine replacement dose was sufficient to suppress TSH 
secretion in 80% of patients with central hypothyroidism (128).  A normal, non-
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suppressed TSH, in the context of thyroxine replacement for central hypothyroidism, 
should raise the suspicion of an insufficient thyroxine dose.   
 
Beyond suppression of TSH, serum freeT4 is, currently, the most clinically 
useful measure of the adequacy of thyroxine replacement in central hypothyroidism. 
Limited evidence suggests that freeT4 concentration correlates well with clinical 
impression of thyroid status (127). Adjusting the dose of thyroxine with the aim of 
raising the serum T4 into the upper half of the reference range has been 
recommended by many experts (100). This is based on research data showing a 
high-normal serum freeT4 is associated with a more favourable metabolic 
phenotype (lower BMI, lower serum cholesterol) than a low-normal serum freeT4 in 
patients with central hypothyroidism (124).  
 
Serum freeT3 is less useful for judging thyroxine replacement in central 
hypothyroidism. In fact, serum freeT3 levels are sometimes low in this condition. 
This led investigators to assess the role of combined T3 and T4 treatment but this 
did not confer any metabolic advantages or an improved quality of life in 
comparison with T4 replacement alone (128). 
 
 Therefore, the limited utility of routine thyroid function test in central 
hypothyroidism, has led some investigators to evaluate the utility of peripheral 
biomarkers of thyroid hormone action as a means of assessing tissue exposure to 
thyroid hormone. Thyroid hormone receptors are expressed in virtually every tissue 
and a variety of biomarkers have been measured in both primary and central 
hypothyroidism (128). Serum markers derived from muscle, liver and bone, which 
are sensitive to the circulating concentration of thyroid hormone, have been most 
commonly evaluated. More recently, metabolic rate measurements and cardiac time 
intervals on echocardiography have demonstrated potential as biomarkers of thyroid 
hormone action.  
 
 
40 
 
 
1.7  Peripheral biomarkers of thyroid hormone action 
 
1.7.1  Serum biomarkers 
 
Sex hormone binding globulin 
 
Sex hormone binding globulin (SHBG) is a glycoprotein, produced by the liver,  
which acts as a transport protein for androgens and oestradiol in the plasma (129). 
The circulating concentration of SHBG is influenced by many factors including 
gender and age (130). Pre-menopausal women have a higher concentration in the 
plasma compared with men. SHBG levels are highest in the pre-pubertal boys and 
lowest in post-menopausal women (130). In vivo and in vitro studies have 
demonstrated that a variety of hormones can influence the plasma SHBG 
concentration. Testosterone suppresses, while 17βoestradiol stimulates, SHBG 
production  (131). Therefore, SHBG levels decline markedly during puberty in boys 
and following the menopause in women (132). Also, in vitro studies demonstrated 
SHBG inhibition by cortisol, prolactin, insulin and IGF-I (133-135). However, the 
plasma concentration of SHBG has also been shown to be particularly sensitive to 
the circulating thyroid hormone levels (136).  
 
Several human studies have demonstrated thyroxine to be a potent stimulus 
for SHBG production with higher concentrations observed in thyrotoxic patients and 
lower levels in patients with hypothyroidism (137, 138). Previous research has 
confirmed the utility of plasma SHBG as a marker of hepatic exposure to thyroid 
hormone. In patients with inappropriate TSH secretion, (hyperthyroxinaemia with a 
non-suppressed TSH) plasma SHBG determination has been promoted as a 
method of differentiating patients with thyroid hormone resistance (THR) from those 
with a TSH secreting pituitary adenoma (139). In the latter disease state, the patient 
is truly thyrotoxic and the liver will manufacture excessive amounts of SHBG. In 
contrast, in THR the liver is resistant to the action of thyroxine due to a germline 
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mutation in the gene encoding thyroid hormone receptor β and, therefore, will not 
produce excess SHBG despite high circulating levels of thyroid hormone (140).  
While circulating SHBG levels are considerably lower in patients with primary 
hypothyroidism, there is a paucity of clinical data in patients with central 
hypothyroidism. Limited clinical data suggest that the confounding effect GH and 
oestrogen may limit the utility of SHBG, as a marker of thyroid hormone action in 
hypopituitarism (110, 128). Isolated TSH deficiency is rare and the impact of other 
pituitary hormone deficiencies may confound the interpretation of SHBG levels. In 
particular, GH has been shown to influence SHBG production. GH deficient subjects 
have higher SHBG levels than age and gender matched controls, while patients 
with acromegaly a have lower circulating concentration (137, 141).  The interaction 
of GH and SHBG may have clinically important consequences with previous 
researchers suggesting that the higher SHBG levels in boys with isolated GHD may 
be responsible for the delay in pubertal development which often accompanies this 
condition - high SHBG level results in less tissue exposure to free androgens, 
including testosterone (142).  
 
There is inconsistent data on the effect of GH replacement on SHBG 
production. In non-hypopituitary, obese men, a continuous infusion of GH results in 
an acute suppression of circulating SHBG levels (143). In patients with 
hypopituitarism, various studies report that GH replacement either has no effect or 
suppresses SHBG levels. Studies in GHD children have shown that SHBG levels 
decline after GH replacement but this effect may take up to twelve months to be 
observed (141, 144). The effect of GH on SHBG levels in adult patients is 
conflicting; some studies show suppression similar to that observed in hypopituitary 
children and other studies, in hypopituitary women, report no changes in SHBG 
levels (145, 146). The conflicting results of studies in this field may be attributable to 
different study populations, with differing aetiology of GHD, as well as the 
confounding effect of alterations in other hormone levels i.e fluctuations in thyroid 
and sex hormone levels, both of which can influence SHBG production.  Overall, the 
literature supports a suppressive effect of GH on SHBG production from the liver.  
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It is unclear if GH directly suppresses SHBG production or whether this is 
dependent on IGF-1 which mediates most peripheral effects of GH. Previous ex 
vivo experiments in a hepatoma cell line have shown than IGF-1 can reduce SHBG 
production (135). However, the expression of IGF-1 receptors in human liver is 
believed to be considerably less than in hepatoma cells (147). Furthermore, human 
studies of GH replacement which have demonstrated a suppression of SHBG levels 
have failed to show a correlation between the rise in serum IGF-1 favouring a direct 
effect of GH on SHBG inhibition (145).  
 
 
Ferritin 
 
Serum ferritin is manufactured in the liver and widely distributed in the body. 
It is a well-established marker of hepatic iron stores. Many factors affect serum 
ferritin concentration - iron stimulates synthesis of ferritin, delayed hepatic uptake 
prolongs its clearance from the plasma and inflamed endothelial cells release the 
peptide into the circulation (148). In addition, serum levels display sexual 
dimorphism with higher levels observed in men.  
 
Several clinical studies have observed that serum ferritin levels are higher in 
patients with thyrotoxicosis and decline, in line with serum thyroid hormone levels, 
after treatment with anti-thyroid drugs (149). Similarly, thyroid hormone 
replacement, in patients with primary hypothyroidism, results in an increase in 
serum ferritin (150). Since several factors may influence serum ferritin 
concentration, the reference range in healthy individuals is quite broad and overlaps 
with that of the hyper- and hypothyroid range. Epidemiological research has failed 
to show an association between serum ferritin and thyroid hormone levels at a 
broad population level (151). However, there is generally a good correlation 
between longitudinal changes in thyroid hormone and ferritin concentration during 
treatment of thyroid disorders (150). This suggests that changes in the serum ferritin 
concentration reflect alterations of the thyroid status in individual subjects. The 
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effect appears to be is rapid and measureable after seven days of T3 replacement 
in hypothyroid patients.  
 
Serum ferritin has been used to try and differentiate thyroid hormone 
resistance from thyrotroph pituitary adenomas, in patients with inappropriate TSH 
secretion (152). However, there is very little data available for its use in patients with 
central hypothyroidism, either to detect those with mild TSH deficiency (in which T4 
levels are still maintained in the normal range) or to judge the adequacy of thyroxine 
replacement (128).  
 
The mechanism by which thyroid hormone influences serum ferritin 
concentration is poorly understood. Serum iron levels are not affected but the 
metabolism of iron and generation of ferritin may be altered by fluctuations in 
circulating thyroid hormone levels (30).  
 
Patients with GHD are reported to have low haematopoetic precursor cells 
and occasionally a normocytic anaemia (153, 154). Human and animal studies have 
shown that GH replacement has a beneficial effect on haemoglobin levels and red 
cell mass (155-157). Available data suggests that this is due to direct of GH/IGF-1 
on bone marrow (158, 159). The impact of GH replacement on serum ferritin has 
only been assessed in a small number of human trials with conflicting results. Some 
investigators found that serum ferritin declined after the introduction of GH 
replacement in adults (155, 160). They hypothesised that the stimulation of 
erythropoiesis by GH led to the consumption of iron stores and a consequent 
decline in serum ferritin. However, they did not report a correlation between the 
decline in serum ferritin and the rise in serum IGF-1 concentration. In addition, 
many patients in these studies were anaemic before starting GH replacement.  
Other authors have reported that serum ferritin levels did not change in children 
who received GH substitution despite an rise in haemoglobin and red cell number 
which showed a positive correlation with the rise in IGF-1 (156).   
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Therefore, serum ferritin has the potential as a biomarkers of the hepatic 
action of thyroid hormone in patients receiving GH replacement.    
 
 
Creatinine Kinase 
 
Muscle pain and stiffness is a common sign inpatients with hypothyroidism. 
Indeed, human studies have confirmed a clinically important myopathy, with 
impairment of muscle function and structure, in hypothyroidism (161). The muscle 
enzyme, creatinine kinase (CK), was first reported to be a marker of peripheral 
thyroid hormone action several decades ago (162, 163).  The original studies 
demonstrated a direct correlation between the degree of hypothyroidism and seum 
CK levels in overtly hypothyroid patients. Since then, it has been confirmed that CK 
is elevated in the serum of approximately 60% of overtly hypothyroid patients – 
usually less than ten times the upper limit of normal (164-166). A direct correlation 
between serum TSH and CK elevation is evident in both overt and subclinical 
hypothyroidism; however, statistically significant elevations of CK are usually 
confined to patients with overt hypothyroidism (167, 168). A direct relationship 
between circulating T4 levels and CK has been demonstrated in some but not all 
studies in this field (168-170). This may be due to marked inter-individual variation 
in serum CK activity in healthy individuals dependent on age, race, muscle mass 
and physical activity.  
  
Elevations in serum CK appear to occur early in the development of 
hypothyroidism and can be observed during a brief withdrawal of thyroid hormone 
for radioiodine treatment following thyroidectomy for thyroid cancer (171, 172). In 
addition, the release of large amounts of CK into the circulation, in extreme cases of 
profound hypothyroidism, has been reported to cause rhabdomyolysis and 
consequent renal failure in rare case reports (173, 174). Treatment of 
hypothyroidism, both primary and central, with thyroxine therapy has been shown to 
suppress serum CK (128, 175, 176). The relationship between serum CK and T4 
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levels in hyperthyroid patients is less well established, although some studies have 
also shown a correlation between T4 levels and CK in thyrotoxic patients (163).  
 
The mechanism whereby hypothyroidism leads to skeletal muscle damage 
and elevation of serum CK is not fully understood. Indeed, the mechanism may 
differ depending on the degree of hypothyroidism. Deregulation of mitochondrial 
oxidative function in muscle fibres occurs in the presence of subclinical 
hypothyroidism while overt hypothyroidism leads to more marked abnormalities of 
muscle metabolism including impairment of glycolysis and accumulation of glycogen 
(161, 177).  
 
Muscle is also a target for GH/IGF-1 signalling. GHD is associated with 
reduced lean skeletal muscle mass and reduced muscle strength (178). GH 
replacement has been shown to improve lean muscle mass while reducing fat mass 
(179). Prospective controlled trials of recombinant GH replacement in adulthood, 
using conventional, physiological dosing, have not reported any significant change 
in serum CK levels. However, serum CK levels can be elevated in active 
acromegaly and isolated reports of elevated CK have been reported in children 
receiving GH replacement (180, 181). The latter situation may be attributable to a 
high dose of GH or unrecognised central hypothyroidism.  
 
 
Trace elements  
 
It has long been observed that thyroid hormones can affect the homeostasis 
of trace elements including copper (Cu), selenium (Se), magnesium (Mg) and zinc 
(Zn) (182-184). Alterations in Se and Cu, in particular, appear to reflect the hepatic 
actions of thyroid hormone. Cu metabolism has been shown, in human and animal 
studies, to be regulated by thyroid hormone, principally through a direct hepatic 
effect on the regulation of the copper transport protein caeruloplasmin. Animal 
experiments have confirmed that administration of T4 increases hepatic 
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caeruloplasmin mRNA expression with a parallel increase in serum caeruloplasmin 
concentration (185). The induction of hypothyroidism in the animals produced the 
opposite effects on caeurloplasmin activity.  Similarly, serum Cu has been shown to 
correlate with serum thyroid hormone concentration in an animal model (186).  In 
human, clinical studies, serum Cu showed a significant positive correlation with T3 
and T4 before and after treatment of hyperthyroid patients with radioiodine 131I 
ablation  (187). Therefore, some investigators have suggested that serum Cu and/or 
caeruloplasmin could be useful markers of hepatic exposure to thyroid hormone.   
 
There is a complex relationship between serum Se and thyroid hormone 
levels. Se is an essential component of the iodothyronine deiodinase enzymes 
which are responsible for the peripheral activation of T4 to T3 and deactivation of 
into reverse T3.  All three deiodinase isoenzymes contain essential selenocysteine 
residues in their active site. The activity of these enzymes can be affected by 
severe selenium deficiency or marked alteration in selenium exposure (81, 82). 
Also, Se has an important, direct role in the thyroid hormone production in the 
thyroid gland - adequate Se intake increases the efficiency of thyroid hormone 
synthesis (188). The precise role of Se in thyrocytes is not clear but it may protect 
the thyroid peroxidase (TPO) enzyme from inactivation by degrading excess H202.  
 
Serum Se concentrations are mainly controlled by hepatically-derived Sepp, 
the Se transport protein accounting for most of the circulating Se in both humans. 
Some investigators have suggested that serum Se levels could be a reflection of the 
hepatic action of thyroid hormone. Mittag et al demonstrated, in a murine model, 
that thyroid hormone positively affects serum Se levels and regulates the production 
of several selenoproteins (189). The euthyroid sick syndrome (or non-thyroidal 
illness), observed in critically ill patients, provides a model for this theory. The 
syndrome is characterised by a down-regulation of the HPT axis with low serum 
TSH levels and T3 levels. Interestingly, circulating Se concentrations decline in 
parallel to the deranged HPT-axis in critical illness (190, 191). However, the trials of 
Se supplementation in critically ill patient have produced conflicting results. The 
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potential benefits of this treatment are still debated and the relationship between 
serum thyroid hormone levels and serum selenium is lost during Se 
supplementation (192-194).  
 
In addition, serum selenium status is altered in many thyroid conditions; low 
selenium levels have been reported in Graves’s and Hashimoto’s thyroiditis where a 
poor correlation exists between serum selenium and thyroid hormone levels (195). 
Therefore, given the complex interaction between Se and the HPT axis, Se as 
opposed to Cu, is less likely to be a reliable biomarker of thyroid hormone action. 
Indeed, both Se and Cu, along with caeruloplasmin, are acute phase reactants and 
are their production is responsive to inflammatory cytokines (196). This may limit 
their utility as thyroid hormone biomarkers in routine clinical practice. However, 
there are no studies to date which have analysed the utility of trace elements as 
markers of peripheral thyroid hormone exposure in patients with central 
hypothyroidism.  
 
 
There is a paucity of data regarding the impact of GH on Cu or Se 
metabolism. Preliminary studies in humans suggest that Cu metabolism is not 
significantly affected by GH replacement in adults (197, 198). A small, single study 
in patients with acromegaly found that caeruloplasmin activity, but not its plasma 
concentration, was significantly increased in patients with acromegaly in 
comparison with healthy controls. The authors concluded that the enhanced activity 
of caeruloplasmin may lead to greater oxidation of LDL particles in the serum and a 
consequent higher risk of atherosclerosis (199).  
 
The relationship between Se and GH appears more complex with data 
showing that plasma Se levels increased both with human GH replacement and 
following surgical treatment of acromegaly (197). Further evidence for a complex 
relationship between Se and GH is derived from historical data, which showed that 
rats fed a Se deficient diet had smaller pituitary glands with less immunopositivity 
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for GH than control animals fed a normal diet (200). Selenium can become 
deposited in the pituitary gland at very high serum concentrations where it appears 
to have a toxic effect on somatotroph function; this effect appears to be partially 
reversible (201). In humans, however, standard supplemental doses of selenium do 
not appear to impair GH release or IGF-1 generation in healthy subjects (202).  
 
 
Lipoproteins 
 
The relationship between lipid metabolism and thyroid status has been 
recognised for nearly 80 years (203). Thyroid hormone regulates some of the key 
enzymes involved in lipoprotein transport and metabolism. Thyroid hormone 
stimulates hepatic synthesis of cholesterol by inducing hydroxymethyl glutaryl co-
enzyme A (HMG CoA) reductase, resulting in an increased synthesis of cholesterol 
in hyperthyroidism and a reduction in hypothyroidism (204). However, thyroid 
hormone also affects with the degradation of low-density lipoprotein (LDL) 
cholesterol; thyroid hormone enhances the expression of LDL receptors on hepatic 
cell surface at an mRNA level and promotes clearance of LDL from the plasma 
(205, 206). The net effect is a decrease in serum LDL in hyperthyroidism and an 
increase in hypothyroidism (207). Therefore, hypothyroidism, both overt and 
subclinical, is an important cause of secondary hyperlipidaemia and may represent 
a risk factor for ischaemic heart disease.  
 
Thyroid status also regulates hepatic lipase and cholesterol ester transfer 
protein (CETP) (208). The latter enzyme is responsible for the net transfer of lipids 
between lipoproteins; specifically CETP transfers cholesterol esters between from 
high-density lipoprotein 2 (HDL2) to very low-density lipoprotein (VLDL) and 
intermediate-density lipoprotein (IDL) and conversely from triglyeride to HDL2. 
Hepatic lipase catalyses the conversion of HDL2 to HDL3. The differential effect of 
thyroid hormone on these two enzymes has resulted in conflicting results in respect 
of the impact of thyroid status on HDL. Serum HDL level has been reported normal 
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or elevated in hypothyroidism. However, the ratio of total to HDL cholesterol is 
normally increased (204).  
 
Lipoprotein (a) [Lp(a)] is rich in cholesterol ester and contributes modestly to 
the circulating pool of cholesterol. It contains a glycoprotein, apo(a) which has a 
high degree of homology with plasminogen and may compete with plasminogen at 
its receptor to promote the synthesis of plasminogen activator inhibitor 1 (PAI1) 
which has prothrombotic effects (209). Therefore, elevated Lp(a) levels have been 
linked with atherosclerosis. The effect of thyroid hormone on serum Lp(a) is 
controversial although some studies have shown suppression of Lp(a) levels in 
patients with over hypothyroidism receiving thyroxine replacement (210).  
 
Interestingly, there is generally a good correlation between serum LDL and 
the degree of thyroid failure, both in overt and subclinical hypothyroidism (211, 212). 
Also, changes in the lipid profile in hypothyroidism are reversible with treatment. 
Thyroxine replacement results in a significant decrease in total and LDL cholesterol; 
triglycerides and HDL:total cholesterol ratio remains unchanged (207, 213).   
 
The close relationship between thyroid status and certain serum lipoprotein 
levels, in particular LDL, makes changes in the lipid profile an attractive tool for 
monitoring the adequacy of thyroid hormone replacement in hypopituitary patients 
with central hypothyroidism. Higher serum LDL levels have been reported in 
retrospective studies of patients with secondary hypothyroidism (214, 215). In fact, 
the lipid profile in secondary hypothyroidism is reported to be more atherogenic than 
that in primary hypothyroidism, largely owing to lower HDL levels (216).  Previous 
research has shown that withdrawal of thyroid hormone in patients with central 
hypothyroidism, where serum T4 levels are allowed to fall into the sub-normal range 
leads to a significant rise in serum LDL levels; this is reversible upon reintroduction 
of thyroxine replacement. However, the authors did not report whether there was a 
significant negative correlation between the serum LDL and T4 (or T3) levels (128). 
Furthermore, a prospective trial in patients with central hypothyroidism, comparing a 
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body weight-adjusted dose of thyroid hormone with an empiric dose, resulted in a 
more euthyroid phenotype with the former dosing schedule; in particular, the lipid 
profile was more favourable with significantly lower total and LDL cholesterol levels 
(125). Taken together, this data suggests that the cholesterol may be a useful 
marker of thyroid hormone action in central hypothyroidism. However, the data in 
this field is not consistent. Research in patients with central hypothyroidism has also 
shown no significant difference in serum lipid profiles between patients taking a high 
dose (≥1.58μg/kg/day) versus low dose (≤1.18μg/kg/day) thyroxine replacement 
where T4 levels were maintained within the normal range (214). Most studies in this 
field have been retrospective in design and have not measured LDL or HDL 
subclasses. A more detailed assessment of the lipid abnormalities in patients with 
central hypothyroidism, with the measurement of lipoprotein subclasses, may better 
define the lipid phenotype in this cohort and allow refinement the thyroid hormone 
replacement regimen. 
 
Central hypothyroidism is typically a component of a multiple pituitary 
hormone deficiency syndrome and other pituitary hormone deficiencies may 
confound the interpretation of the lipid profile. Notwithstanding the suppressive 
effects of oestrogen on LDL cholesterol, there is a wealth of data confirming the 
influence of GH on the serum concentration of lipoprotein particles. An adverse lipid 
profile has long been recognised in both childhood onset and adult-onset GHD 
(217-219). Several placebo controlled trials have demonstrated that GH 
replacement in adulthood results in a reduction in circulating total and LDL 
cholesterol (220-222). However, the results of one study suggests the effect may be 
transient (29).  Animal studies and ex vivo studies have demonstrated that GH acts 
to recruit LDL receptors to the hepatic cell surface thus explaining the LDL lowering 
effects of the hormone.  
 
However, the effect of GH replacement on LDL concentration is likely to be 
modest. The original studies of GH replacement in adulthood used relatively high 
doses, based on weight, which would be considered excessive by contemporary 
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standards. A high replacement doses of 3U/m2/day only produced a fall of 12% in 
total serum cholesterol. In contrast, modern, open-label studies using dose titration 
of GH to maintain serum IGF-1 levels above the median, but within the age-
adjusted normal reference range, reported smaller, albeit significant, reductions in 
serum LDL (32). The LDL lowering effects of GH appear to be most marked in those 
with the highest baseline values.  
 
The effects of GH on HDL levels are more controversial. The baseline serum 
levels of HDL in adulthood onset GHD have been reported to be normal (29) and 
reduced (220) in different studies. Most studies have reported no change in HDL 
levels with GH replacements in adults although small increases have been recorded 
by some investigators (35, 220, 221). Overall, the effect of GH on HDL levels 
appears to be marginal, if present at all. Clinical trials of GH replacement have 
failed to show a significant effect on serum triglyceride levels. In addition, the 
association between acromegaly and hypertriglyceridaemia, as well as the 
observation that pharmacological (high-dose) GH treatment provokes a rise in 
serum triglyceride, strongly suggest that GHD is not a cause of 
hypertriglyceridaemia (223, 224). 
 
Lp (a) may also be affected by GH replacement. The data in this area is 
mixed, possibly due to assay variability (34). High dose GH replacement, in GHD 
and GH sufficient individuals results in a rise serum concentration of this 
atherogenic lipoprotein (35, 225). However, in keeping with the data on LDL 
lowering, the alterations in Lp(a) metabolism are less obvious at lower GH 
replacement doses (226).   
 
Overt and subclinical hypothyroidism have been associated with an elevated 
serum concentration of Lp(a) (227, 228). The direct effect of thyroxine replacement 
on modulating serum Lp(a) level is a matter of debate. However, limited research 
supports a suppressive effect of thyroxine (229). 
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A decline in serum freeT4 levels (often accompanied by a rise in serum T3) 
is common following commencement of GH replacement in both adults and children 
(61). The alterations in thyroid hormone metabolism, provoked by GH replacement, 
have led previous investigators to speculate about the selective effects of GH and 
thyroid hormone on the changes observed in the lipid profile. Limited data from a 
study of children suggests that the improvement in the lipid profile, expected with 
GH supplementation, becomes attenuated when GH induces a fall in serum T4 
(230). Data from the adult literature is mixed.  Klose et al , in a study of hypopituitary 
adults receiving GH replacement, reported that changes in total and LDL cholesterol 
correlated negatively with changes in serum freeT4 levels, even after correction for 
changes in serum IGF-1 and GH dosage (215). In contrast, Porretti et al found only 
a transient reduction serum freeT4 in apparently euthyroid patients following high-
dose GH replacement; however this was accompanied by a temporary reduction in 
total and LDL cholesterol (63). Finally, research from the UK reported no change in 
the lipid profile of patients who manifested central hypothyroidism after commencing 
GH replacement (62).  
 
The conflicting results from different studies may be due to different GH 
dosing schedules, variable patient characteristics across different cohorts or the 
confounding effect of additional pituitary hormone deficits. Recent research data 
from animal studies has given new insights into the selective effects of GH and 
thyroid hormone on the serum lipid profile in hypopituitarism. Hypophysectomised 
rats displayed markedly increased intestinal cholesterol absorption which is 
normalized following replacement with thyroid hormone but not with cortisol or GH 
(231). However, there is no human data to support this finding. Overall, in view of 
the increased cardiovascular mortality reported in patients with hypopituitarism, the 
relative impact of GH/IGF-1 and thyroid hormone on the lipid alterations in observed 
following GH replacement warrants further investigation (4).  
Bone turnover markers 
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Bone is a metabolically active tissue that undergoes a continuous cycle of 
remodelling. Bone formation by osteoblasts and bone resorption by osteoclasts are 
tightly coupled processes; normally the bone resorption phase, which last ten days, 
is followed by a longer period of bone formation, lasting up to three months. These 
integrated processes are critical to the maintenance of bone integrity and are 
usually regulated by systemic hormones (parathyroid hormone, Vitamin D) and local 
cytokines and growth factors in bone.  Uncoupling of these processes can lead to 
changes in bone strength and mass. A variety of biochemical markers of bone 
turnover can be measured in serum and/or urine (Table 1.2). In general, they are 
classified according to the metabolic bone process they best reflect.  
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Table 1.2 
 
Serum & urine bone turnover markers (BTMs) measured in routine clinical practice 
and research. They are classified according to the metabolic bone process they 
best reflect. BMTs are measured in the serum unless stated otherwise. 
 
Bone formation markers Bone resorption markers 
Osteocalcin (OCI) C-terminal type I collagen 
telopeptide (CTX-1) 
N-terminal propeptide of type 1 
procollagen (P1NP) 
Aminoterminal crosslinked 
telopeptide of 
type I collagen 
(NTX-I) 
C-terminal propeptide 
of type I procollagen 
(P1CP) 
Urine and serum pyridinoline 
Bone-specific alkaline phosphatase 
(BALP) 
Urine and serum deoxypyridinoline 
 Urine hydroxyproline 
 Tartrate-resistant acid 
phosphatase 
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Serum markers of bone formation include bone-specific alkaline phosphatase 
(BALP), osteocalcin and N-terminal propeptide of type 1 procollagen (PINP). BALP 
is a membrane-bound enzyme of osteoblasts. Its exact physiological role is not 
clear although it appears to play an important role in osteoid formation. It has been 
commonly measured in serum for many decades as a marker of osteoblast activity 
and is a useful clinical marker of both mineralisation defects (osteomalacia) and 
abnormal remodelling (such as Paget’s disease). However, assay interference has 
limited the utility of BALP with some assays displaying up to 20% cross-reactivity 
with liver-derived alkaline phosphatase, particularly in those with raised liver 
enzymes. More specific serum markers of bone formation are now available.  
 
P1NP is derived from precursor of Type 1 collagen which account for 90% of 
bone matrix. Type 1 procollagen contains both N (amino) and C (carboxy) terminal 
extensions which are cleaved by proteases during the conversion to Type 1 
collagen. Thus, measurement the N-terminal (P1NP) is a marker of collagen 
deposition and bone formation. Type 1 collagen propeptides may arise from other 
tissues including skin, dentine and blood vessels. However, the turnover of collagen 
in these tissues is much slower than bone such that they do not contribute 
significant quantities to the circulating pool of P1NP.  
 
Osteocalcin is a bone-specific, non-collagen protein which is produced by 
osteoblasts. Its production is dependent on Vitamin K – it has three Vitamin K 
dependent gammacarboxyglutamic acid residues which are responsible for the 
calcium binding properties of the protein. After secretion by osteoblasts it is 
incorporated into bone matrix and secreted into the circulating plasma. Intact 
osteocalcin (1-49 amino acids) and the N-MID fragment (1-43 amino acids) circulate 
in the plasma. However, the intact molecule is unstable due to protein cleavage 
between amino acids 43 and 44. The N-MID fragment is more stable and amenable 
to in vitro measurement as a marker of osteoblast function and bone formation.  
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The majority of bone resorption markers are degradation products of bone 
collagen. During normal bone turnover mature type 1 collagen is degraded by 
osteoclasts and breakdown fragments are released into the circulation and excreted 
via the kidneys. Amongst these breakdown products are the cross linked 
telopeptides of type 1 collagen – carboxyterminal and aminoterminal telopeptides. 
Several immunoassays are now available for measurement of carboxyterminal 
telopeptides of type 1 collagen with antibodies directed against a variety of 
epitopes.   An ELISA (termed β-CTX) recognises the C-terminal type I collagen 
telopeptide containing an isoaspartyl (β-aspartyl) peptide bond in its L-enantiomeric 
form. The β−L-aspartyl is believed to result mainly from the ageing of extracellular 
proteins. These isomerized telopeptides are highly specific for the degradation of 
type I collagen dominant in bone. Serum levels rise in patients with increased bone 
resorption and decline with anti-resorptive therapy. 
 
The bone remodelling cycle in adults is sensitive to numerous hormonal 
stimuli; oestrogen, in particular, has powerful anabolic effects on bone metabolism 
by stimulating osteoblasts in premenopausal women. However, GH, thyroxine and 
glucocorticoids also have a significant impact on bone remodelling, emphasising the 
complex effects of hypopituitarism, and its treatment, on bone health.  
 
Most of the data concerning the relationship between markers of bone 
turnover and thyroid hormone is derived from studies of hyperthyroid patients. Overt 
thyrotoxicosis has long been associated with enhanced bone remodelling, 
osteoporosis and an increased risk of fracture (232). Biochemical markers of bone 
formation (serum BALP & osteocalcin) and resorption (CTx1, urinary pyridinoline 
and hydroxyproline) are elevated although the net effect is clearly one of resorption 
(233, 234). Interestingly, the degree of elevation of bone turnover markers 
correlates with disease activity as reflected by serum thyroid hormone levels (234). 
Serum and urine concentration of bone turnover markers decline when a euthyroid 
state is restored.  
 
57 
 
 
Most studies in subclinical hyperthyroidism have reported a lower BMD but 
the data in respect of bone biomarkers is conflicting. Some investigators have 
reported similar findings to those in overt hyperthyroidism, with elevation of bone 
turnover markers and a good correlation between the markers (235, 236). However, 
other studies have not found any difference between bone biomarkers in patients 
with subclinical hyperthyroidism in comparison to controls (237, 238). This may 
relate to differences in the definition of subclinical hyperthyroidism. 
 
Research in patients with primary hypothyroidism has confirmed the negative 
correlation between serum TSH and markers of bone turnover (239). Treatment of 
hypothyroidism increases BTMs; in contrast BTMs in urine and serum decline after 
withdrawal of thyroxine therapy.  
    
Further evidence for the potential utility of bone biomarkers as markers of 
peripheral thyroid hormone action is provided by studies examining the effect of 
thyroid hormone therapy in athyrotic patients. Patients receiving suppressive doses 
of thyroxine, often following treatment of thyroid cancer, have higher serum/urine 
concentration of bone turnover markers than matched euthyroid controls. Research 
data shows that both done resorption markers (CTX, urine hydroxyproline) and 
bone formation markers (PINP, BALP, osteocalcin) increase when 
supraphysiological doses of thyroxine are used to suppress TSH (234, 240-243). 
One notable exception is the study by Marcocci et al where bone turnover markers 
were comparable to controls when the absolute minimal dose of thyroxine was used 
to suppress TSH (244). When thyroxine therapy is withdrawn there is a rapid 
decline in the concentration of bone turnover markers within a few weeks 
demonstrating that these markers are highly and rapidly responsive to fluctuations 
in serum thyroid hormone levels.  However, in athyrotic patients taking thyroid 
hormone, changes in serum thyroid hormone concentration do not consistently 
correlate with fluctuations in the level bone turnover makers. Therefore, these 
markers of peripheral thyroid hormone action may be more useful in patients with 
endogenous hyper/hypothyroxinaemia.  
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Limited research has explored the clinical usefulness of bone turnover 
markers in the diagnosis and management of central hypothyroidism. Ferretti et al 
found that withdrawal of thyroxine replacement, in a cohort of patients with central 
hypothyroidism, led to a significant decrease in both a serum bone resorption 
(ICTP) and a marker of bone formation (bone GLA protein) when freeT4 levels 
declined below the reference range (128). The levels of serum bone biomarkers 
rose when the full replacement dose of thyroxine was restored. Furthermore, the 
investigators report a strong correlation between the serum level of bone turnover 
markers and serum freeT4 and or freeT3. Other pituitary hormone replacement was 
not altered during the study; in particular, subjects did not receive GH replacement. 
Persani et al also showed highly significant correlations between serum levels of 
carboxyterminal terminal telopeptide of Type 1 collagen (ICTP) and freeT4 and T3 
in patients with central hypothyroidism (245). This study also highlighted the utility of 
bone turnover markers, as indices of thyroid hormone action, when investigating 
patients with inappropriate secretion of TSH. After ruling out laboratory assay 
interference, the clinical challenge is to differentiate patients with thyroid hormone 
resistance from patients with a TSH secreting pituitary adenoma.  Data in this 
specialised field indicate that markers of bone turnover can help differentiate the 
two diseases, further emphasising the utility serum/urine bone indices as 
biomarkers of thyroid hormone action.  
 
 
Hypopituitarism in adulthood is associated with osteopaenia; bone mineral 
density (BMD) at the lumbar spine and femoral neck is approximately 10% lower in 
hypopituitary patients than in age-matched controls. The relative effect of GHD, in 
comparison with hypogonadism and over replacement with thyroid hormone or 
glucocorticoids is controversial. However, a role for GH in maintaining bone mass is 
implied by the positive correlation recognised between bone density and serum 
IGF-I concentration (44, 246). In addition, ex vivo evidence supports the theory that 
GH stimulates osteoblast differentiation and proliferation in humans (247). 
Furthermore, serum markers of bone formation –BALP and osteocalcin – are lower 
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in adults in GHD (38, 248). There are inconsistencies in the data related to the risk 
of fracture; however several studies support an increased risk of nonvertebral and 
morphometric vertebral fracture in GHD patients, independent of the presence of 
additional pituitary hormone deficiencies (249-251). 
  
The effect of GH on bone marker indices has been extensively studied. 
Evidence suggests that bone remodelling is increased by GH replacement in 
adulthood. Serum markers of bone formation – BALP, osteocalcin, P1NP - increase, 
as do markers of bone resorption – CTX1, pyridinoline, deoxypyridinoline and 
hydroxyproline (29, 45, 46, 252-254). The initial increase in bone turnover with GH 
replacement increases the bone remodelling space; bone resorption precedes 
formation leading to a transient reduction in BMD during the first few months of 
treatment (255). The original trials, demonstrating an increase in bone turnover 
markers with GH replacement, were conducting in patients with childhood-onset 
GHD using pharmacological doses of GH. However, more recent studies in patients 
with adult-onset GHD, have confirmed the effect of GH substitution on serum and 
urine markers of bone turnover using physiological doses.  
 
Baum et al, in a 18 month prospective, placebo controlled study showed, on 
average, a doubling of serum osteocalcin and urine pyridinoline concentration in 
adults treated with GH compared with controls (46). This was accompanied by a 5% 
and 2.4% accrual of bone density in the lumbar spine and femoral neck 
respectively. These findings were confirmed by Hansen et al who showed a 
significant rise in serum bone formation markers BALP, OCI among adults receiving 
GH replacement when compared with placebo treated controls; bone resorption 
markers including serum CTX1 and urinary pyridinoline also increased significantly 
in the GH treated group (253). However, there was no clear correlation between the 
rise in serum IGF-1, induced by GH replacement, and the alteration in bone 
formation markers. Also, contemporary studies have also shown a sexually 
dimorphic effect of GH on bone mass in adults. In men, GH replacement clearly 
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improves BMD but in women the effect appears to be stabilise BMD despite similar 
increments in bone turnover markers.  
 
Therefore, it is clear that bone turnover markers are sensitive to circulating 
changes in thyroid hormone and GH/IGF-1. However, the relative influence of GH 
and thyroxine replacement, in hypopituitary adults, on bone mass and bone 
turnover markers has been under-researched. In addition, bone biomarkers may 
provide useful insight into the clinical significance of the changes in the HPT axis 
following GH replacement.  
 
 
1.7.2  Resting Energy Expenditure 
 
 
Resting energy expenditure (REE) is the rate of fuel energy consumption by 
a resting individual without the effect of meal consumption or physical activity. In 
humans, it accounts for approximately 60% of total energy expenditure and 
metabolic processes such as maintenance of transmembrane ion gradients and 
resting cardiometabolic activity. Non-resting energy expenditure is mainly in the 
form of physical activity and accounts for approximately 30% of total energy 
expenditure. The remaining 10% of energy expenditure is associated with the 
thermic effect of feeding (256). 
 
The effect of thyroid hormone on thermogenesis and metabolic rate was first 
described over a century ago (257). Since then, several theories have been 
explored to explain the stimulatory effect of thyroid hormone on resting energy 
expenditure (258). Na/K ATPase activity, which maintains the essential 
transmembrane ionic gradient, appears to be stimulated by T3 administration and 
this may account for part of the thermogenic effect of the hormone (259). Increased 
calcium cycling across the cell membrane of skeletal muscle cells is stimulated by 
T3; this process has high energy demands and may also contribute to the rise in 
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REE induced by thyroid hormone (260). Interactions between thyroid hormone and 
mitochondrial energy transfer, which have been extensively investigated, appear to 
have a less important influence on REE than originally expected (258).  The 
augmentation of REE by thyroid hormone is, of course, clinically apparent in overt 
thyroid dysfunction. In particular, thyrotoxicosis is characterised by weight loss 
when an increase in metabolic rate stimulates several synthetic and catabolic 
pathways. Ultimately, an increased appetite is often insufficient to compensate for 
the increased fuel demands of an accelerated metabolic rate (261) . In contrast, 
profound hypothyroidism can result in a 25% reduction in REE in humans (138).  
 
More subtle abnormalities in the circulating concentration of thyroid hormone 
can also have an impact on metabolic rate. Al-Adsani et al varied the dose of 
thyroxine replacement in patients with primary hypothyroidism and measured 
resting energy expenditure (REE) at various TSH levels (262). Serum free T4 
remained within the normal reference range throughout – akin to subclinical thyroid 
dysfunction. The investigators showed a significant change in REE with alteration in 
the replacement dose of thyroxine and a negative correlation between serum TSH. 
However, there was no clear relationship between REE and induced changes in 
circulating T3 or T4. The authors speculated that the locally generated, tissue 
concentration of T3, generated by deiodination of T4, may be more important than 
the circulating concentration thyroid hormone in regulating energy expenditure. This 
theory is supported by animal data; in rodents, brown adipose tissue thermogenesis 
depends largely on locally generated T3 by DIO2 (263).  
 
The relationship between REE and degree of thyroid dysfunction may be 
useful as a marker of peripheral thyroid hormone action. However, there is scant 
data on the performance of this biomarker in patients with central hypothyroidism. 
The relationship between TSH and REE appears to be more consistent than 
between serum T3/T4 and REE. Also, the confounding effect of other pituitary 
hormones, most notably GH, may present difficulties interpreting REE 
measurements in hypopituitary patients.  
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GH has undoubted stimulatory effects on REE independent of changes in 
lean body mass. A placebo controlled trial, in healthy subjects, reported an increase 
in REE after a five hour intravenous infusion of GH with concomitant use of a 
euglycaemic clamp (264). Furthermore, several lines of evidence confirm that 
resting energy expenditure is increased following GH replacement in GHD adults 
(265-268). Conversely, metabolic rate is increased in patients with acromegaly 
(269). The mechanism whereby GH increases REE is not fully understood although 
some authors have suggested that the GH induced changes in the HPT axis may, 
at least in part, explain the rise in REE (65, 67).  
 
Several studies have demonstrated a rise in serum T3 with GH substitution in 
adults and children (63, 67, 270-273).  In a six month study measuring the response 
of basal metabolic rate (BMR) to GH replacement, the rise in serum free T3 was 
positively correlated with BMR (67). However, in vivo experiments show that 
administration of T3 alone, to healthy subjects, does not fully mimic the GH induced 
rise in REE(274). This implies that GH has an independent effect on REE. 
Interestingly, the stimulation of REE may be an independent effect of GH; 
administration of IGF-1 alone leads to a less pronounced rise in REE in comparison 
to GH which may be due to the suppressive effect of IGF-1 on insulin (275). Some 
investigators have suggested that direct effects of GH on protein synthesis may 
account for the rise in REE (179). However, GH replacement also raises cardiac 
output; the consequent increased blood flow to skeletal muscle, among other 
organs, may well account for the stimulation of REE (276, 277).   
 
The positive relationship between GH and REE is emphasised by research in 
acromegaly. Previous studies in human subjects have shown that REE is increased 
in active acromegaly in comparison with BMI-matched health controls (269). 
Furthermore, REE was elevated in proportion to serum IGF-1 and declined with 
successful treatment of acromegaly.  
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1.7.3 Cardiac structure and function  
 
Thyroid hormone has both direct and indirect effects on the cardiovascular 
system. The hormone can stimulate cardiac contractility directly (278).The direct 
cardiac effects of thyroid hormone are mainly mediated through interaction of T3 
with the thyroid hormone nuclear receptor. However, non-genomic mechanisms 
also appear to be important.  
 
Recent animal studies have found that the alpha isoform of the thyroid 
hormone receptor (TR) predominate in the heart (279). Once the T3–occupied 
receptor binds to thyroid hormone responsive elements (TREs) of cardiac myocyte, 
DNA transcription of many T3-responsive myocardial genes ensues. The 
expression of the sarcoplasmic reticulum Ca2+ATPase is induced by T3 in 
myocytes. The result is a more efficient removal of Ca2+ from the cytosol leading to 
enhanced systolic contractile function and faster diastolic relaxation in the 
hyperthyroid heart (280). Thyroid hormone, via its nuclear action, can alter the 
balance of contractile proteins including myosin. A healthy heart contains all three 
myosin isoforms - V1, V2 and V3 - whereas in hypothyroidism the V3 predominates 
(281). The myosin ATPase activity of V3 is lower than V1 and V2 resulting in a 
decreased velocity of contraction of hypothyroid heart muscle. Conversely, T3 
promotes V1 myosin formation in the hyperthyroid heart leading to accelerated 
contraction.  
 
Non-genomic effects of thyroid hormone also appear to be important in the 
myocardium. In particular, T3-induced changes in ion flux can be demonstrated 
within several minutes. The activity of plasma membrane Na+/K+ATPase, which 
extrudes Na+ from the cell in exchange for extracellular K+, is promoted by T3 which 
alters the electrochemical and mechanical performance of the myocardium (280). 
 
  T3 also acts directly on vascular smooth muscle to cause vasodilatation and 
a reduction in peripheral arterial vascular resistance (282).  The direct consequence 
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of reduced systemic vascular resistance is an effective deficit in arterial filling; this 
leads to activation of the renin, angiotensin, aldosterone system with renal salt 
retention (283). Thyroid hormone also stimulates erythropoietin production (278). 
The combined effect results in an increase in blood volume and augmentation of 
cardiac output (284). Finally, conflicting evidence exists about the interaction 
between thyroid hormone and the sympathoadrenal system. However, the balance 
of evidence suggests that there is enhanced sympathetic sensitivity in 
hyperthyroidism which may be mediated through an increased number of β-
adrenergic receptors on the myocardium (280).  
 
The effect of thyroid hormone on systolic function has been quantified by 
previous researchers. Myocardial systolic time intervals have been shown to be 
particularly sensitive indicators of cardiac exposure to thyroid hormone. These can 
be measured non-invasively and are independent of heart rate (285). However, they 
can be affected by changes in blood pressure and some indices, in particular the 
myocardial performance index (see below) increases with age (286, 287). 
Historically, measurement of cardiac cycle time intervals was required the combined 
use of electrocardiography, phonocardiogram and pulse tracing (288). However, 
modern Doppler echocardiography can easily measure these time indices. This 
cardiac imaging technique is already in widespread clinical use; it is convenient, 
non-invasive and inexpensive for both patient and clinician.  
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Figure 1.2  
 
Cardiac time intervals on echocardiography and electrocardiogram. 
 
ICT (isovolumetric contraction time). This is the time when the ventricles have 
begun to contract, but the volume of the chambers has not yet changed. It occurs 
immediately after the period of electromechanical delay, following electrical 
stimulation of the ventricles.  
 
IRT (isovolumetric relaxation time). This occurs at the end of systole when the semi-
lunar valves shut and the ventricles relax; this results in a fall in the intraventricular 
pressure, initially with no change in the chamber volume.  
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Figure 1.2 (contd) 
 
ET (ejection time). After the semilunar valves open, the ventricles can eject the 
stroke volume into the systemic circulation during a period known as ET. 
 
Myocardial performance index (MPI) is also known as the Tei index. It incorporates 
both systolic and diastolic time intervals in expressing global systolic and diastolic 
ventricular function. MPI = (ICT+IRT)/ET. 
 
Interval a (from cessation to onset of mitral inflow) is equal to the sum of 
isovolumetric contraction time (ICT), ejection time (ET) and isovolumetric relaxation 
time (IRT).  
 
Left ventricular ET (b) is the duration of left ventricular outflow velocity profile. Thus, 
the sum of ICT and IRT was obtained by subtracting the time interval b from a.  
 
MPI was calculated as (a -b)/b. 
 
 IRT was measured by subtracting the interval d (time between the peak of the 
electrocardiographic R wave and cessation of LV outflow) from interval c (between 
R wave and onset of mitral inflow). 
 
Isovolumetric contraction time (ICT) is obtained by subtracting IVRT from (a -b).  
 
Reproduced with permission of Elsevier Publishing (289).  
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Primary hypothyroidism and hyperthyroidism have been shown to have 
opposing effects on systolic time intervals. The isovolumetric contraction time 
(IVCT) is prolonged and MPI is increased in hypothyroidism and vice versa (290). 
The left ventricular ejection time (ET) is shortened in hypothyroidism with a resultant 
increase in ICT:ET ratio (290). These abnormalities are reversible with restoration of 
the euthyroid state. Studies in primary subclinical hypothyroidism have also 
confirmed the significant prolongation of systolic time intervals which are normalise 
in parallel with TSH following replacement with thyroxine (291-293). 
  
Limited data suggests that measurement of systolic time intervals in patients 
with hypopituitarism may be useful for the diagnosis and management of central 
hypothyroidism. Doin et al showed that adult patients with overt central 
hypothyroidism (i.e. low serum free T4 concentration in presence of low or normal 
TSH level) had a significantly prolonged ICT with a higher MPI in comparison with 
controls. ICT correlated negatively with serum freeT4 levels. Also, the change in 
ICT was proportional to the rise in serum freeT4 after thyroxine replacement was 
commenced or the dose adjusted  (289). Using ROC curve analysis the authors 
found that IVCT > 53ms and ICT/ET ratio >0.18 had an accuracy, positive and 
negative predictive values of 90, 96 and 84% respectively. When this prediction tool 
was applied to patients with primary subclinical hypothyroidism, the serum TSH was 
in agreement with the systolic interval prediction model in 80% of cases. When the 
model was extended further to a group of patients with hypopituitarism, who had a 
serum freeT4 in the normal reference range, it was estimated that 56% had 
subclinical hypothyroidism.    
 
The utility of systolic time intervals, as markers of peripheral thyroid hormone 
exposure, has been further emphasised in a study of children and adolescents with 
GH deficiency. Martins and colleagues showed that thyroxine replacement in 
children with central hypothyroidism resulted in shortening of the IVCT to a time 
comparable to control subjects (294). Interestingly, the investigators found an 
inverse correlation between serum total T3 and IVCT in children receiving GH 
68 
 
 
replacement; no such correlation was appreciable in GHD children not 
supplemented with GH. This led the authors to speculate that the GH improved the 
biological effects of thyroid hormone. However, prospective analysis of a seven 
children receiving GH replacement did not show a significant correlation between 
the shortening of IVCT and either the rise in serum totalT3, the fall in freeT4 or the 
rise in IGF-1.  
 
GH has specific effects on myocardial structure and function. Experimental 
studies in animals found that found evidence IGF-I, as opposed to GH, augmented 
myocardial contractility by sensitizing myofilaments to calcium ions (295). Also, IGF-
1 retards cardiac myocyte apoptosis (296). Clinically, the effect of GH on the heart 
is most apparent in acromegaly where excess GH causes a specific 
cardiomyopathy with initial hyperkinesis, left ventricular hypertrophy and diffuse 
interstitial fibrosis (41). If untreated, this progresses to diastolic dysfunction and 
congestive cardiac failure. In contrast, effect GHD on the structure and function of 
the human heart has been a matter of some controversy. Several cardiac 
parameters have been reported to be abnormal in patients with GHD including a 
reduced left ventricular mass (LVM), ejection fraction (EF) and fractional shortening 
(the degree of shortening of the left ventricular diameter between end-diastole and 
end-systole) (39, 40). However, these abnormalities have not been consistently 
reported and may be more marked in CO-GHD in comparison with AO-GHD. In 
addition, the abnormalities, appear to be subtle and are more easily detected with 
equilibrium radionuclide angiography than conventional echocardiography (297).  
 
A recent meta-analysis examined the results of 16 studies which used 
echocardiogram to measure the effect of GH replacement in adults on a variety of 
indices of ventricular structure and function (298). The results confirmed and 
improvement in LVM, interventricular septal thickness, left ventricular end-diastolic 
diameter and stroke volume. Overall, there was no effect of GH replacement on 
either IRT or fractional shortening. However, studies of the effect of GH on the heart 
have not routinely assessed the impact on systolic time intervals which are known 
69 
 
 
to be sensitive biomarkers of thyroid hormone action. This approach may be useful 
to determine the selective effects of GH and thyroid hormone, on the heart, in 
hypopituitary patients.  
 
 
1.7.4 Quality of life 
 
Biochemical and echocardiographic measurements give little insight into 
patient symptoms or well-being. Modern healthcare places a greater focus on 
patient reported outcomes (PROs). Self-assessment of health status, using generic 
or disease-specific tools, provides insight into the quality of life (QOL) deficits in 
particular diseases. Furthermore, PROs provide a useful assessment of the impact 
of therapeutic interventions. 
 
Previous research has demonstrated a convincing association between 
hypopituitarism and poor health-related quality of life (QOL) (299). Van der Kalaauw 
et al compared 403 pituitary patients with treated acromegaly (n=118), treated 
Cushing’s disease (n=58), prolactinomas (n=128) and non-functioning pituitary 
adenoma (NFPA) (n=99) to 82 subjects with paraganglionoma and to 440 healthy 
controls from similar socio-economic backgrounds (300).  All QOL subscales were 
reduced in patients compared to controls and the presence of hypopituitarism 
negatively influenced the total QOL score. When QOL measures in pituitary patients 
were compared to the paraganglionoma subgroup, but with no pituitary disease, 
there was no difference in overall QoL score. However, patients with pituitary 
adenomas experienced greater impairment in the following subscales of quality of 
life:  role functioning due to emotional and physical problems on the Short Form 36 
(SF 36), more pain and impairment in physical ability in the Nottingham Health 
Profile (NHP); the authors suggest that hypopituitarism and imperfect endocrine 
replacement may be a contributing factor to these altered QOL findings.  
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Nielsen et al examined 109 patients with a history of NFPA, 27% of whom 
were panhypopituitary and 46% with less severe hypopituitarism (301). They were 
unable to demonstrate any decrease in QOL compared to healthy controls, except 
in those who had undergone craniotomy. In contrast, Dekkers et al found multiple 
pituitary hormone deficiency to be an independent predictor of impaired QoL, 
especially with respect to social and physical functioning and increased general 
fatigue in a group of 99 subjects with a history of NFPA (302). The difference in 
findings between these studies may be due to the higher rate of hypopituitarism in 
Dekkers’ study where 93% had some degree of hypopituitarism and 48% were 
panhypopituitary compared to 73% and 27% in Nielsen’s group respectively.  
 
In addition to the syndrome of panhypopituitarism and multiple pituitary 
hormone deficiencies, deficiency of individual pituitary hormones including ACTH, 
gonadotrophins, GH and TSH have been linked with impaired QOL. Therefore, the 
selective utility of QOL scores in assessing the clinical impact of alteration in thyroid 
and growth hormone exposure is controversial.  
 
Impaired health-related QOL is a well-recognised feature of the syndrome of 
adult GHD (303). Many of the original, placebo-controlled studies of GH 
replacement demonstrated an improvement in QOL when assessed using a generic 
health status questionnaires (49, 51). More recent, open label studies, which used 
doses of GH now considered excessive, have also recorded an improvement in 
QOL (54, 304). Interestingly, there does not appear to be a clear dose response, in 
terms of QOL, with GH replacement. Subjects treated with high-dose GH – many of 
whom achieved a serum IGF-1 level exceeding the upper limit of the reference 
range - gained a similar improvement in well-being as subjects with a IGF-1 
maintained within the normal range while receiving lower doses of GH (54).  More 
recently, the disease specific tool, AGHDA, has shown a high degree of specificity 
and reproducibility in measuring well-being in GHD adults (55, 305). Contemporary 
practice in many countries mandates demonstration of poor QOL, using the AGHDA 
self-assessment tool, to warrant GH replacement in adulthood and clear evidence of 
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an improvement in QOL, after three to six months, to justify long-term prescription of 
GH. Therefore, the measurement of QOL is a key clinical parameter in the 
monitoring of GH replacement in adulthood. The possible confounding effect of 
other hormonal deficiencies in the measurement of QOL, in particular thyroid 
hormone deficiency, is worthy of consideration.   
 
Primary hypothyroidism has a clear association with an impaired sense of 
well-being (306). There is clear data supporting an impaired quality of life in patients 
with overt hypothyroidism. However, the evidence in subclinical hypothyroidism is 
conflicting (307). This may be due to the differences in the populations studied and 
length of follow-up as well as a variable definition of subclinical hypothyroidism. 
Furthermore, generic health questionnaires may have a poor sensitivity for 
detecting QOL deficits in hypothyroidism as studies using variable doses of 
thyroxine to target different TSH values, within the normal reference range did not 
detect a difference in health-related QOL (308). Recently, some investigators have 
validated disease-specific questionnaires in attempt to further characterise deficits 
in QOL in patients with thyroid dysfunction (309, 310). Further complicating the 
relationship between thyroid hormone deficiency and QOL is the finding that a 
significant minority of patients “adequately” treated for primary hypothyroidism 
continue to report an impaired sense of well-being (311, 312).  
 
Cast against this complex interaction between GH, thyroid hormone and 
QOL is a paucity of data in the field of central hypothyroidism. Slawick et al 
compared three doses of thyroid hormone replacement in patients with central 
hypothyroidism (n=29), not receiving concomitant GH replacement (125). Two body 
weight adapted (1.6µg/kg) replacement doses (one regimen of T4 only and one of 
combined T4 and T3) were compared to an empiric dose of T4. Overall, there was 
no difference in the QOL parameters measured using generic questionnaires 
including SF 36. Interestingly, serum T3 levels were supra-therapeutic in the 
regimen including T3 replacement; however, this did not appear to have an impact 
on self-reported health status. 
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Recent research on patient reported outcomes has shed new light on the 
clinical importance of changes in the thyroid axis induced by GH replacement. Agha 
et al described the unmasking of central hypothyroidism in 36% of adults, previously 
considered euthyroid after commencing GH replacement according to a standard 
clinical protocol (62). Patients who became hypothyroid after GH replacement had a 
higher AGHDA score (indicating poorer QOL) after three months than those who 
remained euthyroid. Following T4 replacement, AGHDA score were equivalent in 
both groups. This preliminary evidence suggests that self-assessed QOL – a key 
clinical metric in the evaluation of GH replacement in routine practice – is 
significantly affected by concurrent modulation of the HPT axis. Further research is, 
therefore, warranted to further elucidate the selective effects of GH and thyroid 
hormone on well-being and patient reported outcomes in hypopituitary subjects. 
 
 
1.8 Aims of the thesis 
 
The aims of this study are as follows: 
 
1. Prospectively examine the impact of physiological GH replacement on 
changes in the HPT axis in hypopituitary adults 
 
2. Define the mechanisms underlying changes the serum concentration of 
thyroid hormones, provoked by GH replacement, by measuring: 
 deiodinase enzyme activity in subcutaneous fat  (adipose tissue was 
selected for tissue analysis due to ease of accessibility in human subjects 
 TSH, thyroid binding globulin and thyroglobulin levels.  
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3. Investigate the clinical importance of changes in the thyroid axis, during GH 
replacement in adults, by measuring the parallel response among a variety of 
peripheral biomarkers of thyroid hormone action including: 
 serum biomarkers derived from liver and bone 
 serum creatinine kinase 
 resting energy expenditure 
 cardiac time intervals on echocardiography 
 health-related quality of life 
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Chapter 2 
 
 
Methodology 
 
 
2.1 Identification and recruitment of study subjects 
 
When eligible patients attended the pituitary out-patient clinic in Beaumont Hospital 
for a routine scheduled appointment, they were informed of the study aims and 
protocol. If they were willing to be assessed for eligibility then they were assessed 
for inclusion and exclusion criteria described below.  
 
If the patient was deemed an appropriate candidate by inclusion and 
exclusion criteria described below they were given a detailed patient information 
leaflet and asked to consider participating in the study. Unless the subjects had 
denied permission to contact them again about the study, I telephoned them 
between five to seven days later to discuss their willingness to participate. 
 
 
2.1.1 Inclusion criteria 
 
 Severe growth hormone deficiency and suitable for replacement therapy as 
per usual clinical practice 
 Adults between ages 18-80 years 
 Stable on other hormone replacements (for at least three months) as per 
standard clinical practice for patients with pituitary hormone deficiencies 
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2.1.2 Exclusion criteria 
 
 Unwilling to give consent 
 Age < 18 years or > 80 years 
 Pregnant women 
 Lactating women 
 Women who are planning to be pregnant during the study period 
 Uncontrolled high blood pressure 
 History or diagnosis of diabetes mellitus 
 Significant kidney / renal impairment Creatinine > 150μmol/L 
 Significant liver impairment ALT > 100IU/L 
 Any abnormality in the complete blood count, specifically anaemia – as 
defined as haemoglobin level below the gender matched reference range.  
 Conditions associated with altered bone turnover such as Paget’s disease, 
osteoporosis or fracture within the previous 1 year  
 Taking medications that significantly influence research results e.g. long term 
inhaled steroids for asthma 
 History of cancer, significant heart disease or other conditions which 
significantly impact the person’s ability to do either tests, or have a markedly 
reduced life expectancy 
 
 
2.1.3 Definition of hormone abnormalities 
 
All subjects had dynamic pituitary hormone testing at the time of their original 
diagnosis and as part of routine assessment and treatment of pituitary disease. In 
the event that patients had multiple treatments and repeat dynamic testing, the most 
recent results were used to define hormone abnormalities. 
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2.1.3.1 Anterior pituitary function 
 
Severe GH deficiency was confirmed by a GH stimulation test, either insulin 
tolerance test (ITT) or glucagon stimulation test (GST); a serum GH peak less than 
3 µg/L was taken as evidence of severe GH deficiency.  ACTH deﬁciency was 
deﬁned as a peak cortisol of less than 500 nmol/L during the ITT and less than 450 
nmol/l during the GST.  
 
In pre-menopausal women, hypogonadotrophic hypogonadism was defined 
as olgio/amennorhoea in the presence of low or normal serum gonadotrophin 
levels. In post-menopausal women, hypogonadotrophic hypogonadism was defined 
as serum FSH < 25u/L after at least one year since menopause. In men, 
hypogonadotrophic hypogonadism was deﬁned by a low serum testosterone 
concentration in combination with inappropriately normal or low gonadotrophins. 
TSH deﬁciency was deﬁned by low serum free T4 levels, with normal or low serum 
TSH level.  
 
 
2.1.3.2 Posterior pituitary function 
 
Cranial diabetes insipidus (CDI) was diagnosed on the basis of failure to 
concentrate urine to >600mOsm/kg, with a plasma osmolality >298mOsm/kg, 
following a water deprivation test. If formal WDT was not carried out, CDI was 
diagnosed in the appropriate clinical setting (post neurosurgery) in conjunction with 
hypernatraemia (Na >145mmol/l), polyuria >3.5litres/24hours and an early morning 
fasting urine osmolality <300mOsm/kg.   
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2.2 Study design 
 
We performed a prospective, observational study of 20 adult hypopituitary 
patients with severe GH deficiency. GH replacement was offered as part of routine 
clinical care. If the patient had multiple pituitary hormone deficiencies (defined as 
deficiency in two or more pituitary hormones), other hormones were adequately 
replaced for at least three months prior to commencing GH replacement. Subjects 
with and without TSH deficiency were included. 
 
Prior to commencing GH replacement, subjects attended for research studies 
(described below). All subjects then were commenced on recombinant GH at a 
starting dose of 0.3mg/day administered subcutaneously – Saizen® (somatropin 
(rDNA origin) for injection) Merck Serono Ltd. Serum IGF-1 was checked after one 
month and the dose was titrated to achieve an IGF-1 in the upper half of age-related 
reference range. Tests were repeated after 3-6 months on a stable dose of GH. 
 
 
2.3 Study procedures 
 
The subjects completed a 24 hour urine collection at home. Subjects were 
advised to discard the first early morning urine sample and collect all urine 
thereafter for 24 hours during this admission. Once the urine collection was 
completed, the total urine volume was recorded and three 5ml aliquots were 
preserved for storage at -80degrees until quantitative analysis for urine iodine 
excretion, urine copper concentration and protein oxidation could be performed. 
 
The following day, after an overnight fast, they attended the Clinical 
Research Laboratory at the School of Health and Human Performance Dublin 
Clinical Research Centre. Resting energy expenditure (REE) was measured by 
open circuit indirect calorimetry using the Deltatrac® system. Detailed methodology 
is described below (section 2.4).  
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All subjects then had a percutaneous biopsy of subcutaneous fat, from the 
anterior abdominal wall, using a 6mm Bergström needle. The Bergström needle 
consists of an outer cannula with a small window at the side of the tip and an inner 
trocar with a cutting blade at the distal end. Under 2% lignocaine local anesthesia 
and aseptic conditions, the needle was advanced into the subcutaneous fat through 
an incision in the skin (<1cm) and fascia. Next, suction was applied to the inner 
trocar using a 50ml syringe and suction catheter; the outer trocar was pulled back 
and adipose tissue was drawn into the window of the outer cannula by the suction. 
The inner trocar was rapidly closed, cutting the fat tissue sample. The needle was 
rotated 90° and the cutting procedure was repeated. This process was repeated 
three to four times. This technique typically produced a fat sample of 150-200 mg 
from each subject.  
 
A sterile, waterproof dressing was applied to the incision site. Subjects were 
able to resume their activities of daily living immediately. However, they were asked 
to abstain from vigorous physical activity for 72 hours. They were instructed to 
inspect the wound daily and take simple analgesia for discomfort as required. 
 
Subjects were then transported by car to the RCSI, Clinical Research Facility 
at Beaumont Hospital. Venepunture was performed to measure baseline pituitary 
function, full blood counts, urea & electrolytes, serum TSH, free & total T4, free & 
total T3, rT3, thyroid binding globulin (TBG), anti-thyroid peroxidase (TPO)  antibody 
titre, selenium, insulin like growth factor-1 (IGF-1), testosterone and creatinine 
kinase (CK). Liver and bone- derived biomarkers of thyroid hormone action were 
also measured (see below). Blood samples were centrifuged at 3000 rpm for 10 min 
at room temperature, and stored was stored at -80°C until the end of the study. 
 
Weight (kg) and height (meters) were measured to calculate body mass 
index (BMI). A BMI of greater than 30 kg/m2 was considered representative of 
obesity. Blood pressure and heart rate were recorded while resting on three 
separate occasions during the morning of the research testing schedule. Subjects 
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were then given breakfast. After eating they were asked to complete quality of life 
questionnaires in a quiet, brightly lit room. Finally, each subject had an 
echocardiogram performed to measure cardiac time intervals. Echocardiograms 
were performed by an experienced cardiac technician and supervised by a 
Consultant Cardiologist.  
 
Tests were repeated after 3-6 months on a stable dose of GH. 
 
2.4  Resting Energy Expenditure  
 
Resting energy expenditure (REE) was measured by open circuit indirect 
calorimetry using the Deltatrac® system. This measures the rate of O2 and CO2 
exchange in the lungs and this can be used to estimate energy expenditure (313).  
 
Subjects were asked to lie in a supine position immediately after arriving at 
the testing facility. They remained in this habituation period for one hour in a quiet, 
thermo neutral (22˚C) dimly lit room. After one hour, a plastic hood with two outlets 
was placed over the subjects head. Open circuit indirect calorimetry was conducted 
using a transparent canopy in the dilution testing mode. Ambient air was drawn 
through the hood by negative pressure created by the pump. The subject was 
supplied with room air via the inlet valve at a rate of 40 L/min, while extracts of the 
expired air was obtained via the outlet valve. The pump was set so that an 
appropriate amount of air will flow through the canopy and this was determined by 
the subject’s minute ventilation. This was to ensure that dilute expired carbon 
dioxide (FEO2) is maintained within the correct range (0.5%-1.0%) (314). Expired 
air was analyzed by mixing chamber to establish VO2 and VCO2. 
  
The canopy consisted of an inlet and an outlet valve. Both valves were connected to 
the calorimeter (Deltatrac II) via tubes. The Deltatrac II recorded the oxygen 
consumption (VO2) and carbon dioxide production (VCO2) from the inlet and outlet 
gas samples of the valves and calculates the oxygen consumption (VO2) and 
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carbon dioxide production (VCO2) in ml/min by differentiation. Values for all 
parameters were averaged over 1 minute intervals. Subsequently, these values 
were used to estimate REE and substrate utilization (% carbohydrate and % fat) 
using the Weir equation (315). In addition, 24 hour urine collection was obtained to 
account for protein oxidation and to complete the energy expenditure measurement. 
 
Protein oxidation 
 
Urea nitrogen excretion was measured by spectrophotometry and converted 
to urea nitrogen excretion in g/d. Assuming that urea nitrogen excretion is a 
constant proportion (85%) of total urinary nitrogen [Ref], protein intake was derived 
from the formula 6.253(urinary nitrogen + 2), as suggested by Isaksson (316). 
 
 
2.5 Echocardiographic assessment  
 
A complete, transthoracic, two-dimensional and Doppler echocardiogram 
was performed using a 2.0- to 2.5-MHz transducer according to standard technique. 
Two dimensional M-mode echocardiograms were recorded from parasternal short-
axis view at mid-left ventricular (LV) level to determine LV dimensions. Left 
ventricular ejection fraction (EF) was obtained by biplane Simpson’s method. 
Pulsed wave Doppler was used to measure cardiac time intervals by sequential 
recording of the mitral inflow (from the apical four chamber view) and the left 
ventricular outflow tract (from the apical long axis view). Myocardial performance 
index (MPI) was defined as sum of the isovolumetric contraction time (ICT) and 
isovolumetric relaxation time (IRT) divided by the left ventricular ejection time (ET).  
 
Tissue Doppler imaging (TDI) measurements were made during the 
echocardiographic examination from an average of 5 consecutive heart beats. Time 
intervals were measured from mitral inflow and LV outflow velocity traces. Separate 
measurements were taken from the septal and lateral wall – see Figure 2.1. Interval 
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a (from cessation to onset of mitral inflow) is equal to the sum of isovolumetric 
contraction time (ICT), ejection time (ET) and isovolumetric relaxation time (IRT). 
Left ventricular ET (b) is the duration of left ventricular outflow velocity profile. Thus, 
the sum of ICT and IRT was obtained by subtracting the time interval b from a. MPI 
was calculated as (a -b)/b. IRT was measured by subtracting the interval d (time 
between the peak of the electrocardiographic R wave and cessation of LV outflow) 
from interval c (between R wave and onset of mitral inflow). Isovolumetric 
contraction time (IVCT) is obtained by subtracting IVRT from (a -b). The IVCT/ET 
ratio was also calculated. 
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Figure 2.1 
 
Cardiac time intervals on echocardiography and electrocardiogram. 
 
ICT (isovolumetric contraction time). This is the time when the ventricles have 
begun to contract, but the volume of the chambers has not yet changed. It occurs 
immediately after the period of electromechanical delay, following electrical 
stimulation of the ventricles.  
IRT (isovolumetric relaxation time). This occurs at the end of systole when the semi-
lunar valves shut and the ventricles relax; this results in a fall in the intraventricular 
pressure, initially with no change in the chamber volume.  
ET (ejection time). After the semilunar valves open, the ventricles can eject the 
stroke volume into the systemic circulation during a period known as ET. 
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Figure 2.1 (contd) 
 
Myocardial performance index (MPI) is also known as the Tei index. It incorporates 
both systolic and diastolic time intervals in expressing global systolic and diastolic 
ventricular function. MPI = (ICT+IRT)/ET. 
 
Reproduced with permission of Elsevier Publishing (289) 
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2.6 Assessment of quality of life (QOL) 
 
During each testing session subjects were administered the following health-related 
QOL questionnaires –  
 
 Nottingham Health Profile (NHP) 
 Short Form 36 (SF 36) 
 Assessment of Growth Hormone Deficiency in Adults (AGHDA)  
 
The Nottingham Health Profile (NHP) Questionnaire 
 
The NHP contains 38 yes/no questions over 6 health domains; 1. energy (three 
items), 2. pain (eight items), 3. emotional reaction (nine items), 4. sleep (five items), 
5. social isolation (five items) and physical mobility/functioning (eight items). Each 
question is weighted and the sum of each domain is 0-100 with higher scores 
indicating worse quality of life in this case (129) (Appendix 1) 
 
The Short Form 36 (SF 36) Questionnaire 
 
The SF 36 aims to assess general well-being over the preceding 4 weeks by 
evaluating responses to statements through 8 domains of health; 1. physical 
functioning, 2. social functioning, 3. role physical – limitations in role activities due to 
physical health problems, 4. role emotional – limitations in role activities because of 
emotional problems, 5. mental health, 6. vitality, 7. pain and 8. general health . 
Scores are coded and transformed to a scale of 0-100 with higher scores indicating 
a better quality of life (128) (Appendix 2). 
 
Assessment of Growth Hormone Deficiency in Adults  (AGHDA) 
 
The AGHDA questionnaire consists of 25 questions, with YES/NO responses, 
derived from the symptoms most commonly reported by adults with severe GHD. A 
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score of 25/25 indicate the worst possible QOL score. Scores of 4/25 or less have 
been recorded in a healthy, general population. (Appendix 3) 
 
 
 
2.7 Laboratory methods 
 
 
2.7.1 Deiodinase isoenzyme activity 
 
DIO1 and DIO2 activities were assayed in tissue sample homogenates 
prepared in 0.1 M potassium phosphate, 2 mM EDTA, and 2 mM dithiothreitol 
(DTT), pH 7.0. Protein concentration was determined by Bradford’s method using 
BSA as a standard. Tissue samples were assayed in duplicates. DIO1 activity was 
measured using 25–50 μg protein in 100 μl reaction mixture, [125I]-rT3 (100 000 
c.p.m./tube),400 nM rT3, and 2 mM DTT. Incubation was carried at 37°C for 1 h, 
with or without 1 mM propylthiouracil(PTU). Results are expressed in pmol/min per 
mg protein. 
 
DIO2 activity was measured using 50 μg protein in 100 μl reaction mixture 
consisting of [125I]-T4 (200 000 c.p.m./tube), 2 nM T4 or 500 nM T4 (to inhibit DIO2 
activity), 1 mM T3 (to inhibit DIO3 activity), 20 mM DTT, and 1 mM PTU for 2 h at 
37 °C. Results are expressed in fmol/min per mg protein.  
Before each assay, [125I]-T4 and [125I]-rT3 (Perkin Elmer, Billerica, MA, USA) 
were purified by dialysis as described previously (14). For DIO1 and DIO2 activity 
assays, reactions were stopped by adding 100 μl of cold 2% BSA and 800 μl of 
10% trichloroacetic acid. After centrifugation at 2000 g for 10 min, 800 μl 
supernatant was applied to AG 50W-X2 columns (bed volume=1 ml) (Bio-Rad 
Laboratories) and eluted with 10% glacial acetic acid. The [125I] generated in the 
assay was counted in a gamma scintillation counter (Packard Cobra Gamma 
Counter, Perkin Elmer, Waltham, MA, USA). Blanks were performed in 
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quadruplicates by substituting the volume of tissue homogenates for assay buffer. 
Assay detection limit was calculated as the average of [125I] produced by blanks 
multiplied by 3.3 times SD. 
 
DIO3 activity was measured as in accordance with the methodology 
described previously by van Zeijl et al (317). Adipose tissue (approximately 40 mg) 
was homogenized on ice in 500µl PE buffer (0.1 M sodium phosphate, 2 mM EDTA 
pH 7.2) containing 50 mM dithiothreitol (DTT) using a Polytron (Kinematica, Luzern, 
Switzerland). Protein concentration has been measured with the Bio-Rad protein 
assay (Bio-Rad Laboratories, Veenendaal, The Netherlands), according to 
manufacturer’s instructions.  
 
Samples were measured in duplicate using 75 μl homogenate in a final 
volume of 0.15 ml in the presence of 1nM T3 or 500nM T3 (tissue blank, 500 nM T3 
saturates DIO3 activity) with the addition of approximately 1*105c.p.m. [3`-125I]T3 
(NEX110X, Perkin Elmer) in PE buffer. Samples were incubated for 2h. The activity 
reactions were stopped by adding 0.15 ml ice-cold ethanol. After centrifugation, 
0.125 ml of the supernatant was added to 0.125 ml 0.02 M ammonium acetate (pH 
4), and 0.1 ml of the mixture was applied to 4.6 x 250 mm Symmetry C18 column 
connected to a Waters HPLC system (Model 600E pump, Model 717 WISP auto-
sampler, Waters, Etten-Leur, The Netherlands). The activity of T3 and T2 in the 
eluate was measured online using a Radiomatic 150 TR flow scintillation analyser 
(Perkin Elmer, Waltham, MA, USA) D3 activity is expressed as fmol generated 
3,3`T2 per minute per mg tissue. DIO3 activity when incubated with 1nM T3, minus 
the activity measured when incubated with 500nM T3 represents true D3 activity. 
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2.7.2 Biochemical indices 
 
 
Pituitary and thyroid function 
 
Total T3 was measured by a competitive binding protein, chemiluminescent 
immunoassay (UniCel DxI 800, Beckman Coulter). Reverse T3 (rT3) was measured 
by liquid chromatography/tandem mass spectrometry (Quest Diagnostics, San Juan 
Capistrano, CA). The remainder of the serum thyroid hormones (total T4, free T4 
and free T3) and TSH were measured using fluoroimmunometric and sensitive 
“second generation” assays respectively (DELFIA, PerkinElmer Life Sciences). 
Thyroid binding globulin (TBG) was measured by immunoassay (Siemens 
Immunlite). Inter-assay and intra-assay coefficients of variation (CV) were less than 
10% throughout. 
 
Thyroglobulin was measured using a paramagnetic chemiluminescent 
immunoassay using 4 biotinylated mixture of 4 monoclonal anti thyroglobulin 
antibodies. Inter-assay co-efficient of variation was 5.6% and 2.5% at serum 
concentrations of 0.97 and 4.42 ug/L respectively. Anti-TPO IgG was quantified by 
fluorenzyme-immunoassay (Elia Phadia 250). 
 
IGF-1 was measured in a chemiluminescent immunoassay using an 
acridinium labelled anti-IGF 1 antibody (IDS-iSYS). Inter-assay and intra-assay 
coefficients of variation (CV) were less than 10%. 
 
Testosterone was measured using a liquid phase radioimmunoassay 
(Spectria, Cisbio Bioassays). The assay is a liquid phase radioimmunoassay using 
antibody-coated tubes.125I-labelled testosterone competes with testosterone in the 
patient sample for a fixed number of antibody binding sites in the tube. At the end of 
the incubation period, unbound material is removed by decanting and washing. The 
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amount of testosterone in the patient’s serum is inversely proportional to the amount 
of radioactivity in the coated tube. 
Bone-derived serum biomarkers 
 
Bone formation markers 
 
The concentration of bone-specific alkaline phosphatase (BALP), a marker of 
both bone mineralisation and maturation, were measured by an immunoenzymatic 
assay (Ostase, Immunodiagnostic Systems Ltd, Bolton, UK) on an automated 
ELISA platform with inter-assay and intra-assay coefficients of variation (CV) values 
of 5.8% (at 8.4µg/L) and 6.5% (at 7.4µg/L) respectively. The minimum detectable 
concentration is estimated to be 0.7µg/L.  
 
The concentrations of total procollagen type I N-propeptide (PINP) were by 
electrochemiluminescence immunoassay measured on the Elecsys 2010 analyser 
(Roche Diagnostics) with intra-assay CV values of 2.6%, 1.8% and 1.3% and inter-
assay CV of 4.1%, 2.3% and 2.2% at concentration values of 12.8, 57.2 and 
527µg/L respectively. Lower limit of detection was 5µg/L. 
 
The concentrations of osteocalcin 1–49 (OCI) were measured using the 
same analyser (Roche Diagnostics) with intra-assay CV of 1.4%, 1.1% and 1.7% 
and inter-assay CV values of 3.1%, 3.1% and 3.0% at concentration values of 6.1, 
12.2 and 35.6µg/L respectively and a lower limit of detection of 0.5µg/l.  
 
 
Bone resorption markers 
 
The concentrations of C-terminal cross-linking telopeptide (CTX-I) were 
measured using an electrochemiluminescence immunoassay on the Elecsys 2010 
analyser (Roche Diagnostics) with intra-assay CV values of 3.5%, 2.1% and 2.0% 
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and inter-assay CV values of 8.4%, 3.8% and 2.8% at concentration values of 
0.051, 0.488 and 2.35µg/l respectively. The lower detection limit was 0.07µg/l.  
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Liver-derived serum biomarkers 
 
 
Sex hormone binding globulin 
 
Quantitative measurement of sex hormone binding globulin (SHBG) was 
performed using a two-step chemiluminescent microparticle immunoassay 
(ACHITECT iSystem, Abbott). Intra-assay CV was 4.78%, 4.8% and 5.24% and 
inter-assay CV values of 9.54%, 5.65% and 7.55% at concentration values of 8.8, 
24.5 and 152.8nmol/L respectively; analytical sensitivity was calculated to be 
0.02nmol/L. 
 
 
Ferritin  
 
The Ferritin assay is a two-site chemiluminescent, immunoenzymatic 
(“sandwich”) assay (Beckman DxI 800 Series). Subject sample was added to a 
reaction vessel with goat anti-ferritin-alkaline phosphatase conjugate and 
paramagnetic particles coated with goat anti-mouse:mouse anti-ferritin complexes. 
Serum ferritin binds to the immobilised monoclonal anti-ferritin on the solid phase, 
while the goat anti-ferritin enzyme conjugate reacts with different antigenic sites on 
the ferritin molecules. After incubation in a reaction vessel, materials bound to the 
solid phase are held in a magnetic field while unbound materials are washed away. 
Then, the chemiluminescent substrate Lumi-Phos* 530 is added to the vessel and 
light generated by the reaction is measured with a luminometer.  The light 
production is directly proportional to the concentration of ferritin in the sample.  
Inter-assay co-efficient of variation was 7%. 
 
Serum iron  
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Iron (Fe) was analysed by a spectrophotometric assay (Beckman AU Series 
Analyser). The automated analyser utilises TPTZ [2,4,6-Tri-(2-pyridyl)-5-triazine] as 
the chromogen. In an acidic medium, transferrin-bound iron dissociates into free 
ferric ions and apo-transferrin. Hydrochloric acid and sodium ascorbate reduce the 
ferric ions to the ferrous state. The ferrous ions then react with TPTZ to form a blue 
coloured complex which can be measured bichromatically at 600/800 nm. The 
increase in absorbance is directly proportional to the amount of iron present. Inter-
assay CV was 2.4%. 
 
 
Total iron binding capacity (TIBC)  
 
Total iron binding capacity (TIBC) (was calculated based upon the total iron 
present and the unbound iron binding capacity or UIBC) UIBC was estimated by a 
spectrophotmetric assay (Beckman AU Series Analyser). Fe2+ from reagent 1 reacts 
with Nitroso-PSAP from reagent 2 to form an intense green complex. When sample 
is added a part, or all of the iron ions bind specifically with transferrin at unsaturated 
iron binding sites at alkaline pH. They are thus not available for the colour reaction 
with Nitroso-PSAP. The difference between the resulting changes in the measured 
absorbance’s with or without samples is equivalent to the iron quantity bound to 
transferrin. This is the unsaturated iron binding capacity (UIBC). Inter-assay CV was 
3%. 
 
Caeruloplasmin 
 
Serum caeruloplasmin was measured using an automated immunoassay 
(Beckman AU Series Analyser). Subject sample mixed with buffer and antiserum. 
Human caeruloplasmin reacts specifically with the anti-human caeruloplasmin 
antibodies to yield insoluble aggregates. The absorbance of these aggregates is 
proportional to the caeruloplasmin concentration in the sample. Inter-assay CV was 
4%. 
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Trace elements 
 
Serum selenium (Se) and copper (Cu) levels were determined by inductively 
coupled plasma mass spectrometry (ICP-MS), on an Elan 6100 DRC plus (SCIEX 
Perkin-Elmer, Beaconsfield). For each analyte, samples were run against matrix 
matched calibration curve, spiked with the standard solution. The elements were 
measured individually against calibrations standards of up 3.0µmolL-1 for selenium 
(Selenium standard solution 1000ppm, Fisher Chemicals), 50µmolL-1 for plasma 
copper and 20µmolL-1 for urine copper (Copper standard solution 1000ppm, Fisher 
Chemicals). For serum copper, intra-assay CV was estimated at 1.1%, 1.4% & 
0.9% and inter-assay CV 5.0%, 2.9% & 3.2% at 7.5, 15 & 21µmol/L respectively. 
For urine copper intra-assay CV was estimated 8.1% at 0.2µmol/L and 1.4% at 
0.9µmol/; inter-assay CV 13.7% at 0.2µmol/L and 7.7% at 0.9µmol/L. For selenium 
intra-assay CV was estimated at 3.7%, 3.5% & 5.2% and inter-assay CV 7.9%, 
8.2% & 6.8% at concentrations of 0.6, 1.2 & 2.2µmol/L respectively. 
 
 
Lipoproteins 
 
Total cholesterol, triglyceride (Trig) and HDL cholesterol (HDL-C) were 
measured using standard laboratory techniques (CV<5%). LDL cholesterol (LDL-C) 
was calculated using the Friedewald equation.  
 
LDL and HDL subfractions were separated using the Quantimetrix Lipoprint 
system (Redondo Beach, CA) (318). The Lipoprint System uses non-denaturing, 
linear polyacrylamide gel electrophoresis to separate and measure the lipoprotein 
fractions. High-resolution 3% polyacrylamide gel tubes were used for 
electrophoresis. Twenty-five microlitres of sample were mixed with 200 microlitres 
of Lipoprint loading gel, which contained Sudan Black B dye to stain the 
lipoproteins. This was placed on the upper part of 3% polyacrylamide gel. After 30 
min of photopolymerization at room temperature, samples were electrophoresed for 
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60 min with 3 mA for each gel tube. The electrophoresis was followed by resting the 
tubes in the dark for 1 hour before performing densitometry. Densitometry was 
performed at 610 nm.  
 
Raw data from the densitometer were imported into a Microsoft Excel© 
spreadsheet. Using a computerized method that was developed for the 
Quantimetrix Lipoprint system using NIH image program version 1.62 (Bethesda, 
MD), and subfractions were identified and quantified.  
 
The Lipophpor system (Quantimetrix) was used as quality control. Each 
chamber had two quality controls. Very low-density lipoprotein (VLDL), seven LDL, 
and ten HDL subclasses were quantified and further classified as large, 
intermediate, and small subfractions. Using a weighted scoring system developed 
by the manufacturers, LDL scores were also calculated. On the basis of LDL 
migration rates on the scan, LDL phenotypes A (predominantly large, buoyant LDL) 
or non-A(predominantly small, dense LDL) were assigned to scores of less than 5.5 
for phenotype A and greater than 5.5 for non-A.  
 
 
Miscellaneous 
 
Cretainine Kinase (CK)  
 
CK was measured by a spectrophotometric assay (Beckman AU Series 
Analyser). CK reversibly catalyses the transfer of a phosphate group from creatine 
phosphate to adenosine diphosphate (ADP) to give creatine and adenosine 
triphosphate (ATP) as products. The ATP formed is used to produce glucose-6-
phosphate and ADP from glucose. This reaction is catalysed by hexokinase (HK) 
which requires magnesium ions for maximum activity. The glucose-6-phosphate is 
oxidised by the action of the enzyme glucose-6-phosphate dehydrogenase (G6P-
DH) with simultaneous reduction of the coenzyme nicotinamide adenine 
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dinucleotide (NADP) to give NADPH and 6-phosphogluconate. The rate of increase 
of absorbance at 340/660 nm due to the formation of NADPH is directly proportional 
to the activity of CK in the sample. Inter-assay CV was 1.5% 
 
 
Urinary iodine 
 
Iodine levels were determined by inductively coupled plasma mass 
spectrometry (ICP-MS), on an Elan 6100 DRC plus (SCIEX Perkin-Elmer, 
Beaconsfield. For each analyte, samples were run against matrix matched 
calibration curve, spiked with the standard solution. The elements were measured 
individually against calibrations standards of up to 10µmolL-1 (Potassium iodide, 
BDH, Poole). Sample volumes for the calibration, test and quality control, were 
diluted quantitatively (from 1in 15 to 1in 50) with a diluent containing 0.3% ammonia 
(BDH, Poole).  Inter-assay coefficient of variation was 9.7% at 0.65µmol/L and 6.2% 
at 2.4µmol/L. 
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2.8 Statistical analysis  
 
Biochemical indices were analysed for normality using the D'Agostino–
Pearson normality test. Mean and standard error of the mean (SEM) were 
determined for normally distributed continuous data and median (and range) was 
used for data not normally distributed.  
 
Paired continuous variables were analysed by paired t-test for normally 
distributed data and by Wilcoxon rank sum test for data not normally distributed. Chi 
square test was used to compare paired categorical variables. Correlation between 
continuous variables was determined by calculating the Pearson correlation 
coefficient for data sampled from a Gaussian distribution and Spearman coefficient 
for data with a non-Gaussian distribution. Significance was defined for p-values less 
than 0.05.  
 
Statistical analysis was performed using GraphPad Prism 5 software 
(GraphPad Inc., La Jolla, CA, 2010). 
 
 
2.9 Ethics 
 
Informed consent was obtained from all subjects to participate in this study which 
was approved by Beaumont Hospital and Dublin City University Ethics (Medical 
Research) Committee. 
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Chapter 3 
 
 
Alterations in the hypothalamic-pituitary-thyroid axis following growth 
hormone replacement 
 
 
3.1 Introduction 
 
Complex alterations in the hypothalamic-pituitary-thyroid (HPT) axis have been 
reported following growth hormone (GH) administration in both adults and children, 
with and without growth hormone deficiency. The most consistent effect on the HPT 
axis, reported by previous investigators, is a reduction in serum free thyroxine (free 
T4) (62, 63, 66, 270, 271, 319, 320). In hypopituitary patients, GH replacement has 
been reported to lead to a decline in serum freeT4 to the subnormal range in 36%-
47% of patients previously considered euthyroid (61). However, some investigators 
have reported no change in free T4 (64, 321).  
 
Serum tri-iodothyronine (T3) concentration has been observed to rise (63, 
67, 69) or remain unchanged (64, 66, 70, 322, 323). Similarly, reductions in serum 
thyroid stimulating hormone (TSH) secretion, following GH supplementation, have 
been reported in some but not all studies (67, 69, 322). A small number of studies 
have measured the hormone by-product, reverse T3 which usually declines 
following GH replacement (63, 67). Furthermore, some researchers have reported 
changes in the HPT axis following GH replacement to be transient and, therefore, of 
less clinical significance (270, 324). The inconsistencies in the literature about these 
perturbations may be due to different study populations and design, thyroid 
hormone assay imprecision or lack of purity of cadaveric GH, used in older studies, 
which was occasionally contaminated with TSH.  
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The aim of this part of the study was to prospectively define the impact of 
physiological GH replacement on a cohort of adult hypopituitary patients treated 
with a standard clinical protocol.  
 
3.2 Methods 
 
Subjects 
 
We performed a prospective, observational study of 20 adult hypopituitary patients 
with severe GH deficiency. GH replacement was offered as part of routine clinical 
care. If the patient had multiple pituitary hormone deficiencies (MPHD), other 
hormones were adequately replaced for at least three months prior to commencing 
GH replacement. Subjects with and without TSH deficiency were included. Informed 
consent was obtained from all subjects to participate in this study which was 
approved by Beaumont Hospital Medical Research (Ethics) Committee. 
 
Baseline tests performed before GH supplementation included serum TSH, 
free & total T4, free & total T3, rT3, anti-thyroid peroxidase (TPO) antibody titre and 
insulin like growth factor-1 (IGF-1). All serum samples were collected after an 
overnight fast.  Weight (kg) and height (metres) were measured to calculate body 
mass index (BMI). 
 
All subjects were commenced on recombinant GH at a starting dose of 
0.3mg/day administered subcutaneously – Saizen® (somatropin (rDNA origin) for 
injection) Merck Serono Ltd. Serum IGF-1 was checked after one month and the 
dose was titrated to achieve an IGF-1 in the upper half of age-related reference 
range. Tests were repeated after 3-6 months on a stable dose of GH. 
 
Biochemical indices 
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Total T3 was measured by a competitive binding protein, chemiluminescent 
immunoassay (UniCel DxI 800, Beckman Coulter). rT3 was measured by liquid 
chromatography/tandem mass spectrometry (Quest Diagnostics, San Juan 
Capistrano, CA). The remainder of the serum thyroid hormones (total T4, free T4 
and free T3) and TSH were measured using fluoroimmunometric and sensitive 
“second generation” assays respectively (DELFIA, PerkinElmer Life Sciences). Anti-
TPO IgG was quantified by fluorenzyme-immunoassay (Elia Phadia 250). IGF-1 
was measured in a chemiluminescent immunoassay using an acridinium labelled 
anti-IGF 1 antibody (IDS-iSYS). 
 
 
3.3 Results 
 
Baseline characteristics are outlined in Table 3.1. Fourteen subjects were treated 
for pituitary adenomas (10 non-functioning, 4 lactotroph tumours), one had a treated 
germinoma, one a craniopharyngioma and four had idiopathic hypopituitarism. 
Seventeen (85%) had multiple pituitary hormone deficiencies (MPHD); three 
patients had isolated GH deficiency (in the latter cases GH deficiency was 
confirmed by two dynamic tests). Subjects with isolated GH deficiency comprised 
two patients with previously treated pituitary adenomas and one with isolated 
idiopathic GH deficiency. 
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Table 3.1  
Baseline characteristics of the study cohort. Demographic data is also displayed for 
the sub-groups with and without central hypothyroidism (CH).  All patients with CH 
were prescribed thyroxine replacement. Data for age and BMI displayed as median 
(range)  
GHD growth hormone deficiency.  
a Comparison of patients with and without CH. 
 
 All 
patients 
Patients with 
CH 
Patients 
without CH 
p value 
n 20 13 7  
Male/Female 20/0 13/0 7/0 
    
Aetiology of 
GHD  
   
NFPA  10 6 4 
Prolactinoma 4 3 1 
Other  6 4 2 
    
MPHD n (%) 17 (85) 13(100) 4(57) 
    
Age (range) 53.1  
(22.3-69.3) 
42.51  
(22.3-69.3) 
57.26  
(35.1-68.2) 
0.05a 
BMI kg/m2 
(range) 
31.3  
(19.2-49.7) 
33.9  
(19.2-49.6) 
30.5  
(23.6-37.6) 
0.42a 
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Serum testosterone levels did not change during the course of the study 
(14.20±11.95nmol/L vs. 14.95±10.40nmol/L, p=0.45). Three patients had cranial 
diabetes insipidus. Serum electrolyte levels were recorded at each visit; there were 
no abnormalities suggestive of over- or under-replacement with ddAVP. All patients 
had serum freeT4 and free T3 levels within the normal reference range prior to 
commencing GH replacement (Table 3.2). 
 
The mean daily dose of growth hormone was 0.34±0.11 mg (range 0.15 - 
0.5mg) administered subcutaneously. Serum IGF-1 levels rose significantly, as 
expected, during the course of the study (+114.4±12.3µg/L, p<0.0001). Following 
GH replacement, freeT4 levels declined (-1.09±1.99 pmol/L, p=0.02). Total T4 
levels also fell (-9.61± 4.25 nmol/, p=0.035) (Table 3.2). There was a strong positive 
correlation between the change in total and free T4 suggesting a parallel decline in 
the free and protein-bound form of the hormone (r 0.7620, p=0.0001).  Reverse T3 
levels also fell (-3.44±1.42 ng/dL, p=0.03) and freeT3 levels increased (+0.34±0.15 
pmol/l, p=0.03) after GH replacement. In addition, the serum T3/T4 and fT3/rT3 
ratio rose significantly (Figure 3.1). The rise in serum IGF-1 correlated with the fall 
in freeT4 (r -0.46; 95% CI -0.755 to -0.006, p=0.048) while there was a trend 
towards a significant correlation with the rise in freeT3 and IGF-1 (r 0.442; 95% CI -
0.0291 to 0.753, p=0.058) (Figure 3.2).  
 
All changes in circulating thyroid hormone levels occurred within the normal 
reference range; no study subject required adjustment of or commencement of 
thyroxine replacement during the time course of the study.   
 
There was no significant change in early morning, fasting serum TSH levels 
during the study period. Sub-group analysis of subjects with a detectable TSH level 
confirmed stable, baseline TSH levels throughout. Similarly, serum concentration of 
thyroglobulin and TBG were unchanged by growth hormone therapy (Table 3.2).  
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Table 3.2   
Alteration in circulating thyroid hormones following replacement of growth hormone. 
Data is reported as mean±SEM where variable is normally distributed (TT4, fT3, 
rT3) and median±SD where variable is not normally distributed (fT4 & TT3). Only 
those with a detectable pre-treatment TSH level (n=13) were included in this 
analysis – reported as median (range). * p<0.05. GH Growth Hormone. 
  
Pre GH 
 
Post GH 
 
Δ 
Ref. 
range 
P 
value 
 
95% CI 
 
FreeT4 
(pmol/L) 
 
12.9±4.0 
 
12.1±3.2 
 
-1.09±1.99* 
 
9-20  
 
0.02 
 
-2.24 to -0.32 
       
 
Total T4 
(nmol/L) 
 
109±4.9 
 
99.5±4.5 
 
-9.6±4.25* 
 
69-141 
 
0.04 
 
-18.5 to -0.72 
       
 
Free T3 
(pmol/L) 
 
5.4±0.2 
 
 
5.7±0.2 
 
+0.34±0.15* 
 
3.0-7.5  
 
0.03 
 
0.03 to 0.65 
       
 
Total T3 
(nmol/L) 
 
1.72±0.4 
 
1.62±0.4 
 
-0.02±0.32 
 
1-3 
 
0.76 
 
-0.1 to 0.19 
       
 
Reverse T3 
(ng/dL) 
 
17.6±1.4 
 
14.2±0.8 
 
-3.44±1.42* 
 
8-25 
 
0.03 
 
-6.44 to -0.45 
       
 
TSH  
(mU/L) 
 
1.1  
(0.4-5.1) 
 
1.1  
(0.2-3.3) 
 
-0.1±1.09 
 
0.4-4.0 
 
0.31 
 
-0.87 to 0.17 
 
102 
 
 
fT
3
/f
T
4
 P
re
fT
3
/f
T
4
 P
o
s
t
0 .0
0 .2
0 .4
0 .6
0 .8
f r e e T 3 /f r e e T 4
*
p = 0 .0 0 2
fT
3
/r
T
3
 P
re
fT
3
/r
T
3
 P
o
s
t
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
f r e e T 3 /r e v e r s e T 3
*
p = 0 .0 3 2 7
 Figure 3.1.  
Ratio of freeT3/freeT4 and freeT3/reverse T3 before (white boxes) and after (grey 
boxes) GH supplementation. * p<0.05. 
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Figure 3.2  
Correlation between rise in serum IGF-1 concentration (ΔIGF-1; µg/L) and 
change in serum freeT3 (ΔfT3; pmol/L) (A) and freeT4 (ΔfT4; pmol/L) (B) following 
growth hormone replacement. 
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Body mass index (BMI) did not change during the study; 31.38±1.649 kg/m 2 
vs. 31.07±1.679kg/m2, p=0.26. The initial BMI did not correlate with the baseline T4 
or T3 levels. However, subjects with a higher BMI before commencing GH 
replacement had a more significant rise in free T3 during the study (Figure3.3). Age 
of the subjects did not influence the changes observed in the circulating 
concentration of thyroid hormones.   
 
Two subjects had an elevated titre of anti-TPO antibodies; exclusion of these 
subjects from the analysis did not significantly alter the changes observed in 
circulating thyroid hormones. No subject developed anti-TPO antibodies during the 
course of the study. 
 
Subgroup analysis was performed on patients with central hypothyroidism 
i.e. TSH deficiency. This subgroup consisted of patients (n=13) with more profound 
hypopituitarism i.e. MPHD including TSH deficiency; all were taking thyroxine 
replacement. The subgroup was formed after the exclusion of three patients with 
isolated GHD, two with GHD and gonadotrophin deficiency and two with GHD and 
ACTH deficiency. All patients in this subgroup had an organic cause of 
hypopituitarism. Baseline characteristics are shown in table 3.3. There was no 
difference in the baseline values of free & total T3, free and total T4, reverse T3, 
TSH or IGF-1 in those with or without TSH deficiency.  
 
When patients with TSH deficiency were analysed separately, a similar 
pattern of biochemical changes was observed (Table 3.4). GH replacement induced 
a fall in free T4 (-2.15 ±1.89pmol/L; 95% CI -3.39 to -0.98, p=0.004) and total T4 (-
14.07 ± 4.3nmol/L; 95% CI -23.45 to -4.69, p=0.007). Reverse T3 also declined (-
4.15 ±1.72ng/dL; 95% CI -7.94 to 0.39, p=0.03). However, the rise in free and total 
T3 did not reach statistical significance. Serum IGF-1 concentration rose as 
expected (+134.7 ±14.6μg/L; 95%CI 102.9 to 166.5, p<0.001).  
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Table 3.3  
Alteration in circulating thyroid hormones following GH replacement in subjects with 
TSH deficiency (n=13). Data is reported as mean±SEM where variable is normally 
distributed (TT4, fT3, TT3, rT3) and median±SD where variable is not normally 
distributed (fT4). * p<0.05. GH Growth Hormone. 
 
  
Pre GH 
 
Post GH 
 
Δ 
Ref. 
range 
P 
value 
 
95% CI 
 
FreeT4 
(pmol/L) 
 
13.5 
±4.59 
 
12.20 
±3.66 
 
-2.15 ±1.89* 
 
9-20  
 
0.004 
 
-3.39 to -0.98 
       
 
Total T4 
(nmol/L) 
 
116.7 
±4.58 
 
102.6 
±4.3 
 
-14.07±4.3* 
 
69-141 
 
0.007 
 
-23.45 to -4.69 
       
 
Free T3 
(pmol/L) 
 
5.312 
±0.23 
 
5.74  
±0.28 
 
+0.43±0.22 
 
3.0-7.5  
 
0.085 
 
-0.07 to 0.22 
       
 
Total T3 
(nmol/L) 
 
1.65 
±0.11 
 
1.83 
±0.12 
 
+0.18±0.08 
 
1-3 
 
0.05 
 
0.005 to 0.36 
       
 
Reverse 
T3 (ng/dL) 
 
19.17 
±1.54 
 
15.00 
±0.77 
 
-4.15±1.72* 
 
8-25 
 
0.03 
 
-7.94 to -0.39 
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3.4 Discussion 
 
In this prospective clinical study, we describe the impact of GH replacement on 
alterations in the hypothalamo-pituitary-thyroid axis in adult patients with 
hypopituitarism. Our results demonstrate a decreased circulating concentration of 
free and totalT4 in conjunction with an increase in freeT3 following initiation of GH 
replacement. These alterations occurred despite TSH levels remaining unchanged.  
 
Previous research in this field has produced divergent results. Much of the 
data concerning patients with GHD is derived from small studies of children using 
high doses of GH. Some studies have not demonstrated any significant changes in 
the thyroid hormone levels. Rubio et al, in a study of 12 GHD children in the 1970’s, 
found no change in the concentration of serum TSH, thyroid hormones or thyroidal 
response to exogenous TSH following six months GH replacement (325). In 
contrast, more contemporary studies have demonstrated a fall in T4 and reverse 
T3, accompanied by a rise in T3, following GH replacement in children (270, 271, 
320). However, new development or unmasking of central hypothyroidism was rare 
in these studies, leading some authors to question the clinical significance of these 
alterations. Furthermore, previous studies in GHD children have also suggested that 
changes in the HPT axis may be  transient; in one study they resolved after 12 
months (324) and after 24 months in another study (270). However, the children in 
these studies had isolated idiopathic GHD and, by definition, a normal thyroid axis. 
This may explain the milder and transient changes in the HPT axis in these studies,  
 
A diversity of findings is also apparent in studies of adults with GHD. Amato 
et al, in a small study of nine adults, with mostly childhood onset GHD, showed no 
change in thyroid parameters following GH substitution (64). A larger study of 21 
adults by Monson et al reported a fall in serum freeT4 concentration in the euthyroid 
group only (273). Serum T3 levels rose in the whole group but this appeared to be a 
transient phenomenon. One patient developed a freeT4 level below the normal rang 
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after commencing GH treatment; however this subject had a normal serum T3 and 
rT3 with no clinical signs of central hypothyroidism.  
 
The discrepancies among the results of previous studies are likely due to 
several factors. Most have been small studies with a variation in whether the 
patients had isolated idiopathic GHD or MPHD. In the latter situation the HPT axis 
will be intact and pehaps less subject to manipulation by GH replacement. Also 
different assays have been used to measure the serum concentration of thyroid 
hormone with variable precision and reproducibility. Furthermore, a variety of GH 
dosing schedules have been employed in different studies; also older studies used 
cadaveric GH which was occasionally contaminated with TSH.  
 
Despite the inconsistencies in the published literature, the pattern of change 
in circulating thyroid hormones that we report is largely in keeping with recent 
studies of larger cohorts of patients with organic pituitary disease (62, 63, 66, 68). 
Porretti et al studied 66 patients with MPHD receiving GH replacement and reported 
a significant fall in T4 and rT3 in addition to a transient rise in T3 (63). Also, the 
authors described the development of central hypothyroidism in 47% of previously 
euthyroid subjects; 18% of those with treated hypothyroidism required an increase 
in thyroxine dose.  
 
In the largest adult study in the field to date, Agha et al evaluated the effect 
of standard clinical replacement of GH 243 patients, of whom 159 patients had 
previously diagnosed central hypothyroidism and were appropriately treated with 
thyroxine prior to commencing GH replacement. GH dose was titrated to achieve a 
target serum IGF-1 level in the upper half of the age-related reference range. In the 
euthyroid group (n=84), serum free T4 concentration declined to below the 
reference range in 36% of subjects necessitating thyroxine replacement at three to 
six months after GH substitution. No further changes were seen after nine to 12 
months of GH replacement. The main predictor for exposing post-GH central 
hypothyroidism in this group was the presence of multiple pituitary hormone 
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deficiencies. Sixteen per cent of the treated hypothyroid group had a reduction in 
serum free T4 level requiring increased thyroxine dose with no further changes 
seen after 6 months of GH replacement.  
 
In our current study, all changes in thyroid hormone concentration occurred 
within the normal reference range. This may be due to increasing awareness of the 
GH-induced fall in T4, resulting in a tendency to optimise T4 replacement prior to 
initiating GH by keeping the serum freeT4 concentration in the upper half of the 
normal range. 
 
Subgroup analysis of patients with central hypothyroidism, taking thyroxine 
replacement, showed a more marked decline in serum free and total T4 in 
comparison to the whole study group. However, changes in T3 in this subgroup 
were more mixed; the rise in free T3 was more modest whereas the increase in total 
T3 was greater than the full study cohort. The small number in this subgroup (n=13) 
make it difficult to draw firm conclusions about the impact of thyroxine replacement 
on GH-induced changes in the HPT axis. Furthermore, previous studies in this field 
have reported conflicting results when comparing the results of GH replacement in 
those with and without a previous diagnosis of central hypothyroidism. Similar to our 
results, Jørgensen et al, in a placebo controlled study, found that the decline 
circulating T4 levels was more accentuated in those with central hypothyroidism in 
comparison to patients not taking thyroid hormone supplementation.  In contrast,  
Agha et al reported less marked changes in the HPT axis of patients treated for 
central hypothyroidism in comparison to the apparently euthyroid subjects. Thyroid 
hormone assay methodology and a variable study design may explain the diversity 
of these research findings.    
 
Suppression of serum TSH, both basal and TRH – stimulated levels, has 
previously been reported in some studies of GH replacement (69, 322, 326). 
However, the data is inconsistent. The secretion of TSH demonstrates diurnal 
variation and is characterised by a nocturnal surge. GH replacement has been 
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shown, in a previous small study, to inhibit this nocturnal rise, possibly through 
increased somatostatinergic tone (67). In our study, we evaluated basal TSH levels 
after an overnight fast. Patients with previously diagnosed central hypothyroidism 
took thyroxine replacement in the evening for two weeks prior to the research study 
visits. This dosing schedule was designed to ensure stable serum thyroid hormone 
levels during the morning of the study visits. Seven patients (all taking thyroxine 
replacement) had a suppressed serum TSH throughout the study. This constitutes 
54% (7/13) of patients with central hypothyroidism. Previous research has 
confirmed that suppression of TSH is common in patients with central 
hypothyroidism. An audit of all patients with central hypothyroidism at a tertiary 
referral centre in the USA revealed that 64% had a subnormal serum TSH 
concentration. Indeed, some investigators have suggested that a serum TSH 
concentration >1.0mU/L is a reflection of inadequate thyroxine supplementation in 
central hypothyroidism. However, this is complicated by the fact that some patients 
with genuine central hypothyroidism have a high serum TSH. This is believed to be 
due to abnormal post-translational modification of the molecule leading to highly 
immunoreactive but biologically inactive TSH (114, 327). In our study, considering 
all patients with a detectable serum TSH, GH replacement, at a standard clinical 
dose, did not induce changes in serum TSH concentration. This is in keeping with 
comparable studies of adult patients with hypopituitarism (62, 63, 68).  
 
   
 Alterations in the HPT axis have also been reported in non-GHD subjects 
treated with GH. Taken together the results of these studies are also variable, for 
much the same reasons discussed above. Nonetheless, the overall trend in 
biochemical changes in TSH and thyroid hormone are similar to those observed in 
subjects with GHD. In a placebo-controlled study in obese healthy women, GH 
treatment resulted in a reduction in freeT4, an increase in serum T3 but no change 
in TSH (328). In contrast, Moller et al found no change in freeT4 but a consistent 
rise in serum T3 after fourteen days of high dose GH (4mg/day), in comparison to 
placebo, in healthy individuals (65).   
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 The findings of this study, confirm the significant impact of GH replacement 
on the HPT axis. These effects were observed during routine clinical practice using 
low dose GH supplementation and aiming to maintain the serum IGF-1 in the upper 
half of the age-related reference range. The decline in T4 and rise in T3 serum 
concentrations, that we observed, are largely in keeping with previous studies in 
similar populations. The mechanism underlying these changes is not fully 
understood. The rise in freeT3/freeT4 ratio is suggestive of an enhanced peripheral 
activation of the T4 prohormone. However, no direct human evidence for this theory 
exists. Also, other potential mechanism may influence the changes in the HPT axis 
including the effect of GH replacement on TSH dynamics.  Finally, clinical 
importance of a fall in T4, particularly a rising serum T3 concentration (the 
biologically active form of the hormone) is worthy of further investigation.  
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Chapter 4  
 
 
 
Potential mechanisms responsible for changes in the thyroid axis induced by 
growth hormone replacement 
 
 
4.1 Introduction 
 
Administration of exogenous growth hormone (GH) may provoke changes in the 
hypothalamo-pituitary-thyroid axis in both children and adults (61). This is apparent 
in both hypopituitary and healthy subjects after commencing GH supplementation 
(62, 65, 68, 328).  In Chapter 3, I described the alterations in the serum 
concentration of circulating thyroid hormones after administration of GH to a cohort 
of men with severe GHD. We observed a significant fall in free & total T4. Reverse 
T3 also declined and freeT3 concentration increased. TSH, in those with a 
detectable level, did not change during the study.  While previous data in adults 
suggests that GH replacement can unmask central hypothyroidism in approximately 
40% of adults with pituitary disease (63), all changes in thyroid hormone 
concentration, in our study, occurred within the normal reference range.  
 
 Several theories exist about the mechanisms which could mediates these 
changes in the thyroid axis. These include derangement of TSH dynamics, 
alteration in serum concentration of thyroid hormone binding proteins and a direct 
effect on hormone synthesis in the thyroid gland. However, the changing pattern of 
circulating thyroid hormone concentrations, with a fall in serum T4 often 
accompanied by a rising T3, is suggestive of an alteration in the peripheral 
interconversion of thyroid hormone subtypes.  
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T4, secreted by the thyroid, is a prohormone and must be activated into T3 in 
peripheral tissues, by removal of an iodine moiety from the outer (phenolic) ring 
(Figure 4.1). Reverse T3 (rT3), an inactive hormone by-product, can also be 
produced peripherally, by removal of the inner (tyrosyl) ring. It has been argued that 
GH affects deiodination of thyroid hormones in peripheral tissue. These reactions 
are catalysed by iodothyronine deiodinase enzymes (72). There are 3 subtypes of 
deiodinase enzymes - DIO1, DIO2 and DIO3 - which are differentially expressed 
depending on the tissue type. For example, DIO1 is highly expressed in liver and 
kidney while DIO2 is expressed more avidly in brain, pituitary and brown adipose 
tissue (329). T4 is converted into the biologically active hormone T3 by outer ring 
deiodination – a reaction catalysed by DIO2 and DIO1. DIO3 converts T4 into the 
biologically inactive hormone rT3. 
 
The hypothesis, that an effect on deiodinase activity is the mechanism for 
GH-induced changes in thyroid hormone metabolism, is supported by the findings of 
some but not all studies. Some investigators have observed a fall in T4 levels 
without a parallel rise in T3 or changes in reverse T3 following GH treatment (66, 
330). Ultimately, however, there is no conclusive evidence from human studies, to 
date, in support of the hypothesis that GH affects the peripheral deiodination of 
thyroid hormone.   
 
The primary aim of this study was to prospectively examine the relationship 
between changes in the serum concentration of thyroid hormones and deiodinase 
activity in subcutaneous fat, following GH replacement, in hypopituitary subjects. 
Adipose tissue was selected for analysis due to ease of accessibility in human 
subjects.   Secondary aims included assessment of the effect of GH therapy on 
circulating thyroid hormones, TSH, thyroid binding globulin and thyroglobulin levels. 
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Figure 4.1  
Peripheral metabolism of iodothyronines by deiodinase isoenzymes (DIO1, DIO2, 
DIO3). Removal of an iodine moiety (blue circles) from the outer ring of T4 
(deiodination) produces the active hormone T3 which can interact with the thyroid 
hormone nuclear receptor. Alternatively, removal of an iodine moiety from the inner 
ring of T4 deactivates the compound into reverse T3 (rT3). T3 can be deactivated, 
by undergoing further deiodination with DIO3, producing the inactive T2 molecule 
which is rapidly metabolised. 
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4.2 Methods 
 
4.2.1 Subjects 
 
We performed a prospective, observational study of 20 adult hypopituitary patients 
with severe GH deficiency. GH replacement was offered as part of routine clinical 
care. Diagnosis of GHD and pituitary hormone deficiencies is defined in Chapter 2.  
If the patient had multiple pituitary hormone deficiencies (defined as deficiency in 
two or more pituitary hormones), other hormones were adequately replaced for at 
least three months prior to commencing GH replacement. Subjects with and without 
TSH deficiency were included. Informed consent was obtained from all subjects to 
participate in this study which was approved by the local hospital Medical Research 
(Ethics) Committee. 
 
Prior to commencing GH replacement, a biopsy of subcutaneous fat was also 
performed on all subjects. Under aseptic conditions and local anaesthesia with 2% 
lignocaine, a Bergström biopsy needle was used extract a sample of subcutaneous 
fat from the anterior abdominal wall. Samples were snap frozen in liquid nitrogen 
and stored at −80°C until analysis. 
 
Baseline tests performed before GH supplementation included serum TSH, 
free & total T4, free & total T3, rT3, TBG, thyroglobulin, anti-thyroid peroxidase 
(TPO) antibody titre, selenium, insulin like growth factor-1 (IGF-1), testosterone and 
electrolytes. A 24 hour urine collection was analysed for iodine concentration. All 
serum samples were collected after an overnight fast.  Weight (kg) and height 
(metres) were measured to calculate body mass index (BMI). 
 
All subjects were commenced on recombinant GH at a starting dose of 
0.3mg/day administered subcutaneously – Saizen® (somatropin (rDNA origin) for 
injection) Merck Serono Ltd. Serum IGF-1 was checked after one month and the 
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dose was titrated to achieve an IGF-1 in the upper half of age-related reference 
range. Tests were repeated after 3-6 months on a stable dose of GH.  
 
4.2.2 Biochemical indices 
 
Total T3 was measured by a competitive binding protein, chemiluminescent 
immunoassay (UniCel DxI 800, Beckman Coulter). Reverse T3 was measured by 
liquid chromatography/tandem mass spectrometry (Quest Diagnostics, San Juan 
Capistrano, CA). The remainder of the serum thyroid hormones (total T4, free T4 
and free T3) and TSH were measured using fluoroimmunometric and sensitive 
“second generation” assays respectively (DELFIA, PerkinElmer Life Sciences). TBG 
was measured by immunoassay (Siemens Immunlite). Thyroglobulin was measured 
by chemiluminescent immunoassay (Beckman Coulter Access 2). Anti-TPO IgG 
was quantified by fluorenzyme-immunoassay (Elia Phadia 250).  
 
IGF-1 was measured in a chemiluminescent immunoassay using an 
acridinium labelled anti-IGF 1 antibody (IDS-iSYS). Testosterone was measured 
using a liquid phase radioimmunoassay (Spectria, Cisbio Bioassays). Serum 
selenium and urinary iodine levels were determined by inductively coupled plasma 
mass spectrometry (ICP-MS), on an Elan 6100 DRC plus (SCIEX Perkin-Elmer, 
Beaconsfield). Inter-assay and intra-assay coefficients of variation were less than 
10% throughout. 
 
4.2.3 Deiodinase isoenzyme activity 
 
DIO1 and DIO2 activities were assayed in tissue sample homogenates prepared in 
0.1 M potassium phosphate, 2 mM EDTA, and 2 mM dithiothreitol (DTT), pH 7.0. 
Protein concentration was determined by Bradford’s method using BSA as a 
standard. Tissue samples were assayed in duplicates. DIO1 activity was measured 
using 25–50 μg protein in 100 μl reaction mixture, [125I]-rT3 (100 000 
c.p.m./tube),400 nM rT3, and 2 mM DTT. Incubation was carried at 37°C for 1 h, 
115 
 
 
with or without 1 mM propylthiouracil(PTU). Results are expressed in pmol/min per 
mg protein. 
 
DIO2 activity was measured using 50 μg protein in 100 μl reaction mixture 
consisting of [125I]-T4 (200 000 c.p.m./tube), 2 nM T4 or 500 nM T4 (to inhibit DIO2 
activity), 1 mM T3 (to inhibit DIO3 activity), 20 mM DTT, and 1 mM PTU for 2 h at 
37 °C. Results are expressed in fmol/min per mg protein.  
 
Before each assay, [125I]-T4 and [125I]-rT3 (Perkin Elmer, Billerica, MA, USA) 
were purified by dialysis as described previously (14). For DIO1 and DIO2 activity 
assays, reactions were stopped by adding 100 μl of cold 2% BSA and 800 μl of 
10% trichloroacetic acid. After centrifugation at 2000 g for 10 min, 800 μl 
supernatant was applied to AG 50W-X2 columns (bed volume=1 ml) (Bio-Rad 
Laboratories) and eluted with 10% glacial acetic acid. The [125I] generated in the 
assay was counted in a gamma scintillation counter (Packard Cobra Gamma 
Counter, Perkin Elmer, Waltham, MA, USA). Blanks were performed in 
quadruplicates by substituting the volume of tissue homogenates for assay buffer. 
Assay detection limit was calculated as the average of [125I] produced by blanks 
multiplied by 3.3 times SD. 
 
DIO3 activity was measured as described previously by van Zeijl et al (317). In brief, 
adipose tissue (approximately 40 mg) was homogenized on ice in 500µl PE buffer 
(0.1 M sodium phosphate, 2 mM EDTA pH 7.2) containing 50 mM dithiothreitol 
(DTT) using a Polytron (Kinematica, Luzern, Switzerland). Protein concentration has 
been measured with the Bio-Rad protein assay (Bio-Rad Laboratories, Veenendaal, 
The Netherlands), according to manufacturer’s instructions.  
 
Samples were measured in duplicate using 75 μl homogenate in a final volume of 
0.15 ml in the presence of 1nM T3 or 500nM T3 (tissue blank, 500 nM T3 saturates 
DIO3 activity) with the addition of approximately 1*105c.p.m. [3`-125I]T3 (NEX110X, 
Perkin Elmer) in PE buffer. Samples were incubated for 2h. The activity reactions 
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were stopped by adding 0.15 ml ice-cold ethanol. After centrifugation, 0.125 ml of 
the supernatant was added to 0.125 ml 0.02 M ammonium acetate (pH 4), and 0.1 
ml of the mixture was applied to 4.6 x 250 mm Symmetry C18 column connected to 
a Waters HPLC system (Model 600E pump, Model 717 WISP auto-sampler, 
Waters, Etten-Leur, The Netherlands). The activity of T3 and T2 in the eluate was 
measured online using a Radiomatic 150 TR flow scintillation analyser (Perkin 
Elmer, Waltham, MA, USA) D3 activity is expressed as fmol generated 3,3`T2 per 
minute per mg tissue. DIO3 activity when incubated with 1nM T3, minus the activity 
measured when incubated with 500nM T3 represents true D3 activity. 
 
4.3 Results  
 
Baseline characteristics are outlined in Table 4.1. All patients had serum freeT4 and 
free T3 levels within the normal reference range prior to commencing GH 
replacement (Table 4.2). The mean daily dose of growth hormone was 0.34±0.11 
mg (range 0.15 - 0.5mg) administered subcutaneously. Serum IGF-1 levels rose 
significantly, as expected, during the course of the study (+114.4±12.3µg/L, 
p<0.0001). Body mass index (BMI) did not change during the study; 31.38±1.649 
kg/m 2 vs. 31.07±1.679kg/m2, p=0.26. Serum testosterone levels did not change 
during the course of the study (14.20±11.95nmol/L vs. 14.95±10.40nmol/L, p=0.45). 
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Table 4.1 
 
Baseline demographic features for the full study cohort. 
MPHD Multiple Pituitary Hormone Deficiencies. GHD Growth Hormone Deficiency. 
NFPA Non-functioning pituitary adenoma. 
 
 
Male/Female 20/0 
Aetiology of GHD n(%) 
NFPA  10(50) 
Prolactinoma  4(20) 
Other  6(30) 
 
MPHD n(%) 17(85) 
 
On Thyroxine  n(%) 13(65) 
 
Age (median) 53.1 years range 22.3-69.3 
BMI (median) 31.3 kg/m2 range 19.2-49.7 
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4.3.1 Changes in serum thyroid hormones, TSH and thyroglobulin 
concentrations 
 
Following GH replacement, freeT4 levels declined (-1.09±1.99 pmol/L, p=0.02). 
Reverse T3 levels also fell (-3.44±1.42 ng/dL, p=0.03) and freeT3 levels increased 
(+0.34±0.15 pmol/l, p=0.03) (Table 4.2). In addition, the serum T3/T4 and fT3/rT3 
ratio rose significantly (Figure 4.2). All changes in circulating thyroid hormone levels 
occurred within the normal reference range; no study subject required adjustment of 
or commencement of thyroxine replacement during the time course of the study.   
 
There was no significant change in early morning, fasting serum TSH levels 
during the study period. Sub-group analysis of subjects with a detectable TSH level 
confirmed stable, baseline TSH levels throughout. Similarly, serum concentration of 
thyroglobulin and TBG were unchanged by growth hormone therapy (Table 4.3).  
 
Two subjects had an elevated titre of anti-TPO antibodies; exclusion of these 
subjects from analysis did not significantly alter the changes observed in circulating 
thyroid hormones. No subject developed anti-TPO antibodies during the course of 
the study. 
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Table 4.2   
Alteration in circulating thyroid hormones following replacement of growth hormone. 
Data is reported as mean±SEM where variable is normally distributed (TT4, fT3, 
rT3) and median±SD where variable is not normally distributed (fT4 & TT3). Only 
those with a detectable pre-treatment TSH level (n=13) were included in this 
analysis – reported as median (range). * p<0.05. GH Growth Hormone. 
  
Pre GH 
 
Post GH 
 
Δ 
Ref. 
range 
P 
value 
 
95% CI 
 
FreeT4 
(pmol/L) 
 
12.9±4.0 
 
12.1±3.2 
 
-1.09±1.99* 
 
9-20  
 
0.02 
 
-2.24 to -0.32 
       
 
Total T4 
(nmol/L) 
 
109±4.9 
 
99.5±4.5 
 
-9.6±4.25* 
 
69-141 
 
0.04 
 
-18.5 to -0.72 
       
 
Free T3 
(pmol/L) 
 
5.4±0.2 
 
 
5.7±0.2 
 
+0.34±0.15* 
 
3.0-7.5  
 
0.03 
 
0.03 to 0.65 
       
 
Total T3 
(nmol/L) 
 
1.72±0.4 
 
1.62±0.4 
 
-0.02±0.32 
 
1-3 
 
0.76 
 
-0.1 to 0.19 
       
 
Reverse T3 
(ng/dL) 
 
17.6±1.4 
 
14.2±0.8 
 
-3.44±1.42* 
 
8-25 
 
0.03 
 
-6.44 to -0.45 
       
 
TSH  
(mU/L) 
 
1.1  
(0.4-5.1) 
 
1.1  
(0.2-3.3) 
 
-0.1±1.09 
 
0.4-4.0 
 
0.31 
 
-0.87 to 0.17 
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Figure 4.2 
Ratio of freeT3/freeT4 and freeT3/reverse T3 before (white boxes) and after (grey 
boxes) GH supplementation. * p<0.05. 
 
  
121 
 
 
Table 4.3 
The effect of GH replacement on serum thyroid stimulating hormone (TSH), thyroid 
binging globulin (TBG) and thyroglobulin (Tg). Only those with a detectable pre-
treatment TSH level (n=13) were included in this analysis – (TSH range 0.41-
5.1mU/L). Changes in TBG and Tg were analysed in all patients (n=20). Δ median 
difference. 
 
  
Pre GH  
median 
(range) 
 
Post GH 
median 
(range) 
 
Δ 
 
P 
value 
 
95% CI 
 
TSH 
(mU/L) 
 
1.1  
(0.4-5.1) 
 
1.1  
(0.2-3.3) 
 
-0.1±1.09 
 
0.31 
 
-0.87 to 0.17 
      
 
TBG 
(μg/mL) 
 
14.1 
(8.9-22) 
 
14.1  
(9.1-24) 
 
+1.1±0.83 
 
0.18 
 
-0.59 to 2.88 
      
 
Tg 
(µg/L) 
 
6.8  
(1.8-47) 
 
6.5  
(3.1-39) 
 
-0.65±4.89 
 
0.17 
 
 
-1.50 to 0.0 
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4.3.2 Changes in deiodinases activity in subcutaneous adipose tissue 
 
In subcutaneous fat, DIO2 isoenzyme activity declined (-11.08 fmol/mg per min; 
95% CI -28.95 to 0.19, p=0.036). The decline in DIO2 activity was greater after 
exclusion of outliers (n=3): -12.62 fmol/mg per min; 95% CI -25.40 to -4.96, 
p=0.002). DIO1 and DIO3 isoenzyme activity remained unchanged following GH 
substitution (Figure 4.4). The decline in DIO2 activity correlated with the fall in 
serum freeT4 and totalT4 concentration but not the changes in T3 or reverse T3 
(Figure 4.5). There was no significant correlation between the fall in DIO 2 activity 
and the rise in serum IGF-1 level.   
 
Deiodinase enzymes are selenoproteins and their activity can be affected by 
severe selenium deficiency or marked alteration in selenium exposure.(16, 17) In 
our study, all subjects were replete in selenium (normal population reference range 
0.8 – 2.0 Umol/L). Furthermore, serum selenium levels were not altered following 
GH replacement (1.24±0.04umol/L vs. 1.24±0.04 umol/L; 95% CI -0.096 to 0.088, 
p=0.93).  
 
The study was conducted in Dublin, Ireland. This region is classified as mildly 
iodine deficient based on subnational data (331). However, no patient had severe 
iodine deficiency (defined as urinary iodine concentration <0.16 μmol/L) prior to 
commencing GH. Median urinary iodine concentration was unchanged before and 
after GH replacement – 0.84 μmol/L (range 0.17 - 2.81) vs 0.75 μmol/L (range 0.15-
3.63); 95% CI -0.27 to 0.18, p=0.6215.  Similarly, median 24 hour urinary excretion 
of iodine, a reflection of iodine nutritional status, remained stable throughout the 
study - 1.19 μmol/24hr (range 0.32-3.37)  vs. 1.26 μmol/24hr (range 0.38-5.26); 
95% CI -0.73 to 0.42, p=0.42). 
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Figure 4.3 
 
Deiodinase isoenzyme activity in subcutaneous fat following GH replacement. Data 
for DIO2 is shown following removal of significant outliers (n=3). DIO1 activity 
expressed as pmol/min per mg tissue; DIO3 & DIO2 expressed as fmol/min per mg 
tissue.  
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Figure 4.4 
 
Correlation between fall in DIO2 activity (ΔDIO2; horizontal axis) and decline in 
serum T4 concentration following growth hormone supplementation. 
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4.4 Discussion 
 
In this prospective clinical study, we attempt to shed light on the mechanisms 
underlying the alterations in the hypothalamo-pituitary-thyroid axis following GH 
replacement. Novel studies, including in vitro analysis of human serum and adipose 
tissue, have revealed the complex metabolic processes which occur during GH 
treatment. Our results demonstrate a decreased circulating concentration of freeT4 
in conjunction with an increase in freeT3 following initiation of GH replacement. 
These alterations occurred despite TSH levels remaining unchanged. There are 
inconsistencies in the published literature to date; however, the pattern of change in 
circulating thyroid hormones that we report is largely in keeping with previous 
studies of large cohorts of patients with organic pituitary disease (62, 63, 66, 272, 
320).  
 
In our study, all changes in thyroid hormone concentration occurred within 
the normal reference range. This may be due to increasing awareness of the GH-
induced fall in T4, resulting in a tendency to optimise T4 replacement prior to 
initiating GH by keeping the serum freeT4 concentration in the upper half of the 
normal range. While the underlying mechanism responsible for these alterations 
remains speculative, the rise in T3 in parallel with a fall in T4 levels is suggestive of 
increased peripheral conversion of T4 to T3.  
 
We adopted a novel approach to investigate this potential mechanism 
through in vitro analysis of subcutaneous adipose tissue from adults, before and 
after exposure to recombinant GH. However, direct measurement of DIO2 activity, 
the principal deiodinase isoenzyme responsible for T4 to T3 conversion in 
peripheral tissue, did not reveal changes in DIO2 that would explain the alterations 
observed in the serum levels of thyroid hormones: paradoxically, DIO2 activity, in 
subcutaneous fat, declined following GH exposure. The activity of DIO1, which can 
also generate T3 in peripheral tissue, was unchanged by GH replacement. Serum 
freeT3 concentration rose during our study which could also be explained by 
126 
 
 
reduced deactivation of T3 - a reaction principally catalysed by DIO3; however, the 
activity of this isoenzyme, in subcutaneous fat, was unaltered by GH therapy.   
 
Iodothyronine deiodinase enzymes are selenoproteins responsible for the 
local activation and inactivation of thyroid hormones (72, 73). In healthy humans, 
they maintain T3 homeostasis, both in the serum and in peripheral tissue, by 
controlling the formation and degradation of T3. In euthyroid human subjects, 80% 
of circulating T3 is formed by deiodination of T4 in peripheral tissue (73). We 
speculated that a fall in T4, accompanied by a rise in T3, following GH 
supplementation was due to increased DIO2 activity; however, the opposite effect 
on DIO2 was observed.  
 
The explanation for this unexpected observation is unclear but we suggest a 
number of possible mechanisms. Firstly, previous animal research has 
demonstrated that hypophysectomised rats have an enhanced expression of DIO2 
in brown adipose tissue (332). The investigators hypothesised that pituitary 
hormones exert tonic inhibition of DIO2 activity in peripheral tissue; only GH 
prevented the rise in DIO2 activity when hypophysectomised animals were given 
replacement pituitary hormones. This provides preliminary evidence that GH may 
have a suppressive effect on DIO2 activity in some tissues. Alternatively, the 
increased circulating and/or locally generated T3 may have caused the decline in 
DIO2 activity in an attempt to maintain tissue T3 homeostasis. Previous research 
has confirmed that T3 itself can suppress tissue DIO2 mRNA expression and 
activity in various animal tissues (333, 334). Also, GH is well recognised to cause 
lipolysis and a reduction in DIO2 activity could be an attempt to protect the fat tissue 
from the additional lipolytic action of T3 (261, 335, 336).  
 
The rise in T3 level could also be explained by reduced clearance of T3 as a 
consequence of attenuated activity of DIO3. This is supported by limited animal 
research. Injection of GH into chicken embryos suppresses of hepatic DIO3 activity 
and is associated with a rise in serum T3 levels (337). In our study, DIO3 activity in 
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subcutaneous fat was not affected by GH replacement. However, our deiodinase 
assays measured maximum in vitro activity. These enzymes may not work at 
maximum activity in vivo and small, but clinically significant, changes in sub-
maximum tissue activity may not have been detected by our assay. Ultimately, 
deiodinase enzyme activity was quite low in subcutaneous adipose tissue of our 
study subjects. The activity we observed, before and after GH exposure, may not 
necessarily reflect activity in other organs, such as liver, where the enzymes are 
expressed at a considerably higher level. To our knowledge, there are no previous 
human studies, directly examining the effect of GH replacement on tissue 
deiodinase activity, against which we could compare our findings.   
 
Despite the discordance between the serum and tissue findings in our study, 
modulation of peripheral deiodination of thyroid hormones, by GH, remains a likely 
explanation for the changes in circulating thyroid hormone levels. Thyroid hormone 
influences gene expression in virtually every organ in humans and deiodinase 
enzymes are differentially expressed in a wide variety of tissues (78). DIO1 and/or 
DIO2 activity in other organs, such as the liver, skeletal muscles or kidney, may 
make a greater contribution to the circulating pool of T3 in patients with 
hypopituitarism. DIO3 activity was only measured at low levels in subcutaneous fat, 
in contrast to other tissue, such as skeletal muscle and liver, where it is often 
expressed at much higher levels (76, 338). DIO3 activity in other organs may be 
more sensitive to inhibition by GH and this may account for the rise in free T3 
concentration.   
 
Previous researchers have suggested alternative explanations for GH-
induced alterations in thyroid hormone levels. The vast majority of circulating T4 is 
bound to TBG. A reduced binding capacity of TBG has been demonstrated following 
administration of high dose cadaveric GH (71). However, these findings were not 
reflected by any change in circulating thyroid hormone levels in non-hypopituitary 
subjects. Also, the decline in TBG occurred in parallel with a fall in serum albumin 
and total protein. The results of this study may be explained by fluid retention which 
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can occur with high-dose GH administration. In our prospective analysis, there was 
a parallel change in total and free T4 levels and also a rise in free T3 which do not 
support a possible change in TBG binding capacity. Also, in keeping with previous 
research, direct measurement of TBG serum concentration, before and after 
exposure to recombinant GH for at least three months, did not reveal any significant 
changes (63).  
 
An alteration of TSH dynamics has also been postulated as a mechanism to 
explain the fall in T4 levels observed in many studies following GH replacement. 
Previous studies in adults have demonstrated a more pronounced reduction in T4 
levels among hypopituitary subjects with a measureable serum TSH level (62). 
Porter et al, in a study of GHD adolescents reported a lower basal and TRH-
stimulated TSH following GH replacement (339). However, this study was 
conducted at a time when cadaveric GH - which was occasionally contaminated 
with TSH - was used. Root et al demonstrated a decline in thyroidal I-131 uptake 
following GH replacement in children (340). This occurred without a change in 
iodine exposure and appeared to be reversed by exogenous TSH administration. 
TSH is usually secreted in a pulsatile manner with diurnal variation. Also, Jorgensen 
et al suggested that mean 24 hour secretion of TSH is reduced by GH therapy; in 
particular the nocturnal surge of TSH is attenuated (67). We did not measure TSH 
secretion profiles or the effect of TRH stimulation in our study. However, we found 
that subgroup analysis of subjects with a detectable baseline serum TSH revealed 
less marked changes in circulating thyroid hormone levels. Nonetheless, a direct 
effect of GH on TSH dynamics remains one possible explanation for some of the 
alterations in serum thyroid hormone levels following GH replacement.  
 
Another possible underlying mechanism is a direct effect of GH on the 
thyroid gland, suppressing T4 production or promoting intrathyroidal conversion of 
T4 to T3 – DIO1 and DIO2 are expressed in the thyroid. However, serum 
thyroglobulin levels, a surrogate marker of thyroid hormone synthesis, as well as 
iodine exposure, were unchanged throughout our study.  
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This study extends the findings of previous studies which have examined the 
impact of GH replacement on thyroid hormone metabolism. This is the first 
prospective study, to our knowledge, to attempt to unravel the effects of GH on 
peripheral deiodination of T4 and T3, in hypopituitary subjects, by directly examining 
peripheral human tissue. We selected subcutaneous adipose tissue as it is a well-
known peripheral tissue target of GH and easily accessible in human subjects (336).  
In vitro analysis of the activity of all three selenodeiodinase isoenzymes in 
subcutaneous fat did not explain the serum changes in thyroid hormone. However, 
it remains possible that differential regulation of deiodinase activity in other tissues 
(e.g. liver) explains the fluctuations in thyroid hormones.  
 
The study has some limitations. The study cohort was relatively small and all 
were men. The gender imbalance occurred by chance during open unbiased 
recruitment. However, this may have reduced the confounding effect of oestrogen 
which has been shown to influence deiodinase activity in animal models (341, 342). 
Data from a healthy, match control group would have added to the findings of this 
study. However, this study was designed as a longitudinal observational cohort 
study during routine clinical treatment with each subject acting as their own control. 
The possible impact of altered TSH dynamics, including the response to TRH, was 
not assessed in this study; however, only seven subjects (35%) were TSH 
sufficient. In vitro experiments were limited to subcutaneous fat due to the relative 
ease of tissue accessibility. Analysis of other tissue (such as liver and skeletal 
muscle) may have confirmed a tissue-specific regulation of deiodinase activity by 
GH. Finally, we did not measure deiodinase mRNA expression in peripheral issue 
which may have given further insights into the peripheral modulation of thyroid 
hormone metabolism by GH (72).  
 
In conclusion, DIO2 activity in subcutaneous adipose tissue is suppressed, 
while DIO1 and DIO3 activity are unchanged, following growth hormone 
replacement, in adults with hypopituitarism. This does not explain either the 
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decrease in circulating concentration of freeT4 and reverseT3 or the rise in freeT3 
induced by GH replacement.   
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Chapter 5 
 
 
Clinical consequences of changes induced in the hypothalamic-pituitary-
thyroid axis following growth hormone replacement 
 
 
5.1 Introduction 
 
Central hypothyroidism, a rare cause of thyroid hormone deficiency, is challenging 
to diagnose and treat. Typical symptoms of hypothyroidism may be obscured by 
clinical features of co-existing pituitary hormone deficits such as GH or ACTH 
deficiency. In addition, there is no reliable marker of central hypothyroidism and the 
diagnosis is largely biochemical, based on the finding of a low free serum thyroid 
hormone concentration with inappropriately low serum TSH (110). The diagnosis is 
further complicated by the fact that a serum T4 concentration within the population 
reference range, similar to primary hypothyroidism, does not exclude central 
hypothyroidism. Research evidence suggest that patients with central 
hypothyroidism, in comparison to those with primary thyroid failure, are at risk of 
under-replacement with thyroxine (126). This has largely been attributed to 
difficulties in diagnosing and monitoring central hypothyroidism. 
 
Most patients with central hypothyroidism have co-existing growth hormone 
deficiency (GHD) (100). Previous research has demonstrated that GH replacement 
modulates peripheral thyroid hormone metabolism. The most predictable alteration 
is a reduction in circulating free T4 levels with between 36-47% of previously 
euthyroid subjects requiring thyroxine replacement (61). However, many 
prospective studies in adult cohorts have also shown a concomitant rise in T3 
levels.  The clinical significance of a fall in T4, in the face of a rising T3 level (the 
biologically active form of thyroid hormone) is worthy of consideration. 
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Serum concentration of specific proteins and trace elements, derived from 
the liver and bone, are influenced by minor alterations in circulating thyroid hormone 
levels. In addition, recent evidence suggests that cardiac time intervals (recorded on 
echocardiography) and resting energy expenditure (REE) may be reliable biological 
markers of thyroid hormone action in central hypothyroidism (294). These 
measurements may be useful in the assessment of central hypothyroidism and may 
give new insight in to the clinical relevance of fluctuations in thyroid hormone levels 
observed following growth hormone replacement. 
 
The aim of this study was to examine the relationship between changes in 
serum concentration of thyroid hormones and known biological markers of thyroid 
hormone action following growth hormone supplementation in adults. 
 
 
5.2 Methods 
 
5.2.1 Subjects 
 
We performed a prospective, observational study of 20 adult hypopituitary 
patients with severe GH deficiency. GH replacement was offered as part of routine 
clinical care. Severe GH deficiency was confirmed by a GH stimulation test, either 
insulin tolerance test (ITT) or glucagon stimulation test (GST); a serum GH peak 
less than 3 µg/L was taken as evidence of severe GH deficiency. Additional pituitary 
hormone deficiencies were defined as described in Chapter 2. If the patient had 
multiple pituitary hormone deficiencies (defined as deficiency in two or more 
pituitary hormones), other hormones were adequately replaced for at least three 
months prior to commencing GH replacement. 
 
Baseline tests performed before GH supplementation included serum TSH, 
free & total T4, free & total T3, rT3, insulin like growth factor-1 (IGF-1), testosterone 
and creatinine kinase (CK). Liver and bone- derived biomarkers of thyroid hormone 
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action were measured in serum and 24 hour urine collections. All serum samples 
were collected after an overnight fast.  Resting energy expenditure (REE) was also 
measured in the fasting state. In addition, an echocardiogram was performed to 
measure cardiac time intervals. Weight (kg) and height (metres) were measured to 
calculate body mass index (BMI). Blood pressure and heart rate were recorded 
while resting on three separate occasions during the morning of the research testing 
schedule.  
 
All subjects were commenced on recombinant GH at a starting dose of 
0.3mg/day administered subcutaneously – Saizen® (somatropin (rDNA origin) for 
injection) Merck Serono Ltd. Serum IGF-1 was checked after one month and the 
dose was titrated to achieve an IGF-1 in the upper half of age-related reference 
range.  
 
Tests were repeated after 3-6 months on a stable dose of GH. 
 
5.2.2 Laboratory methods 
 
Biochemical indices 
 
Total T3 was measured by a competitive binding protein, chemiluminescent 
immunoassay (UniCel DxI 800, Beckman Coulter). rT3 was measured by liquid 
chromatography/tandem mass spectrometry (Quest Diagnostics, San Juan 
Capistrano, CA). The remainder of the serum thyroid hormones (total T4, free T4 
and free T3) and TSH were measured using fluoroimmunometric and sensitive 
“second generation” assays respectively (DELFIA, PerkinElmer Life Sciences). TBG 
was measured by immunoassay (Siemens Immunlite).  
 
IGF-1 was measured in a chemiluminescent immunoassay using an acridinium 
labelled anti-IGF 1 antibody (IDS-iSYS). Testosterone was measured using a liquid 
phase radioimmunoassay (Spectria, Cisbio Bioassays).  
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Bone-derived serum biomarkers 
 
The concentration of bone-specific alkaline phosphatase (BALP), a marker of both 
bone mineralisation and maturation, was measured by an immunoenzymatic assay 
(Ostase, Immunodiagnostic Systems Ltd, Bolton, UK) on an automated ELISA 
platform. The serum concentrations of total procollagen type 1 N-propeptide 
(P1NP), osteocalcin 1–49 (OCI) and C-terminal cross-linking telopeptide (CTX-I)  
were measured by electrochemiluminescence immunoassay measured on the 
Elecsys 2010 analyser (Roche Diagnostics).  
 
 
Liver-derived serum biomarkers 
 
Quantitative measurement of sex hormone binding globulin (SHBG) was performed 
using a two-step chemiluminescent microparticle immunoassay (ACHITECT 
iSystem, Abbott). Ferritin was estimated by a chemiluminescent assay (Beckman 
DxI 800 Series). Caeruloplasmin was measured by immunoassay (Beckman AU 
Series Analyser) 
 
Serum lipids, LDL and HDL subfractions were measured using a polyacrylamide gel 
tube electrophoresis method (LipoprintTM LDL System; Quantimetrix, Redondo 
Beach, CA). The Lipoprint System uses non-denaturing, linear polyacrylamide gel 
electrophoresis to separate and measure the lipoprotein fractions. The test uses a 
lipophilic dye that binds to the cholesterol in the lipoprotein particle prior to 
electrophoresis. The electrophoresed gels are scanned to determine the relative 
area of each lipoprotein subfraction which is multiplied by the total cholesterol of the 
sample to calculate the amount of cholesterol in each subfraction.  
 
Inter-assay and intra-assay coefficients of variation (CV) were less than 10% 
throughout. 
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CK was measured by a spectrophotometric assay (Beckman AU Series Analyser). 
Inter-assay CV 1.5% 
 
Serum selenium as well as serum and urine copper concentrations  were 
determined by inductively coupled plasma mass spectrometry (ICP-MS), on an Elan 
6100 DRC plus (SCIEX Perkin-Elmer, Beaconsfield).  
 
 
5.2.3 Resting Energy Expenditure  
 
Resting energy expenditure (REE) was measured by open circuit indirect 
calorimetry conducted using a transparent canopy in the dilution testing mode. 
(Deltatrac®). The canopy consisted of an inlet and an outlet valve. Both valves were 
connected to the calorimeter (Deltatrac II) via tubes. This measures the rate of O2 
and CO2 exchange in the lungs and this can be used to estimate energy 
expenditure. Subsequently, these values were used to estimate REE and substrate 
utilization (% carbohydrate and % fat) using the Weir equation (Weir 1949). In 
addition, 24 hour urine collection was obtained to account for protein oxidation and 
to complete the energy expenditure measurement. 
 
 
5.2.4 Echocardiographic assessment  
 
A complete two-dimensional and Doppler echocardiogram was performed using a 
2.0- to 2.5-MHz transducer according to standard technique. Two dimensional M-
mode echocardiograms were recorded from parasternal short-axis view at mid-left 
ventricular (LV) level to determine LV dimensions. Pulsed wave Doppler was used 
to measure cardiac time intervals by sequential recording of the mitral inflow. Tissue 
doppler imaging (TDI) measurements were also made from an average of 5 
consecutive heart beats. Time intervals were measured from mitral inflow and LV 
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outflow velocity traces. Separate measurements were taken from septal and lateral 
wall.  
Cardiac intervals of interest are shown in Figure 5.1. ICT (isovolumetric 
contraction time) is the time when the ventricles have begun to contract, but the 
volume of the chambers has not yet changed. It occurs immediately after the period 
of electromechanical delay, following electrical stimulation of the ventricles.  
IRT (isovolumetric relaxation time) occurs at the end of systole when the semi-lunar 
valves shut and the ventricles relax; this results in a fall in the intraventricular 
pressure, initially with no change in the chamber volume. After the semilunar valves 
open, the ventricles can eject the stroke volume into the systemic circulation during 
a period known as ejection time (ET).  Myocardial performance index (MPI) was 
defined as sum of the isovolumetric contraction time (ICT) and isovolumetric 
relaxation time (IRT) divided by the left ventricular ejection time (ET).  
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Figure 5.1 
 
ICT (isovolumetric contraction time). This is the time when the ventricles have 
begun to contract, but the volume of the chambers has not yet changed. It occurs 
immediately after the period of electromechanical delay, following electrical 
stimulation of the ventricles.  
 
IRT (isovolumetric relaxation time). This occurs at the end of systole when the semi-
lunar valves shut and the ventricles relax; this results in a fall in the intraventricular 
pressure, initially with no change in the chamber volume.  
 
ET (ejection time). After the semilunar valves open, the ventricles can eject the 
stroke volume into the systemic circulation during a period known as ET. 
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Figure 5.1 (contd) 
 
Myocardial performance index (MPI) is also known as the Tei index. It incorporates 
both systolic and diastolic time intervals in expressing global systolic and diastolic 
ventricular function. MPI = (ICT+IRT)/ET. 
 
Reproduced with permission of Elsevier Publishing (289) 
 
 
5.3 Results 
 
 
Baseline clinical and hormonal characteristics are outlined in Table 5.1. Seventeen 
(85%) had multiple pituitary hormone deficiencies (MPHD) defined as two or more 
pituitary hormone deficiencies; three patients had isolated GH deficiency. Data is 
shown comparing subjects with and without central hypothyroidism (TSH 
deficiency).  Median replacement dose of hydrocortisone for those with ACTH 
deficiency was 20mg/day (range 10-25). Hypertension was defined as prescribed 
anti-hypertensive medication. Hyperlipidaemia was defined as prescription of HMG 
CoA reductase inhibitor (statin).  Fasting glucose was higher in the group without 
central hypothyroidism compared to the group with preserved TSH function. 
However, the former group included two patients with diabetes mellitus (2/7) 
whereas the latter group contained only one with diabetes (1/13).   
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Table 5.1 
 
Baseline clinical characteristics of the study cohort. Data also shown for those with 
central hypothyroidism (CH) (taking thyroxine) and those with preserved TSH 
reserve (not taking thyroxine). Hypertension was defined as prescribed anti-
hypertensive medication. Hyperlipidaemia was defined as prescribed HMG CoA 
reductase inhibitor.  Data for continuous variables are displayed as median (range). 
GHD growth hormone deficiency.  
 
*p<0.05.  ° Comparison of patients with and without CH. 
 
 All patients Patients 
with CH 
Patients 
without CH 
p value° 
n 20 13 7  
 
Male/Female 
 
 
20/0 
 
13/0 
 
7/0 
 
MPHD n (%) 
 
 
17 (85) 
 
13 (100) 
 
4 (57) 
ACTH deficient  
n (%) 
11 (55) 9 (69) 2 (29) 
FSH/LH deficient 
n (%) 
14 (70) 11 (85) 3 (43) 
Hypertension  
n (%) 
5 (25) 3 (23) 2 (29) 
Hyperlipidaemia 
n (%) 
6 (30) 3 (23) 3 (43) 
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Table 5.1 (contd) 
 
 All patients Patients 
with CH 
Patients 
without CH 
p value° 
BMI (kg/m2)  31.3  
(19.2-49.7) 
33.9  
(19.2-49.6) 
30.5  
(23.6-37.6) 
0.42 
 
Systolic BP 
(mmHg)  
119 
(95-158) 
116 
 (95- 138) 
120  
(112-158) 
0.39 
Diastolic BP 
(mmHg)  
73  
(54-81) 
71 
 (54-79) 
80  
(70-81) 
0.15 
Fasting glucose 
(mmol/L) 
4.75  
(3.6-8.0) 
4.6  
(3.6-5.6) 
5.0  
(4.7-8.0) 
0.03* 
Testosterone 
(nmol/L)  
14.2  
(5.6-50.0) 
15.6  
(6.3-50.0) 
12.3  
(5.6-21.2) 
0.08 
IGF-1 (baseline) 
(μg/dL) 
126.5  
(24.2-
199.6) 
100.1  
(24.2-178.7) 
142.2  
(36.39-199.6) 
0.33 
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5.3.1 Hypothalamic-pituitary-thyroid axis 
 
As described in Chapter 3, the mean daily dose of growth hormone was 
0.34±0.11 mg (range 0.15 - 0.5mg) administered subcutaneously. Following GH 
replacement, serum IGF-1 levels rose significantly, as expected, during the course 
of the study (+114.4±12.3µg/L, p<0.0001). Body mass index (BMI) did not change 
during the study; 31.38±1.649 kg/m 2 vs. 31.07±1.679kg/m2, p=0.26. FreeT4 levels 
declined (-1.09±1.99 pmol/L, p=0.02). Reverse T3 levels also fell (-3.44±1.42 ng/dL, 
p=0.03) and freeT3 levels increased (+0.34±0.15 pmol/l, p=0.03) (Table 5.2).  
 
There was no significant change in early morning, fasting serum TSH levels 
during the study period. Sub-group analysis of subjects with a detectable TSH level 
confirmed stable, baseline TSH levels throughout. When patients with TSH 
deficiency (n=13) were considered separately, a similar pattern of biochemical 
pattern of changes was observed for free/total T4 and reverse T3 (Table 5.3). 
However, the rise in free T3 did not reach statistical significance in this group.    
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Table 5.2   
Alteration in circulating thyroid hormones following replacement of growth hormone. 
Data is reported as mean±SEM where variable is normally distributed (TT4, fT3, 
rT3) and median±SD where variable is not normally distributed (fT4 & TT3). Only 
those with a detectable pre-treatment TSH level (n=13) were included in this 
analysis – reported as median (range). * p<0.05. GH Growth Hormone. 
  
Pre GH 
 
Post GH 
 
Δ 
Ref. 
range 
P 
value 
 
95% CI 
 
FreeT4 
(pmol/L) 
 
12.9±4.0 
 
12.1±3.2 
 
-1.09±1.99* 
 
9-20  
 
0.02 
 
-2.24 to -0.32 
       
 
Total T4 
(nmol/L) 
 
109±4.9 
 
99.5±4.5 
 
-9.6±4.25* 
 
69-141 
 
0.04 
 
-18.5 to -0.72 
       
 
Free T3 
(pmol/L) 
 
5.4±0.2 
 
 
5.7±0.2 
 
+0.34±0.15* 
 
3.0-7.5  
 
0.03 
 
0.03 to 0.65 
       
 
Total T3 
(nmol/L) 
 
1.72±0.4 
 
1.62±0.4 
 
-0.02±0.32 
 
1-3 
 
0.76 
 
-0.1 to 0.19 
       
 
Reverse T3 
(ng/dL) 
 
17.6±1.4 
 
14.2±0.8 
 
-3.44±1.42* 
 
8-25 
 
0.03 
 
-6.44 to -0.45 
       
 
TSH  
(mU/L) 
 
1.1  
(0.4-5.1) 
 
1.1  
(0.2-3.3) 
 
-0.1±1.09 
 
0.4-4.0 
 
0.31 
 
-0.87 to 0.17 
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Table 5.3  
Alteration in circulating thyroid hormones following GH replacement in subjects with 
TSH deficiency (n=13). Data is reported as mean±SEM where variable is normally 
distributed (TT4, fT3, TT3, rT3) and median±SD where variable is not normally 
distributed (fT4). GH Growth Hormone.  
 
  
Pre GH 
 
Post GH 
 
Δ 
Ref. 
range 
P 
value 
 
95% CI 
 
FreeT4 
(pmol/L) 
 
13.5 
±4.59 
 
12.20 
±3.66 
 
-2.15 ±1.89* 
 
9-20  
 
0.004 
 
-3.39 to -0.98 
       
 
Total T4 
(nmol/L) 
 
116.7 
±4.58 
 
102.6 
±4.3 
 
-14.07±4.3* 
 
69-141 
 
0.007 
 
-23.45 to -4.69 
       
 
Free T3 
(pmol/L) 
 
5.312 
±0.23 
 
5.74  
±0.28 
 
+0.43±0.22 
 
3.0-7.5  
 
0.085 
 
-0.07 to 0.22 
       
 
Total T3 
(nmol/L) 
 
1.65 
±0.11 
 
1.83 
±0.12 
 
+0.18±0.08 
 
1-3 
 
0.05 
 
0.005 to 0.36 
       
 
Reverse 
T3 (ng/dL) 
 
19.17 
±1.54 
 
15.00 
±0.77 
 
-4.15±1.72* 
 
8-25 
 
0.03 
 
-7.94 to 0.39 
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5.3.2 Hepatic and muscle biomarkers  
 
Changes in serum ferritin, SHBG and CK are shown in table 5.4. Significant 
changes in serum ferritin were not accompanied by changes in serum iron 
(14.40±1.188 μmol/L vs. 15.53±1.24μmol/L; 95% CI -1.1 to 3.37, p=0.3) or total iron 
binding capacity (42.59±2.89μmol/L vs. 45.17±2.51μmol/L; 95% CI -0.15 to 5.31, 
p=0.06). Serum ferritin correlated positively with serum free and total T4 before and 
after GH replacement (Figure 5.2). No such correlation was observed between IGF-
1 and ferritin. The decline in serum ferritin during the study also correlated 
significantly with the fall in serum free & total T4; there was no significant correlation 
between the decline in ferritin and either the rise in freeT3 or IGF-1 (Figure 5.3). 
 
Patients with TSH deficiency were analysed separately and a similar pattern 
of change in serum ferritin concentration was observed (100.4±66.70 vs 61.00± 
59.64; 95% CI -65.06 to -14.14, p=0.003). No significant changes were observed in 
SHBG or CK in the subgroup analysis. 
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Table 5.4  
 
Changes observed in serum biomarkers of thyroid hormone action following growth 
hormone (GH) replacement. Data shown for all subjects (n=20) is expressed as 
mean (SEM) for normally distributed data (CK) and median (SD) for data not 
normally distributed (SHBG, Ferritin). 
CK creatinine kinase SHBG sex hormone binding globulin Δ change in serum 
concentration. 
*p<0.05. 
 
  
Pre GH 
 
Post GH 
 
Δ 
Ref. 
range 
P 
value 
 
95% CI 
Ferritin 
ng/ml 
83.30 
(63.66) 
48.65 
(54.11) 
-26.6  
± 36.09 
 
16-215 
 
0.005* 
 
-44.83 to -8.94 
       
CK  
IU/L 
154.8 
(26.77) 
149.5 
(18.81) 
-4.5  
± 60.43 
 
0-210 
 
0.681 
 
-25.00 to 11.00 
       
SHBG 
nmol/L 
35.85 
(4.26) 
34.09 
(4.12) 
-1.77  
± 2.0 
 
13 -56 
 
0.389 
 
-5.96 to 2.43 
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Figure 5.2 
 
Correlation between serum ferritin and free T4 concentration for the full cohort. 
Previous researchers have shown that serum ferritin levels are sensitive to 
circulating thyroid hormone concentration. There was a significant positive 
correlation between serum ferritin correlated positively with serum free T4 before 
and after GH replacement. 
 
Units: Ferritin ng/ml, free T4 pmol/L. 
 
Δ delta – median change during the study period. 
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Figure 5.3  
 
Correlation between the fall in serum ferritin and changes in free T4 (A), total T4 
(B), free T3 (C) and insulin-like growth factor- 1(D) during the study period. The 
decline in serum ferritin during the study also correlated significantly with the fall in 
serum free & total T4; there was no significant correlation between the decline in 
ferritin and either the rise in freeT3 or IGF-1. 
 
Units: Ferritin ng/ml, IGF-1 µg/L, free T3 pmol/L, free T4 pmol/L, total T4 nmol/L. 
 
Δ delta – median change during the study period. 
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Analysis of copper metabolism, in the entire study group, did not show any 
significant changes in serum (or urine) copper or serum caeruloplasmin 
concentration. However, subgroup analysis of subjects with TSH deficiency (n=13), 
revealed that serum caeruloplasmin declined significantly following GH replacement 
while the decline of serum copper (Cu) was of borderline significance (Table 5.5). 
Urine copper excretion was not affected. Within this subgroup, serum Cu and 
caeruloplasmin correlated positively with serum freeT4 before, but not after, GH 
substitution.  
 
There was no correlation between serum or urine biomarkers of copper 
metabolism and serum IGF-1. A weak correlation was seen between the decline in 
serum freeT4 and serum Cu; however this did not reach statistical significance 
(Figure 5.4). The change in caeruloplasmin did not correlate with either the fall in 
freeT4 or the rise in IGF-1. 
  
149 
 
 
Table 5.5 
 
Serum and urine markers of copper metabolism before and after growth hormone 
replacement. Data shown only for those with TSH deficiency (n=13).  All continuous 
variables were normally distributed and are reported as mean(SEM). 
Cu copper GH growth hormone Caerulo. Caeruloplasmin. *p<0.05. 
 
  
Pre GH 
 
Post GH 
 
Δ 
Ref. 
range 
P 
value 
 
95% CI 
Copper 
μmol/L 
16.97 
(0.97) 
15.35 
(0.93) 
-1.62 
(±0.73) 
 
12-25 
 
0.05 
 
-3.2 to -0.03 
       
Caerulo. 
g/L 
0.26 
(0.01) 
0.23 
(0.02) 
-0.03 
(±0.01) 
 
0.2-0.6 
 
0.036* 
-0.054 to -0.004 
       
Urine Cu 
μmol/L 
0.18 
(0.04) 
0.18 
(0.03) 
+0.004 
(±0.03) 
 
 
 
0.89 
 
-0.056 to 0.063 
       
24hr 
Urine Cu 
excretion 
μmol/24 
hours 
0.26 
(0.05) 
0.25 
(0.03) 
-0.003 
(±0.05) 
 
<0.9 
 
0.96 
 
-0.103 to 0.098 
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Figure 5.4 
 
Previous researchers have shown that hepatic copper metabolism can be 
influenced by exposure to thyroid hormone.  
  
A & B: Correlation between serum copper (Cu) concentration and free T4 before 
and after GH replacement.  
 
C & D: Correlation between the decline in serum copper (ΔCu) and the fall in free 
T4 (Δ free T4) and rise IGF-1 (Δ IGF-1). 
 
Data is shown only for subjects with central hypothyroidism (n=13). 
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There was no significant change in serum total cholesterol, HDL-C or LDL-C 
concentration following GH substitution (Table 5.6). Intermediate density lipoprotein 
(IDL) subclass C declined during the study (p=0.004). This reduction correlated with 
the rise in serum freeT3 (Figure 5.5). There were no differences in LDL particle 
subclasses expressed as absolute values or percentage change over the course of 
the study. Also, mean LDL size did not change (270.5±2.7Å vs 270.5± 2.2Å; p= 
0.2893).  
 
There was a trend towards an increase in the proportion of large HDL 
lipoprotein particles during the study (Table 5.6). More detailed analysis of individual 
subclasses revealed significant increases in the percentage of HDL-2 and HDL-3 
particles in the serum following GH replacement (Figure 5.5). However, the 
percentage of HDL-1 particles, the other component of the “large HDL” particle 
subgroup, did not change significantly during the study. Similar results were found 
when large HDL particles were analysed by absolute change in serum 
concentration.  
 
There was a negative correlation between the rise in IGF-1 and the rise large 
HDL particles, particularly HDL-2 (Figure 5.6). However, no correlation was found 
between the changes in thyroid hormone concentration and rise in large HDL 
subgroups.  Lp(a) level rose significantly following GH exposure (p=0.002). 
However, neither the rise in IGF-1 nor fluctuations in thyroid hormone levels 
correlated with the rise in Lp (a).  
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Table 5.6.  
 
Alteration in serum lipid parameters following replacement of growth hormone. Data 
is reported as mean±SEM where variable is normally distributed and median±SD 
where variable is not normally distributed (Tg, small dense LDL, Mean LDL size and 
Lp (a)). GH Growth Hormone TC Total Cholesterol HDL-C High density lipoprotein 
cholesterol LDL-C Low density lipoprotein cholesterol Trig. Triglyceride VLDL Very 
low density lipoprotein Intr. Intermediate. * p<0.05.  ° χ2. 
 
 
  
Pre GH 
 
Post GH 
 
Δ 
P 
valu
e 
 
95% CI 
 
TC mg/dL 
 
187.4± 
9.54 
 
192.9± 
9.21 
 
+5.55 
±7.77 
 
0.48 
 
-10.72 to 
21.8 
 
LDL-C mg/dL 
 
100.3 
±6.66 
 
103.4 
±6.52 
 
+3.05 
±5.23 
 
0.57 
 
-7.91 to 
14.01 
 
HDL-C mg/dL 
 
47.35 
±2.35 
 
47.15 
±1.75 
 
-0.2 ±1.66 
 
0.91 
 
-3.67 to 
3.27 
 
TC/HDL 
 
3.644 
±0.18 
 
3.718 
±0.18 
 
+0.07 
±0.18 
 
0.69 
 
-0.31 to 
0.45 
 
Tg mmol/L 
 
1.51 ±0.15 
 
1.49 ±0.14 
 
-
0.01±0.16 
 
0.92 
 
-0.35 to 
0.32 
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Table 5.6 (contd) 
 
  
Pre GH 
 
Post GH 
 
Δ 
P 
valu
e 
 
95% CI 
 
VLDL (%) 
 
18.42 ± 
0.72 
 
19.03 ± 
0.65 
 
+0.61 
±0.72 
 
0.41 
 
-0.91 to 
2.12 
Large HDL  
(HDL 1-3) (%) 
 
22.04 ± 
2.29 
 
25.17 ± 
2.25 
 
+3.13 
±1.62 
 
0.07 
 
-0.27 to 
6.52 
Inter. HDL  
(HDL 4-7) % 
 
56.95 ± 
1.38 
 
56.39 ± 
1.25 
 
-0.56 
±1.01 
 
0.59 
 
-2.68 to 
1.56 
Small HDL  
(HDL 8-10) (%) 
 
20.93 
±1.67 
 
18.44 ± 
1.43 
 
-2.49 ±1.5 
 
0.11 
 
-5.64 to 
0.66 
 
ILD-A (%) 
 
6.83 ±0.34 
 
7.4 ±0.59 
 
+0.57 
±0.47 
 
0.23 
 
-0.41 to 
1.55 
 
IDL-B (%) 
 
5.18± 0.23 
 
5.56 ± 0.3 
 
+0.38 
±0.3 
 
0.22 
 
-0.25 to 
1.01 
 
IDL-C (%)  
 
11±0.33 
 
10 ±0.24 
 
-0.98 
±0.29 
 
0.00
4* 
 
-1.6 to -
0.36 
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Table 5.6 (contd) 
  
Pre GH 
 
Post GH 
 
Δ 
P 
valu
e 
 
95% CI 
Large LDL 
(LDL 1+2) (%) 
 
28.48 
±0.74 
 
29.00 ± 
0.98 
 
+0.53 
±0.58 
 
0.37 
 
-0.68 to 
1.73 
Small Dense 
LDL  
(LDL3-7) (%) 
 
0.7 ±1.43 
 
0.6 ±0.75 
 
0.0 ±1.35 
 
0.36 
 
-1.0 to 0.27 
Mean LDL size 
(Å) 
 
270.5 
±2.69 
 
270.5 
±2.22 
 
+0.5 ±2.9 
 
0.29 
 
-0.66 to 
2.06 
Non-A LDL 
pattern (%) 
 
20 
 
5 
  
0.34° 
 
 
Lp(a) nmol/L 
 
27.4 
±52.17 
 
34.25 
±64.9 
 
+2.1 
±21.07 
 
0.00
2* 
 
2.64 to 
22.35 
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Figure 5.5 
Percentage change in large HDL subclasses during the study. A significant rise was 
seen in percentage of HDL-2 and HDL-3 during the study. 
 
*p<0.05. 
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Figure 5.6 
 
Change in the serum concentration of HDL 2 and HDL 3 in proportion to the change 
in IGF-1 during the study.  
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Subgroup analysis of subjects with TSH deficiency (n=13) revealed similar, minor 
changes in the serum lipid profile. There was no overall change in total cholesterol, 
LDL-C or HDL-C. Once again, percentage IDL-C declined; concentration of HDL 2 
& 3 subparticles increased. There was a trend towards a significant reduction in 
small dense LDL (1.1% vs 0.5%; 95% CI -1.28 to -0.03, p=0.05).  
 
Serum testosterone levels did not change during the course of the study 
(14.20±11.95nmol/L vs. 14.95±10.40nmol/L, p=0.45). All patients prescribed a HMG 
CoA reductase inhibitor remained on a stable dose throughout the study.  
 
 
5.3.3 Bone biomarkers 
 
Prior to GH replacement there was no significant correlation between bone 
turnover markers and either IGF-1 or thyroid hormone serum concentrations. Serum 
concentration of total procollagen type 1 amino-terminal propeptide (PINP) rose 
during the study (median rise +57.4%; p=0.0009) while the concentration of bone-
specific alkaline phosphatase (BAP) remained unchanged. (Figure 5.7, Table 5.7). 
Serum osteocalcin (OCI) also rose (median rise +48.6%; p=0.0007).  Isomerized 
C‑terminal telopeptides of type I collagen (CTX-1) – a serum marker of bone 
resorption increased (median rise +73.7%; p=0.002) as outlined in Table 5.7 & 
Figure 5.7.  
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Table 5.7 
 
The changes observed in circulating concentration of bone turnover markers during 
the study period. Significant increases were observed in markers of bone formation 
(most notable P1NP and OCI) as well as markers of bone resorption (CTX-1) SD 
standard deviation, Δ median difference. 
 
  
Pre GH  
median 
(SD) 
 
Post GH 
median 
(SD) 
 
Δ 
 
P 
value 
 
95% CI 
 
P1NP 
(µg/L) 
 
46.96  
(21.56) 
 
89.79 
(59.79) 
 
+26.94 
±61.58 
 
0.0009 
 
15.35 to 72.99 
      
 
BAP 
(µg/L) 
 
10.35  
(3.94) 
 
9.67  
(4.767) 
 
+0.45 
±4.41 
 
0.75 
 
-1.33 to 2.80 
      
 
CTx-1 
(µg/L) 
 
0.30 
(0.22) 
 
0.56  
(0.35) 
 
+0.22 
±0.45 
 
0.002 
 
0.08 to 0.5 
 Mean 
(SEM) 
Mean 
(SEM) 
Mean 
difference 
  
 
OCI 
(µg/L) 
 
16.81 
(1.44) 
 
28.84  
(3.03) 
 
12.03±2.9 
 
0.0007 
 
5.77 to 18.29 
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Figure 5.7 
 
The changes observed in circulating concentration of bone turnover markers before 
(white boxes) and after (grey boxes) GH replacement. Significant increases were 
observed in markers of bone formation (most notably P1NP and OCI) as well as 
markers of bone resorption (CTX-1). 
P1NP procollagen type 1 amino-terminal propeptide. 
OCI osteocalcin. 
BALP Bone alkaline phosphatase. 
CTX-1 C‑terminal telopeptides of type I collagen. 
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There was a strong correlation between the rise in OCI, P1NP and CTX-1 
(Figure 5.8). However, the PINP:CTX-I ratio, an approximation of bone remodelling 
balance, was unchanged (160.3 versus 156.2; p= 0.4980).  
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Figure 5.8 
 
Correlation between changes in bone turnover markers during the study. 
 
There was a strong positive correlation between the medial change Δ  in OCI, PINP 
and CTX-1 indicating a true increase in bone turnover.  
 
Units – μg/L for all bone turnover markers. 
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The rise in osteocalcin, a marker of bone formation, was proportional to the rise in in 
serum IGF-1. However, this relationship did not reach statistical significance. The 
increase in serum osteocalcin was more strongly correlated with the rise in the 
freeT3/free T4 ratio (Figure 5.9).  
 
The rise in P1NP was also strongly associated with the rise in the ratio of fT3/fT4. 
However, a weak correlation was also observed between the rise in P1NP and 
serum IGF-1 (Figure 5.10).  Increases in bone resorption markers, in particular the 
rise in CTX-1, were not associated with the rise in IGF-1 or changes in thyroid 
hormone concentrations. 
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Figure 5.9 
 
Change in serum osteocalcin (OCI) in proportion to change in circulating 
concentration of free T4 (A), freeT3 (B), IGF-1 (C) and the change in the ratio of 
fT3/fT4 (D)following growth hormone supplementation. 
 
Units: OCI μg/L, free T4 pmol/L, free T3 pmol/L, IGF-1 μg/L. 
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 Figure 5.10 
 
 Change in serum total procollagen type 1 amino-terminal propeptide (PINP) in 
proportion to change in circulating concentration of free T4 (A), freeT3 (B), IGF-1 
(C) and the change in the ratio of fT3/fT4 (D) following growth hormone 
supplementation. 
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When the subgroup with TSH deficiency (n=13) were analysed separately, 
highly significant increases were again observed in PINP and OCI; +113%, p=0.007 
and +49%, p=0.001 respectively. However, in this subgroup analysis, BALP levels 
also increased significantly, +19%, p=0.01. Bone resorption marker, CTX-1, also 
increased significantly (+123%, p=0.001). However, the rise in bone turnover 
markers did not correlate with either the rise in serum IGF-1 or the fall in freeT4. 
 
 
5.3.4 Metabolic rate measurement  
  
Resting energy expenditure (REE), measured by indirect calorimetry in 19/20 
study subjects, was not affected by GH replacement (2319± 110.5 kcal.min vs. 
2368± 104.4 kcal.min; p= 0.41). Subgroup analysis of subjects with TSH deficiency 
(n=13) suggested that REE increased during the study; however, the rise in REE 
was not statistically significant (2353±141.1 kcal.min vs. 2477± 125.2 kcal.min; p= 
0.11.) Neither circulating thyroid hormone levels nor serum IGF-1 concentration 
correlated with REE before or after GH replacement.  
 
5.3.5 Cardiac time intervals 
 
Heart rate and blood pressure did not change during the study. In addition, 
left ventricular ejection fraction (EF) was not affected by GH substitution. 
Measurements of cardiac time intervals are outlined in Table 5.8. Overall, there was 
no significant change in cardiac time intervals during the study. Systolic time 
intervals did not correlate with either the serum level of thyroid hormone or IGF-1 
before or after GH exposure.  
 
The subgroup with TSH deficiency was analysed separately (n=13). In this 
group, ICT appeared to be shortened following GH replacement; however, this 
change in ICT did not reach statistical significance (85.45± 13.83ms vs. 
55.82±9.74ms; p=0.08.) In addition, the shortening of ICT, as measured by pulsed 
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wave doppler, was not replicated in tissue doppler measurements of this systolic 
interval. 
 
Table 5.8 
 
Echocardiographic assessment of cardiac time intervals measured by both pulse 
wave doppler and tissue doppler imaging (see Figure 5.1).  Data is shown for all 
subjects and is expressed as mean (SEM). ICT/ET ratio and TDI-ICT-lateral wall 
are not normally distributed and are expressed as median(SD). 
 
ICT Isovolumetric contraction time, IRT Isovolumetric relaxation time, ET Ejection 
time, MPI Myocardial performance index, MPI = (ICT+IRT)/ET, TDI tissue Doppler 
imaging, GH growth hormone, MS milliseconds. 
 
  
Pre GH 
 
Post GH 
 
Δ 
P 
value 
 
95% CI 
 
ICT 
(ms) 
 
73.56 
 
(11.23) 
 
64.50  
(9.21) 
 
-9.06±13.01 
 
0.5 
 
-36.79 to 18.67 
      
 
IRT 
(ms) 
 
76.56 
(7.06) 
 
70.00  
(9.06) 
 
-6.56±11.34 
 
0.57 
  
-30.73 to 17.61 
      
 
ICT/ET 
 
0.24 
(0.2) 
 
0.23  
(0.15) 
 
0.01±0.23 
 
0.75 
 
-0.17 to 0.07 
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Table 5.8 (contd) 
  
Pre GH 
 
Post GH 
 
Δ 
P 
value 
 
95% CI 
 
MPI 
 
0.58  
(0.05) 
 
0.5 
(0.05) 
 
-0.07±0.05 
 
0.19 
 
-0.19 to 0.04 
      
 
TDI – ICT 
Lateral 
wall 
(ms) 
 
81.00 
(33.86) 
 
78.00 
(24.58) 
 
-1.0±34.71 
 
0.67 
 
-24.69 to 13.75 
      
 
TDI – ICT  
Septal wall 
(ms) 
 
94.64 
(10.67) 
 
84.93 
(5.539) 
 
-9.71±10.79 
 
0.38 
 
-33.03 to 13.61 
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5.4 Discussion 
 
This study prospectively assessed the clinical importance of alterations in the 
hypothalamic-pituitary-thyroid axis following GH replacement in hypopituitary men. 
We have demonstrated clear alterations in well-established, clinical biomarkers of 
thyroid hormone action. These occurred in line with fluctuations in the circulating 
concentration of thyroid hormone induced by GH substitution. Our results 
demonstrate that the fall in serum freeT4 and/or rise in T3, induced by GH, resulted 
in complex alterations in peripheral tissue metabolism. In particular, the fluctuations 
in thyroid hormone were reflected in liver and bone metabolism. Interestingly, 
alterations in peripheral biomarkers occurred despite thyroid hormone 
concentrations remaining within the normal reference range and in the presence of 
stable serum TSH levels.  
 
Serum ferritin, a well-recognised marker of hepatic thyroid hormone 
exposure, declined in line with the fall in serum freeT4 concentration. Hepatic 
copper metabolism is also under the influence of thyroid hormone.  The liver derived 
protein, caeruloplasmin, declined during the study, most notably in patients with 
more severe hypopituitarism including TSH deficiency. GH replacement also 
appeared to disrupt the clear relationship between serum freeT4 and 
caeruloplasmin concentration. Taken together, these findings suggest that the 
alterations in circulating thyroid hormone concentration, induced by GH therapy, 
may result in a more hypothyroid hepatic phenotype. SHBG, another hepatic protein 
under the influence of thyroid hormone, did not change during the study. However, 
GH, itself, can influence SHBG production (143, 145). The confounding effect of GH 
may render SHBG an unreliable peripheral biomarker, when assessing the clinical 
impact of fluctuations in serum thyroid hormone levels during GH replacement. CK, 
another serum marker of thyroid hormone action, did not change during the study. 
 
Hepatic exposure to thyroid hormone could also influence serum lipoproteins. 
However, alterations observed in the lipid profile were complex. Lipid parameters 
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measured in routine clinical practice, including total cholesterol, HDL-C and LDL-C 
did not change during the study. A significant decline in the concentration of the 
IDL-C sub-particle was associated with the rise in serum freeT3. In addition, the 
increase in the percentage of large HDL lipoproteins appeared to be influenced by 
growth hormone status. Overall, the changes in the lipid profile were minor and of 
doubtful clinical significance. The confounding effect of GH, which can also 
influence the serum lipid profile, is likely to limit the utility of lipoprotein particles as 
markers of thyroid hormone action in this clinical setting.   
 
This study also demonstrated that serum markers of bone turnover can serve 
as useful biomarkers of thyroid hormone action following GH replacement. The 
parallel rise in markers of bone formation (P1NP and OCI) and resorption (CTX1), 
without a change in the P1NP:CTx1 ratio indicates an increase in bone turnover 
without a disturbance of the normal bone remodelling cycle.  Both GH and thyroid 
hormone can affect bone turnover; however, our results suggest that the selective 
effects of thyroid hormone were more important in determining the serum 
concentration of bone turnover markers.  
 
Physiological replacement of both growth hormone and thyroid hormone has 
previously been shown to stimulate resting energy expenditure (REE) (262, 266-
268). Surprisingly, REE did not change in our study. This may have been due to the 
decline in serum free T4 causing a degree of peripheral tissue hypothyroidism and 
attenuating the expected rise in REE with GH substitution. However, a trend 
towards a rise in REE was observed in the subgroup with TSH deficiency. This 
group was more likely to have multiple pituitary hormone deficiencies and, 
therefore, more profound GH deficiency. Some previous studies in this field have 
suggested that GH-induced changes in the thyroid axis are more marked and 
permanent in patients with more profound hypopituitarism (62).   
 
Cardiac time intervals, which are sensitive to changes in the circulating 
concentration of thyroid hormone, did not change during the study. A trend towards 
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shortening of ICT was seen in the subgroup with TSH deficiency suggesting an 
improved biological action of thyroid hormone on the heart. The overall group may 
not have been of sufficient size to detect subtle changes in cardiac time intervals or 
REE. 
 
The clinical consequences of changes in HPT axis provoked by GH 
replacement are easier to define in children. Previous studies of subjects with 
childhood-onset GHD have shown that a decline in serum T4, following 
commencement of GH therapy, was associated with a reduction in height velocity 
particularly when T4 declined below the normal reference range (70, 320, 322). 
Height velocity was generally restored when thyroxine supplementation was 
commenced or optimised to normalise serum T4 concentration. However, this has 
not been a universal finding and the clinical impact of changes in the HPT axis 
appears to be related to the severity of GHD (320). Children with idiopathic isolated 
GHD were more likely to develop minor, often transient, alterations in serum T4 and 
T3 within the reference range which did not appear to impact on growth. In contrast, 
children with MPHD often experienced more profound and permanent fluctuations in 
circulating thyroid hormone levels.  
 
Characterising the clinical impact of GH-induced changes in the HPT axis in 
adult patients is more challenging. In hypopituitarism, serum free T4, similar to 
primary hypothyroidism, is a sensitive but not a specific marker of central 
hypothyroidism. Ferretti et al found no change in serum ferritin but a significant 
decline in serum SHBG and increase in serum CK after inducing hypothyroidism (by 
withdrawal of  thyroid hormone leading to a low freeT4 in all subjects) in a cohort of 
37 adults with previously diagnosed central hypothyroidism (128). SHBG and CK 
reverted to pre-treatment levels once freeT4 levels were restored on thyroxine 
replacement. In a blinded crossover study, Slawik et al compared the effect of 
various doses of levothyroxine (T4) and liothyronine (T3) replacement on metabolic 
parameters (125). A body weight-adapted dose of either T4 or a combination of T4 
and T3 was associated with a healthier metabolic phenotype in comparison to 
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empiric dosing. Serum CK levels were significantly lower while subjects were taking 
a body weight-adapted dose. The less marked fluctuations in serum T3 and T4 in 
our study (all changes occurred within the normal reference range) may explain the 
divergent findings in respect of the utility of SHBG, CK and ferritin in central 
hypothyroidism.   
 
To our knowledge, the impact of thyroxine replacement, or changes in the 
HPT axis following GH treatment, has not previously been compared to serum 
indices of copper metabolism. Animal studies have highlighted the positive 
correlation between serum T4 and both serum Cu and its transport protein 
caeruloplasmin (185, 186). This has been confirmed in human studies of patients 
with primary thyroid disease (187). Unlike many other markers of peripheral thyroid 
hormone action, GH appears to have little impact on copper metabolism. Therefore 
indices of peripheral Cu metabolism may be useful reflection of the selective effects 
if thyroid hormone in patients receiving GH replacement (197, 198). Our findings of 
a positive relationship between the alterations in free T4 and caeruloplasmin, which 
was most pronounced in subjects with central hypothyroidism, suggest a possible 
role for caeruloplasmin as a marker of hepatic thyroid hormone action.  
 
The utility of serum lipoproteins as a marker of hepatic thyroid hormone 
action, in patients taking GH replacement, is matter of debate. Previous research, in 
relatively large cohorts of adults receiving GH replacement, did not show significant 
short term changes in routinely measured lipid parameters despite a fall in serum 
free T4 and the unmasking of central hypothyroidism in 36-47% of subjects (62, 63). 
However, studies in subjects with central hypothyroidism in whom the dose of 
levothyroxine has been adjusted have shown a significant impact of serum 
lipoproteins. Previous prospective research in adults with central hypothyroidism 
has shown that a body weight-adapted dose of T4 (or combined T4/T3), in 
comparison to an empiric dose, is associated with a lower total cholesterol, HDL-C 
and LDL-C (125). VDL and triglyceride levels were unchanged by different dosing 
schedules. Furthermore, temporary withdrawal of thyroxine replacement, for a 60 
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day period, in subjects treated for central hypothyroidism resulted in a significant 
increase in both total and LDL cholesterol (128). No changes were observed in 
HDL-C or triglycerides. We have measured several lipid sub particles to investigate 
if less dramatic changes in serum thyroid hormone concentration resulted in 
clinically significant alterations in lipid metabolism. Our results reveal only minor 
changes in lipid subparticles which are of uncertain clinical significance. In addition, 
these alterations were variably associated with thyroid and GH status. In particular, 
it was not clear whether the rise in the atherogenic Lp(a) particle was due to 
changes in the thyroid hormone, IGF-1 or both. Previous research has shown that 
both GH replacement and hypothyroidism (overt and subclinical) can lead to a rise 
in serum Lp(a) (225, 226, 343, 344). This may be due to either increased secretion 
or reduced clearance of the lipoprotein particle.  
 
Previous researchers who have assessed the response of the HPT axis to 
GH replacement have not measured the concomitant response among bone 
turnover markers. However, there is limited data concerning bone biochemistry in 
patients with central hypothyroidism. In a study of 37 subjects with central 
hypothyroidism, not receiving GH replacement, the investigators measured the 
response of bone turnover markers after temporary withdrawal of thyroid hormone 
(128). The authors measured serum concentration of bone GLA protein - a maker of 
bone formation - and carboxyterminal telopeptide of type 1 collagen (ICTP) - a bone 
resorption marker. The former is a breakdown product of osteocalcin; the large N-
MID fragment of osteocalcin was measured in my study. ICTP is largely equivalent 
to CTx-1, measured in the current study, although the ICTP assay detects a 
different epitope of carboxyterminal telopeptide of type 1 collagen. The results were 
comparable to my study - both bone GLA protein and ICTP declined significantly 
during withdrawal of thyroid hormone and increased when euthyroid state was 
restored. The authors also demonstrated strong correlations between serum free T3 
and both serum bone GLA protein and ICTP.  
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The clinical utility of bone turnover markers, as biomarkers of peripheral 
thyroid hormone exposure will require careful consideration due to the potential 
interference from other pituitary hormone replacement. As mentioned previously, 
GH can increase bone turnover (45) (46, 252, 253). In addition, bone turnover can 
be suppressed while taking replacement glucocorticoid at a dose that many 
clinicians consider routine (345). Furthermore, sex steroids, in particular oestrogen, 
can stimulate the production of bone turnover markers (346, 347). In this current 
study, all patients were male and serum testosterone concentration did not change 
significantly during the study.  Eleven (55%) had treated ACTH deficiency – median 
daily dose of hydrocortisone 20mg (range 10 -25). The dose of hydrocortisone did 
not change during the study period.   
 
Resting energy expenditure (REE) typically rises with GH replacement 
although the underlying mechanism is still unclear (65, 267). Some authors have 
suggested that the rise in REE following GH substitution may be related to 
consequent rise in serum T3 concentration. Jørgensen et al, in a six month study of 
GH replacement in ten adults, demonstrated a positive correlation between the rise 
in REE and that of serum free T3 following GH replacement (67). A significant 
number of subjects (7/10) had free T3 levels in the subnormal range (despite a 
normal serum T4 concentration) before starting GH; this may have influenced the 
findings. While discordance between circulating T3 and T4 concentrations has been 
reported in some cohorts with central hypothyroidism, we did not observe it in the 
current study cohort. Martins et al, in a study of children with GHD, showed a 
correlation between serum total T3 and REE in subjects established on GH 
replacement; no such relationship was found in those not receiving GH. When GH-
naïve children were given GH replacement, in the rise in REE was proportional to 
the rise in serum total T3. The rise in REE also correlated with the increase in IGF-
1; however this was only of borderline significance.  
 
In my study, REE did not rise as expected following GH replacement. In 
addition, REE did not correlate with either serum IGF-1 or thyroid hormone before 
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or after GH replacement. The divergence between my results and those of other 
investigators may be related to the study populations (children versus adults), 
variable doses of GH and thyroxine replacement as well methodological differences 
in estimation of REE.  
 
Cardiac time intervals, in particular the systolic time interval – isovolumetric 
contraction time (ICT) – have been shown to be highly sensitive to changes in the 
circulating concentration of thyroid hormone (290, 291). ICT is the time when the 
ventricles have begun to contract, but the volume of the chambers has not yet 
changed. It occurs immediately after the period of electromechanical delay, 
following electrical stimulation of the ventricles. ICT is typically prolonged in 
hypothyroidism. This study found that ICT decreased during GH replacement. This 
was most apparent in those with central hypothyroidism; however this did not reach 
statistical significance. Previous research has suggested that ICT may be a useful 
marker of tissue hypothyroidism during GH therapy. In children with GHD, an 
inverse correlation between serum total T3 concentration and ICT was only 
observed in those receiving GH replacement leading the authors to suggest that GH 
improves the biological actions of thyroid hormone (294).  When GH was 
administered to GH naïve children (n=7) the subsequent rise in total T3 only had a 
weak correlation with the rise in ICT. However, the small number of study subjects 
may have led to an underestimation of the utility of ICT as marker of thyroid 
hormone action on the heart.  
 
Further research by Doin et al, has helped to validate the clinical use of ICT 
as biological marker of central hypothyroidism. In a controlled study of adults with 
pituitary disease and primary hypothyroidism, ICT had a high diagnostic accuracy in 
the identification of insufficient T4 replacement or of clinically occult central 
hypothyroidism in patients with pituitary disorders (289). After adjustment or 
commencement of thyroxine replacement the shortening of ICT correlated with the 
rise in serum free T4 concentration.  
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The main limitation of this study is its relatively small size. Differentiating the 
selective effect of thyroid hormone and GH/IGF-1 on tissue biomarkers was 
challenging in this small cohort. Also, the study cohort was exclusively male and 
results do not necessarily extend to female patients. The gender disparity occurred 
by chance, during open, unbiased study recruitment. However, it is likely the effect 
of oestrogen, in premenopausal women, would have had a significant impact on the 
bone and lipid parameters.  Concurrent treatment for hypertension and 
hyperlipidaemia may have influenced the echocardiogram and lipid data 
respectively. The study did not include a health, matched control group which may 
have shed further light on our finding. However, this prospective study was 
designed as a longitudinal observational cohort study during routine clinical 
treatment with each subject acting as their own control.  
 
 
In conclusion, we have prospectively demonstrated that alterations in the 
thyroid axis following GH replacement are associated with significant alterations in 
peripheral markers of thyroid hormone action. Fluctuations in thyroid hormone led to 
complex, tissue specific effects. Hepatic-derived peptides declined under the 
influence of thyroid hormone suggesting a more hypothyroid phenotype. In contrast, 
other tissues displayed, an enhanced biological action of thyroid hormone following 
GH substitution. In particular, the rise in serum T3:T4 ratio led to a marked increase 
in bone turnover. The small changes in thyroid hormone concentration, all of which 
occurred within the normal reference range, were not reflected in cardiac and 
skeletal muscle markers of thyroid hormone action. Therefore, bone and liver 
biomarkers may prove useful tools in assessing the clinical impact of alterations in 
the thyroid axis following GH replacement. 
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Chapter 6  
 
 
The interaction between GH-induced changes in the thyroid axis on health-
related quality of life 
 
 
6.1  Introduction 
 
In previous chapters, I have described the changes in the HPT axis following GH 
replacement. However, all changes in serum thyroid hormone concentration 
occurred within the normal reference range. In addition, the variability in these 
changes, reported in previous studies in the literature, has led many investigators to 
question the clinical significance of these alterations.   
 
In children with GHD, retardation of growth velocity has been described in 
line with a fall in serum T4 concentration (320, 322). However, this finding is not 
universal in the literature.  In Chapter 5, I described the impact of alterations in the 
HPT axis on biological markers of thyroid hormone action derived from a variety of 
peripheral tissues in adult patients. However, the clinical impact on patient 
symptoms, disability and quality of life (QOL) can only be assessed with patient 
reported outcomes including questionnaires. 
 
Overt and subclinical hypothyroidism, are associated with impaired QOL 
when assessed by patient reported outcomes; however, the data in the latter 
condition is more inconsistent (348-350). This may be due to methodological 
differences in key studies including a variable definition of subclinical 
hypothyroidism. Studies using patient questionnaires have revealed that QOL does 
not always normalise after thyroxine replacement (311, 312, 351). This suggests 
that the peripheral tissue concentration of thyroid hormone is not always reflected 
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by the serum concentration and that formal assessment of QOL may have an 
important role in the clinical assessment of patients with hypothyroidism (352).  
  
Similarly, a deficiency in health-related QOL is a well-recognised feature of 
the syndrome of adult growth hormone deficiency. Indeed, this is one of the 
principal indications for GH replacement in adulthood (353). Furthermore, in some 
jurisdictions, the prescription of GH is restricted to those with significantly impaired 
QOL who demonstrate an improvement after receiving substitution. There is 
preliminary evidence, among adults receiving GH replacement, that patients who 
experience a fall in serum T4 below the reference range (i.e. central hypothyroidism 
is unmasked) are less likely to experience an improvement in health-related QOL 
(62). The importance of QOL assessment adults in receiving GH replacement is, 
therefore, complicated by the interaction between GH and the thyroid axis. The 
selective effects of thyroid hormone and GH on QOL merits further consideration.  
 
The aim of this study was to prospectively examine the association between 
changes in generic health-related and disease-specific QOL and changes in 
circulating thyroid hormone in adults receiving GH replacement.   
 
6.2 Methods 
 
Twenty adult men with severe GHD, who received GH replacement as part of 
routine clinical care were prospectively evaluated before, and 3-6 months after, 
commencing treatment. Subjects were recruited from the Pituitary Clinic in 
Beaumont Hospital.  
 
If the patient had multiple pituitary hormone deficiencies (defined as deficiency in 
two or more pituitary hormones), other hormones were adequately replaced for at 
least three months prior to commencing GH replacement. The diagnosis of GHD 
and definition of other pituitary hormone deficiencies including diabetes insipidus is 
outlined in Chapter 2.  
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Baseline tests performed before GH supplementation included serum TSH, free & 
total T4, free & total T3, reverseT3, insulin like growth factor-1 (IGF-1), testosterone 
and electrolytes. Subjects were administered generic health related QOL 
questionnaires - the Short Form 36 (SF36) (Appendix 1) and the Nottingham Health 
Profile (NHP) (Appendix 2). They also completed the GHD disease-specific 
Assessment of Growth Hormone Deficiency in Adulthood (AGHDA) questionnaire 
(Appendix 3). Detailed description of these questionnaires is provided in Chapter 2.   
 
All subjects were commenced on recombinant GH at a starting dose of 0.3mg/day 
administered subcutaneously – Saizen® (somatropin (rDNA origin) for injection) 
Merck Serono Ltd. Serum IGF-1 was checked after one month and the dose was 
titrated to achieve an IGF-1 in the upper half of age-related reference range. 
Replacement doses of hydrocortisone, testosterone and DDAVP, for those suffering 
from other pituitary hormone deficiencies were not adjusted during the study period. 
Tests were repeated after 3-6 months on a stable dose of GH. 
 
6.3 Results 
 
Baseline clinical and hormonal characteristics, similar to previous studies, are 
outlined in Table 6.1. Seventeen (85%) had multiple pituitary hormone deficiencies 
(MPHD) defined as two or more pituitary hormone deficiencies; three patients had 
isolated GH deficiency.   
 
Serum testosterone levels did not change during the course of the study 
(14.20±11.95nmol/L vs. 14.95±10.40nmol/L, p=0.45). Three patients had cranial 
diabetes insipidus. Serum electrolyte levels were recorded at each visit; there were 
no abnormalities suggestive of over- or under-replacement with ddAVP. All patients 
had serum freeT4 and free T3 levels within the normal reference range prior to 
commencing GH replacement (Table 6.2).  
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Mean daily dose of growth hormone was 0.34±0.11 mg (range 0.15 - 0.5mg) 
administered subcutaneously. Following GH replacement, serum IGF-1 levels rose 
significantly, as expected, during the course of the study (+114.4±12.3µg/L, 
p<0.0001). FreeT4 levels declined (-1.09±1.99 pmol/L, p=0.02). Reverse T3 levels 
also fell (-3.44±1.42 ng/dL, p=0.03) and freeT3 levels increased (+0.34±0.15 pmol/l, 
p=0.03) (Table 6.2). 
 
Table 6.1  
 
Baseline characteristics of the full study cohort.  BMI body mass index, GHD growth 
hormone deficiency, MPHD Multiple pituitary hormone deficiencies, NFPA Non-
functioning pituitary adenoma . Data for age and BMI displayed as median (range). 
 
Male/Female 20/0 
Aetiology of GHD n(%) 
NFPA  10(50) 
Prolactinoma  4(20) 
Other  6(30) 
 
MPHD n(%) 17(85) 
 
On Thyroxine  n(%) 13(65) 
 
Age (median) 53.1 years range 22.3-69.3 
BMI (median) 31.3 kg/m2 range 19.2-49.7 
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Table 6.2   
Alteration in circulating thyroid hormones following replacement of growth hormone. 
Data is reported as mean±SEM where variable is normally distributed (TT4, fT3, 
rT3) and median±SD where variable is not normally distributed (fT4 & TT3). Only 
those with a detectable pre-treatment TSH level (n=13) were included in this 
analysis – reported as median (range). * p<0.05. GH Growth Hormone. 
  
Pre GH 
 
Post GH 
 
Δ 
Ref. 
range 
P 
value 
 
95% CI 
 
FreeT4 
(pmol/L) 
 
12.9±4.0 
 
12.1±3.2 
 
-1.09±1.99* 
 
9-20  
 
0.02 
 
-2.24 to -0.32 
       
 
Total T4 
(nmol/L) 
 
109±4.9 
 
99.5±4.5 
 
-9.6±4.25* 
 
69-141 
 
0.04 
 
-18.5 to -0.72 
       
 
Free T3 
(pmol/L) 
 
5.4±0.2 
 
 
5.7±0.2 
 
+0.34±0.15* 
 
3.0-7.5  
 
0.03 
 
0.03 to 0.65 
       
 
Total T3 
(nmol/L) 
 
1.72±0.4 
 
1.62±0.4 
 
-0.02±0.32 
 
1-3 
 
0.76 
 
-0.1 to 0.19 
       
 
Reverse T3 
(ng/dL) 
 
17.6±1.4 
 
14.2±0.8 
 
-3.44±1.42* 
 
8-25 
 
0.03 
 
-6.44 to -0.45 
       
 
TSH  
(mU/L) 
 
1.1  
(0.4-5.1) 
 
1.1  
(0.2-3.3) 
 
-0.1±1.09 
 
0.4-4.0 
 
0.31 
 
-0.87 to 0.17 
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Quality of life questionnaires 
 
Assessment of GH deficiency in adulthood (AGHDA) 
 
The baseline median AGHDA score was 16 (out of a possible total of 25) 
(range 0-24). Higher scores indicate a poorer QOL in the context of GHD. AGHDA 
score (median±SD) declined as expected during the study 16±8.7 vs 12±7.9; 
p=0.003. Subgroup analysis of those in whom serum free T4 declined during the 
study (n=12) demonstrated a blunted and non-significant rise in AGHDA score.  
 
Nottingham Health Profile (NHP) 
 
The self-reported scores in the six domains of the NHP are displayed in 
Table 6.3 and Figure 6.1. Lower scores indicate better health-related QOL. There 
was a decline in the score for social isolation during the study; however, this was 
only of borderline statistical significance. Raw score for social isolation (SI) score 
were – Pre GH 29.4±8.8 versus Post GH 17.3±6.2; p=0.05. There was no change in 
the other QOL domains of NHP during the study. Subgroup analysis of those with 
TSH deficiency (n=13) did not reveal any change in health-related QOL measured 
by NHP.  Similarly, there was no change in NHP scores in subjects who 
experienced a decline in serum free T4 during the study (n=12) 
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Table 6.3  
Quality of life scores before and after GH replacement for the full cohort (n=20). 
Raw scores are reported for Nottingham Health Profile (NHP) and transformed 
scores (raw scores converted to percentage) are displayed for Short Form 36 
(SF36). Data expressed as mean (SEM), *p<0.1 **p<0.05 compared to baseline. 
High scores indicate better quality of life for SF36 and low scores indicate better 
quality of life for NHP. 
 
NHP 
 
Pre GH replacement 
 
Post GH replacement 
   
Energy level 47.4 (9.4) 44.9 (10.2) 
   
Pain 13.9 (4.9) 12.2 (4.1) 
   
Emotional reaction 25 (6.3) 21.9 (6.1) 
   
Sleep  26.2 (7.9) 20.9 (6.7) 
   
Social isolation 29.4 (8.8) 17 (6.2)* 
   
Physical ability 14.1 (4.6) 16.6 (20) 
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Table 6.3 (contd) 
 
 
SF36 
 
Pre GH replacement 
 
Post GH replacement 
   
Physical functioning 63.8 (6.7) 74 (5.3)** 
   
Role physical  43.8 (8.9) 56.3 (8.5)* 
   
Bodily pain 72.8 (6.0) 74.6 (6.3) 
   
General health  58.4 (3.7) 60.2 (6.0) 
   
Vitality 41.3 (5.3) 50.8 (6.0)** 
   
Social functioning 73.1 (5.3) 70 (5.3) 
   
Role emotional 50.0 (10.1) 78.3 (8.1)** 
   
Mental health 69.2 (4.4) 73.0 (3.7) 
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Figure 6.1 
 
Radar plot showing the changes in the six domains of the Nottingham Health Profile 
(NHP), a generic health status questionnaire, during the study period. Lower scores 
indicate a better sense of well-being. Dotted line = pre GH at entry into study. Black 
line = 3 to 6 months after GH replacement.  
 
  
0.00
10.00
20.00
30.00
40.00
50.00
Energy Level (EL)
Pain (P)
Emotional
Reaction (ER)
Sleep (S)
Social Isolation
(SI)
Physical Ability
(PA)
184 
 
 
Short Form 36 (SF 36) 
 
 Transformed scores (raw scores converted to a percentage) for SF 36 are 
displayed in Figure 6.2. Higher scores indicate a better state. There was a strong 
positive correlation between each component scale (all correlation coefficients >0.3) 
indicating good internal consistency. Overall, there was a significant increase in the 
scores for physical function, vitality and emotional role (Table 6.3). However, the 
rise in these scales did not correlate with either the rise in serum IGF-1 or the 
increase in freeT3/freeT4 ratio.  
 
The improvements in health-related QOL observed in the full cohort were not 
apparent when subjects who experienced a decline in free T4 (n=12) were 
examined separately. Analysis of the subgroup with previously diagnosed central 
hypothyroidism (n=13) revealed less marked changes in QOL with a significant 
increase only in the physical function domain during the study.  
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Figure 6.2  
 
Radar plot showing the changes in the eight domains of the generic QOL 
assessment tool, Short Form 36 (SF 36), during the study period. Transformed 
scores are shown (i.e. raw score converted to percentage). Higher numerical scores 
indicate a better health status. Dotted line = pre GH at entry into study. Black line = 
3 to 6 months after GH replacement. 
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6.3 Discussion 
 
In Chapter 3, I discussed the changes in the HPT axis following growth hormone 
replacement in hypopituitary men. In essence, serum free and total T4 declined and 
the ratio of free T3/free T4 rose in proportion to the rise in serum IGF-1 
concentration. In this chapter we have examined to impact of biological alterations 
in the GH and thyroid axis on health-related QOL.  
 
Scores from the AGHDA questionnaire, a GHD disease-specific QOL self-
assessment tool, were relatively high before commencing GH (16/25) indicating a 
poor QOL. This score declined, as expected, while receiving GH replacement 
sufficient to raise serum IGF-1 concentration into the upper half of the age adjusted 
reference range. Interestingly, a significant fall in AGHDA score was not observed in 
the group of subjects who experienced a decline in serum freeT4 during the study.  
 
Subject responses to the NHP, a generic health status survey, suggested an 
overall improvement in QOL, particularly in the social isolation domain. However, 
the decline in NHP scores (suggesting an improved QOL) did not reach statistical 
significance. This remained true when those with previously diagnosed central 
hypothyroidism – which included the subjects with the most severe hypopituitarism - 
were analysed separately. The SF 36, which focuses on general well-being during 
activities of daily living and social interaction, revealed an improvement in a variety 
of domains after GH supplementation. Six months of GH replacement was 
associated with enhancement of QOL in the physical function, vitality and emotional 
role domains. It is noteworthy that improvements in QOL, measured by SF 36, were 
not apparent in the subjects in whom GH induced a fall in serum free T4. This 
finding, in keeping with the data from the disease-specific AGHDA questionnaire, 
suggests that the decline in serum free T4 is clinically important by attenuating the 
expected improvement in QOL following GH replacement.  
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Impaired QOL and sense of vitality are well recognised features of the 
syndrome of adult GHD. GH replacement is restricted to adults with impaired QOL 
in many jurisdictions. Therefore, improvement in QOL is an important clinical 
measure of the effectiveness of GH replacement. The use of generic QOL 
questionnaires is widespread in both placebo-controlled and open label studies of 
GH replacement. For example, using NHP, previous researchers have shown that 
the dimensions of energy level and emotional reaction responded best to treatment 
(49). However, improvements in QOL were sometimes only apparent after 12 
months GH replacement (354). Therefore, lack of significant improvement in NHP 
scores in our study may relate to the relatively short time course. Alternatively, 
some studies have not demonstrated an improvement in well-being using generic 
QOL questionnaires and it may be that these instruments are insensitive to QOL 
deficits in GHD.  
 
The disease specific adult GHD assessment tool (AGHDA) has been shown 
to be a reproducible method of monitoring psychosocial well-being while replacing 
GH (55, 305). AGHDA consists of 25 questions with YES/NO answers; higher 
scores indicate a poorer sense of well-being. Patients who experience an 
improvement in health-related QOL after receiving GH replacement show a 
decrease in AGHDA score after three months which is sustained at six and twelve 
months (303).  However, the response to GH replacement, in terms of QOL, is 
variable and unpredictable. The reasons for are not clearly understood. It may, in 
part, relate to differences in the severity of GHD. However, previous research hints 
that the unmasking of central hypothyroidism may also be implicated in a poor 
response to GH replacement in respect of QOL. Agha et al showed that patients 
who became hypothyroid after GH replacement had a higher AGHDA score 
(indicating poorer QOL) after three months than those who remained euthyroid (62). 
Following T4 replacement, AGHDA score were equivalent in both groups. In our 
study, all changes in thyroid hormone concentration were within the normal range. 
Nonetheless, our data supports the findings of previous research with an attenuated 
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fall in AGHDA score seen in those who experienced a fall in serum free T4 after GH 
substitution.  
 
There is a wealth of data linking primary hypothyroidism, both overt and 
subclinical, with impaired QOL. Patient reported outcomes using generic 
questionnaires such as SF 36 and NHP have highlighted deficits in multiple areas of 
QOL. These deficiencies typically improve after thyroxine replacement; however, 
the data in this field is inconsistent and patients patients who are biochemically 
euthyroid on thyroxine replacement may still exhibit subtle deficits in QOl compared 
to healthy controls. The data regarding QOL in central hypothyroidism is less 
extensive. Previous researcher in central hypothyroidism has shown that using a 
body weight adjusted dose of thyroxine (1.6µg/kg) in comparison to an empiric dose 
did not have a significant impact on well-being assessed by generic health status 
questionnaires including SF 36. The lack of differential response to QOL contrasts 
with the biochemical findings which suggest that the body weight adjusted dose of 
thyroxine resulted in a higher free T4 levels and a healthier metabolic phenotype.  
 
Central hypothyroidism is usually part of a syndrome of multiple pituitary 
hormone deficits. Notwithstanding the selective effects of GH and thyroid hormone, 
the impact of other hormone deficiencies must be considered when using patient-
reported QOL measurements in patients with pituitary disease. Over and under 
replacement of glucocorticoids can impact negatively in self-perceived health status 
(355-357). In addition, sex steroid deficiency and its replacement can influence 
health-related QOL. In our study subjects with ACTH deficiency the dose of 
hydrocortisone remained stable throughout the dose. However, the dose was not 
fixed and was prescribed according to the degree of ACTH deficiency judged by 
treating endocrinologist. All subjects were male - 70% were deficient in 
gonadotrophins and were prescribed testosterone replacement. While the dose 
testosterone replacement and route of administration were variable and decided by 
treating physician, the median serum testosterone concentration did not change 
during the study.   
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The study has limitations. Self-assessment patient reported outcomes are 
subject to considerable placebo effect. Our study was not placebo controlled. 
However, each subject acted as their own control in the longitudinal observational 
design. Generic QOL questionnaires provide a broad overview of a subject’s health 
status but may be insensitive to disease specific deficits in well-being. We used the 
GHD disease specific AGHDA questionnaire but we did not use a hypothyroid 
specific symptom or quality of life scale. A specific QOL tool for thyroid disease may 
have yielded further insights into the clinical relevance of the changes in the HPT 
axis observed during the study. Previous research has shown that changes in QOL 
following GH may take many months or a year to become clinically detectable. The 
short time course, in a small cohort, may have underestimated the improvements in 
health-related QOL. Finally, the gender imbalance may have affected the results – 
all subjects were men. However, this imbalance occurred, by chance, during open, 
unbiased recruitment. 
 
In conclusion, GH replacement is associated with improvements in health-
related QOL. However, in patients who experience a decline in serum free T4 
concentration following GH substitution, the improvement in QOL may have an 
attenuated.  
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Chapter 7 
 
 
Summary Discussion and Recommendations 
 
 
7.1 Summary Discussion 
 
In this prospective human study, we have examined the impact of growth hormone 
(GH) replacement on the hypothalamic-pituitary-thyroid (HPT) axis. Recent 
research, in hypopituitary patients, has highlighted a variety of changes in thyroid 
hormone economy following exposure to GH. However, conflicting results were 
reported by different investigators (61). Variability in patient characteristics (adult 
versus children, GH deficient versus GH replete) may account for some of the 
differences in the results of studies in this field. The formulation (cadaveric versus 
recombinant) and dose of GH, in addition to the retrospective nature of many 
studies, may also have had a significant impact on the result.  
 
 Previous investigators have speculated about the mechanism responsible for 
GH-induced changes in the HPT axis. Several hypotheses have been suggested, 
the most convincing of which is a direct effect of GH on the peripheral activation and 
clearance of thyroid hormone. However, there are no human studies, to date, 
directly examining this theory. Furthermore, there is very little research examining 
the clinical relevance, in adult patients, of changes in the circulating concentration of 
thyroid hormone following GH replacement. Many of the purported benefits of GH in 
hypopituitary adults can also be influenced by changes in thyroid hormone 
exposure. Lipid abnormalities, bone turnover, energy expenditure, cardiac function 
and health-related quality of life are all sensitive to changes in both GH and thyroid 
hormone exposure. However, there is a paucity of research, in human subjects, 
about the selective effects of these hormones on clinically-important biological 
functions in hypopituitary adults.  
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In previous chapters, I have reported the results of prospective observational 
studies conducted in a cohort of hypopituitary adult men with severe GHD. All 
subjects received recombinant GH replacement as part of routine clinical care. 
Research study measurements and procedures were conducted immediately prior 
to commencing GH replacement. The dose of GH was titrated to achieve a serum 
IGF-1 in the upper half of the age-related reference range. All study measurements 
were then repeated after three to six months on a stable dose of GH.  
 
 
7.1.1 Changes in the HPT axis following GH replacement 
 
In Chapter 3, I described the changes in the HPT axis following recombinant 
GH replacement in a cohort of adult hypopituitary men. In summary, mean freeT4 
levels declined (-1.09±1.99 pmol/L, p=0.02). Reverse T3 levels also fell (-3.44±1.42 
ng/dL, p=0.03) and freeT3 levels increased significantly (+0.34±0.15 pmol/l, 
p=0.03).  The concentration of TSH in the serum remained unchanged. All changes 
in thyroid hormone levels occurred within the normal reference range while the 
subjects received routine replacement dose of GH, maintaining serum IGF-1 in the 
upper half of the age-related reference range. The rise in serum IGF-1 correlated 
with the fall in freeT4 (r -0.46; 95% CI -0.755 to -0.006, p=0.048) while there was a 
trend towards a significant correlation with the rise in freeT3 and IGF-1 (r 0.442; 
95% CI -0.0291 to 0.753, p=0.058). Subgroup analysis of those subjects with TSH 
deficiency (n=13, all taking thyroxine replacement) revealed a similar pattern of 
fluctuations in circulating thyroid hormone levels.  
 
 
7.1.2 Mechanistic studies 
 
The mechanism (or mechanisms) responsible for the observed changes in 
the thyroid axis is a matter of debate among endocrinologists. In Chapter 4, I report 
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the findings of studies aimed at shedding new light on the mechanisms for GH-
induced changes in the HPT axis.  Alteration of the serum binding proteins for 
thyroid hormone has been suggested by some investigators (71). However, in our 
study we observed a parallel decline in both total and free T4 following exposure to 
physiological doses of GH – this argues against an alteration in binding proteins. In 
addition, the serum concentration of thyroid binding globulin (TBG), to which the 
majority of T4 in the serum is bound, did not change during the course of the study.  
 
Suppression of TSH or alteration of TSH dynamics has also been 
proposed as potential mechanism for changes in thyroid hormone seen following 
replacement of GH (67). We did not directly evaluate TSH dynamics; however, the 
mean serum concentration of early morning, fasting TSH did not change during the 
study. Many patients with central hypothyroidism have a suppressed TSH level 
(127). In our study, the observed changes in thyroid hormone levels were less 
marked in the subgroup with a detectable TSH level arguing against a crucial role 
for TSH in manipulating thyroid hormone levels following GH replacement. Similarly, 
a direct effect of GH on the thyroid gland itself, suppressing T4 production or 
enhancing the synthesis/secretion of T3, is unlikely. The serum concentration of  
thyroglobulin, the substrate for thyroid hormone, did not change during the course of 
the study.  
 
T4, the main hormonal product of the thyroid gland, is a prohormone. 
It is activated, in peripheral tissue, to T3 by removal of an iodine moiety from the 
molecule – a process known as deiodination (see Figure 1.1). This reaction is 
catalysed by the type 2 isoenzyme of deiodinase (DIO 2). T4 can also be 
deactivated to reverse T3 (an inactive hormone by product) by removal of a different 
iodine atom in peripheral tissue – this reaction is catalysed by the type 3 isoenzyme 
of deiodinase (DIO 3). The peripheral metabolism of thyroid hormones, by a 
process of deiodination, controls the local tissue exposure to T3 and, in turn, alters 
the circulating concentration of thyroid hormones in the serum (73). Therefore, the 
rise in the ratio of free T3/free T4 and free T3/reverse T3 in the serum, following GH 
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replacement is suggestive of an effect of GH on deiodinase enzyme activity in 
peripheral tissue.  
Deiodinase enzymes are widely expressed in tissues throughout the 
body (72). We chose to examine the enzyme activity in subcutaneous adipose 
tissue, before and after GH exposure, as this tissue is easily accessible with 
minimal risk and discomfort to the patient. Also, fat tissue has been previously 
shown to express all three isoenzymes of the deiodinase system – DIO 1, DIO 2 
and DIO 3 (See figure 1.1).  We speculated that a fall in T4, accompanied by a rise 
in T3, following GH supplementation was due to increased DIO2 activity. 
Unexpectedly, the opposite effect on DIO2 was observed. In subcutaneous fat, 
DIO2 isoenzyme activity declined (-11.08 fmol/mg per min; 95% CI -28.95 to 0.19, 
p=0.036). The decline in DIO2 activity correlated with the fall in serum freeT4 and 
totalT4 concentration but not the changes in T3 or reverse T3. There was no 
significant correlation between the fall in DIO 2 activity and the rise in serum IGF-1 
level. DIO1 and DIO3 isoenzyme activity remained unchanged following GH 
substitution  
 
The explanation for this unpredicted observation not clear. However, 
there are several potential explanations. GH is a potent stimulus of lipolysis and a 
reduction in DIO2 activity could be an attempt to protect the fat tissue from the 
additional lipolytic action of T3 (336). Alternatively, the increased circulating and/or 
locally generated T3 may have caused the decline in DIO2 activity in an attempt to 
maintain tissue T3 homeostasis. Previous research from animal studies has 
confirmed that T3 itself can suppress tissue DIO2 mRNA expression and activity in 
various tissues (334). 
 
Despite the discordance between the serum and tissue findings in our 
study, modulation of deiodination of thyroid hormones in peripheral tissue remains a 
likely explanation for the changes in circulating thyroid hormone levels following GH 
supplementation. Thyroid hormone influences gene expression in virtually every 
organ in humans and deiodinase enzymes are differentially expressed in a wide 
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variety of tissues (78). Deiodinase isoenzyme activity in other organs, such as the 
liver, skeletal muscles or kidney, may make a greater contribution to the circulating 
pool of T3 in patients with hypopituitarism. Isoenzyme activity in other organs may 
be more sensitive to inhibition by GH. 
 
 
7.1.3 Clinical implications 
 
Notwithstanding the mechanism responsible for changes in the serum 
concentration of thyroid hormone following GH replacement, the clinical importance 
of a fall in serum free T4, particularly in the presence of a rising serum T3, is 
uncertain. Furthermore, when changes in thyroid hormone occur within the normal 
reference range, the clinical impact may be even more challenging to define. In 
patients with hypopituitarism, one cannot rely on serum TSH to reflect tissue 
exposure to thyroid hormone. In Chapter 5, I report the results of our studies aimed 
at defining the clinical importance of GH-induced changes in the thyroid axis. We 
measured a wide array of tissue biomarkers of thyroid hormone action before and 
after exposure to GH in adults.  
 
Liver biomarkers, sensitive to thyroid hormone action, including serum 
ferritin and caeruloplasmin declined during the study. Fluctuations in these 
biomarkers showed strong associations with serum free T4 suggesting that GH-
induced changes in the thyroid axis lead to a more hypothyroid hepatic phenotype. 
However, other biomarkers of thyroid hormone action in the liver, including SHBG, 
were unchanged during the study. Similarly, minor changes in lipoprotein particles 
did not appear to be directly influenced by changes in serum T4 or T3 
concentration. Alterations in serum SHBG and lipoproteins can be provoked by both 
thyroid and growth hormone. In contrast, ferritin and caeruloplasmin are less likely 
to be affected by routine replacement doses of GH. Therefore, serum markers of 
copper and iron metabolism may be more useful markers of the hepatic action of 
thyroid hormone in patients with hypopituitarism. 
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We also evaluated the peripheral action of thyroid hormone on bone. 
Serum bone turnover markers (BTMs), which are sensitive to the circulating 
concentration of thyroid hormone, increased during the study. There was a parallel 
increase in markers of bone formation and resorption indicating an increase in bone 
turnover with preservation of the bone remodelling cycle. While GH can also 
increase bone turnover, the rise in BTMs was more strongly correlated with the 
increase in free T3/free T4 ratio than the rise in serum IGF-1. This suggests that 
BTMs may also serve as useful biomarkers of peripheral thyroid hormone action in 
patients with central hypothyroidism.  
 
Resting energy expenditure (REE), which is sensitive to the action of both 
thyroid and growth hormone action did not change during the study. GH and thyroid 
hormone have opposing effects on REE with the former promoting an increase in 
the metabolic rate (266).  We have speculated that the lack of an expected rise in 
REE may have been due to the decline in circulating free T4 and a tendency toward 
a hypothyroid metabolic phenotype. Cardiac time intervals have been shown in 
many previous studies to be highly sensitive to circulating concentration of thyroid 
hormone (290). Indeed, studies in both primary and central hypothyroidism have 
shown a good correlation between thyroid status and duration of systolic time 
intervals, particularly the isovolumetric contraction time (ICT) (289, 293). ICT is the 
time when the ventricles have begun to contract, but the volume of the chambers 
has not yet changed. It occurs immediately after the period of electromechanical 
delay, following electrical stimulation of the ventricles (see Figure 1.2). In our study, 
median ICT values did not change following GH substitution. However, there was a 
trend towards shortening of ICT in those with more severe hypopituitarism. 
Fluctuations in thyroid hormone levels may not have been large enough to provoke 
significant changes in cardiac time intervals. Also, the small study sample and lack 
of a matched control group may have impacted on our results. 
 
 The results of studies reported in Chapter 5 suggest that the fluctuations in 
serum thyroid hormone concentration, following GH replacement, may have 
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complex, tissue-specific, clinical effects. The decline in liver-derived markers of 
thyroid hormone action suggests that these alterations in the thyroid axis may 
induce a hypothyroid hepatic phenotype. In contrast, the concentration of BMTs 
increased during the study, in parallel with the rise in the free T3/fee T4 serum ratio. 
This implies that GH replacement may improve the biological action of thyroid 
hormone on bone tissue.  
 
 Patient reported outcomes are an increasingly important measure of quality 
in health care outcomes. GHD, in particular, has been associated with an impaired 
health-related quality of life (QOL) when measured with both generic and disease-
specific questionnaires (304).  Indeed, poor QOL is one of the primary indications 
for the replacement of GH in adulthood (303). However, thyroid hormone can also 
affect QOL. Not surprisingly, hypothyroidism has been shown to negatively impact 
on many domains of well-being (309). In chapter 6, I described the effect of GH 
replacement on health-related QOL in adult hypopituitary men. As expected, QOL 
improved following GH replacement; this was demonstrated using both generic (SF 
36) and disease-specific (AGHDA) questionnaires. Interestingly, self-reported 
improvements in QOL were less apparent when the subgroup of patients, who 
experienced a fall in serum T4 after GH replacement, were analysed separately. 
This was seen using generic and disease-specific questionnaires. Overall, this 
implies that the decline in serum T4, seen after GH replacement, may reflect 
clinically significant hypothyroidism and attenuate the expected rise in health-related 
QOL.  
 
 In conclusion, fluctuations in the thyroid axis are common following GH 
replacement in adult hypopituitary men. DIO2 activity in subcutaneous adipose 
tissue is suppressed, while DIO1 and DIO3 activity are unchanged, following growth 
hormone replacement. This does not explain either the decrease in circulating 
concentration of freeT4 and reverseT3 or the rise in freeT3 induced by GH 
replacement.  Alterations in the serum thyroid hormone levels following GH 
supplementation may have important clinical implications. Complex, often 
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contrasting, tissue-specific effects were observed in thyroid-sensitive clinical 
parameters. In particular, the decline in serum free T4 was associated with an 
attenuation of the expected improvement in QOL following GH replacement.  
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7.2 Recommendations for clinical practice 
 
1. Clinicians caring for adults with GHD should anticipate the likely impact of 
GH replacement on the thyroid axis. Patients with pre-existing central 
hypothyroidism should have the dose of thyroxine optimized prior to 
commencing GH supplementation. Targeting the upper half of the serum free 
T4 reference range may prevent T4 levels declining outside the normal range 
upon commencing GH.  
 
2. A decline of serum free T4 within the normal reference range, following GH 
replacement, should prompt careful evaluation for signs and symptoms of 
hypothyroidism particularly in patients with multiple pituitary hormone 
deficiencies. 
 
3. Longitudinal analysis of biomarkers of thyroid hormone action, before and 
after GH replacement, may provide useful clinical information about the 
impact of fluctuations induced in the thyroid axis.  In particular, the temporal 
trend in multiple thyroid biomarkers may help define the clinical importance of 
equivocal or borderline changes in thyroid hormone levels in selected cases. 
 
4. Suboptimal improvement in health-related QOL following GH replacement in 
adulthood may reflect the unmasking of central hypothyroidism. A poor 
response in QOL should prompt assessment of the effect of GH replacement 
on circulating thyroid hormone levels and consideration of adjustment or 
commencement of thyroxine to optimise serum free T4 levels.  
 
These recommendations are based on my research findings in a group of adult men 
with severe GHD and, therefore, may only be applicable for this group of patients. 
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7.3 Future areas of research 
 
Further research in this field should focus on defining the mechanisms and 
the clinical importance of fluctuations in the thyroid axis induced by GH 
replacement. There is compelling indirect evidence to suggest that GH affects 
peripheral deiodination of thyroid hormone. However, our findings suggest that GH 
may have differential, tissue-specific effects on deiodinase isoenzymes.  
 
We analysed the effect of GH on deiodinase enzymes in subcutaneous fat as 
this tissue is easily accessible. Future research should analyse the effect of GH on 
deiodinase isoenzyme activity in other tissues including muscle and liver. Muscle 
tissue can be attained from human subjects using a technique similar to the one I 
used to extract subcutaneous fat. Human liver tissue samples cannot realistically be 
obtained before and after GH therapy in subjects with severe GHD. However, a 
hypophysectomised animal model could be investigated in this respect. Indeed, the 
analysis of multiple tissue samples from the same animal, before and after GH 
replacement may yield interesting insights into the differential effect of GH on 
specific tissues. The liver is a major site of peripheral deiodination of T4. A cell 
model examining deiodinase activity in cultured human hepatocytes, incubated with 
GH, may advance our understanding of hepatic deiodinase activity in hypopituitary 
patients. Also, measurement of deiodinase mRNA expression in peripheral tissue 
may give further insights into the peripheral modulation of thyroid hormone 
metabolism by GH.  
 
Investigation of other possible mechanism responsible for GH-induced 
changes in the thyroid axis should also continue. Limited evidence suggests that 
GH replacement alters TSH dynamics (67). Jørgensen et al showed that the 
nocturnal surge in TSH is suppressed by a high dose of GH substitution in a study 
of eight hypopituitary adults. Further studies of TSH secretion profiles in a larger 
cohort of hypopituitary adult patients receiving a routine, replacement dose of GH 
may yield further insights into the potential role of TSH dynamics in the altered 
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concentration of thyroid hormone. The concentration of TSH in the serum is often 
suppressed to an undetectable level in patients taking thyroxine for central 
hypothyroidism (127). Therefore, an alteration in TSH dynamics is likely to be of 
greater importance in patients not already taking thyroxine.   
 
Further investigation of peripheral biomarkers will help to inform the clinical 
importance of alterations in the thyroid axis following GH replacement. Preliminary 
evidence, from the studies described in Chapters 5 & 6, suggests that alterations in 
the circulating concentration of thyroid hormones are reflected in biomarkers 
derived from a variety of target peripheral tissues. Future studies should seek to 
evaluate biomarkers which could be utilised in routine clinical practice. Many serum 
biomarkers of thyroid hormone action including ferritin, SHBG, caeruloplasmin, 
lipoproteins and BTMs, can also be influenced by GH or other factors such as 
inflammation or medication. Therefore, their utility in routine clinical practice may be 
limited. The measurement of REE can be cumbersome; it requires specialist 
equipment and expertise. In addition, both GH and thyroid hormone can influence 
metabolic rate which may confound the interpretation of REE measurements in 
hypopituitary patients. However, cardiac time intervals in echocardiography, 
including ICT, can easily be measured in the course of routine clinical practice.  
 
 Preliminary evidence suggest that cardiac systolic time intervals can 
be used in patients with central hypothyroidism to separate those on adequate 
thyroxine replacement from those on insufficient supplementation (289). In the study 
described in Chapter 5, there was a trend towards a shortening of ICT while the 
serum ratio freeT3:free T4 rose in patients with more severe hypopituitarism. This 
suggests that the fluctuations in thyroid hormone, induced by GH, may have 
clinically important and detectable effects on the heart. However, our results did not 
reach statistical significance. A larger cohort of patients, examined prospectively 
before and after GH replacement, and compared with a matched control group with 
no pituitary or thyroid disease, may better define the utility of cardiac time intervals 
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in this clinical setting. This easily accessible clinical measurement holds the 
greatest promise as a biomarker of thyroid hormone action during GH therapy.  
 
Finally, the clinical relevance of a decline in serum free T4 within the normal 
reference range could be further investigated by a clinical trial of thyroxine 
supplementation. In patients with hypopituitarism, the diagnosis of central 
hypothyroidism is complicated by the fact that a serum free T4 concentration within 
the population reference range, similar to the situation of primary hypothyroidism, 
does not exclude central hypothyroidism. Longitudinal observation of a fall in serum 
free T4, within the normal reference range, following GH replacement, may warrant 
thyroxine replacement in selected patients. A placebo-controlled or cross-over trial 
design should be used to evaluate the response of a variety of tissue biomarkers of 
thyroid hormone action and health-related QOL to thyroxine replacement.  
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